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GENERAL INTRODUCTION OF COPD
Introduction 
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease that is character-
ised by airway obstruction and chronic inflammation of the airways. According to the latest 
information of the World Health Organisation (WHO), COPD is the third leading cause of 
death worldwide.[1] The most common symptoms in COPD are dyspnoea, chronic cough 
and sputum production. Components of COPD such as emphysema and chronic bron-
chitis were first described in 17th century.[2] In the 19th century, hyperinflated lungs were 
discovered in particular families, indicating that there should be familial predispositions 
or environmental factors that cause long abnormalities. Nowadays, the most important 
causes of COPD are exposition to noxious gases and tobacco smoking. A diagnosis of 
COPD should be considered in any patient with symptoms of dyspnoea, chronic cough or 
sputum production and a history of risk factors for COPD.[3] 
Diagnosis
If there is a suspicion of COPD, the diagnosis should be confirmed by pulmonary func-
tion testing. Typical for COPD is airway obstruction that is caused by narrowing of the 
small airways, alveolar damage and loss of elasticity of the lungs.[4] Airway obstruction 
is defined as a post-bronchodilator forced expiratory volume in one second (FEV1)/forced 
vital capacity (FVC) lower than 0.7 or FEV1/FVC below the lower limit of normal (LLN). The 
severity of airflow limitation is expressed as a percentage of predicted FEV1. There are four 
COPD stages: mild (FEV1 ≥80% predicted), moderate (50% ≤ FEV1 <80% predicted), severe 
(30% ≤ FEV1 <50% predicted) and very severe COPD (FEV1 <30% predicted).[3] Airflow 
limitation solely is not enough to stage COPD severity. According to the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) statement, patients’ symptoms, history of exac-
erbations and thereby risk of future exacerbations should be taken into account as well.[3] 
Higher symptom burden[5] and a higher number of severe exacerbations are related with 
higher mortality rates.[6, 7] 
Treatment
There are no curative options for COPD. Major treatment goals in COPD are reduction 
of symptoms and prevention of acute exacerbations. Symptoms can be monitored with 
questionnaires. The most widely used questionnaires are the modified Medical Research 
Council (mMRC),[8] COPD Assessment Test (CAT)[9] and Clinical COPD Questionnaire 
(CCQ).[10] For the risk assessment for future exacerbations, the number of moderate 
and severe exacerbations should be used as a predictor, since previous exacerbations are 
the best predictor for future exacerbations.[11] An exacerbation is defined as a sudden 
worsening of respiratory symptoms that results in additional therapy.[3] A low risk for 
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future exacerbations is defined as having had 0 or 1 exacerbation during the previous year 
(not leading to hospital admission); high risk as ≥2 exacerbations or ≥1 leading to hospital 
admission. Pharmacological and non-pharmacological treatment are developed to reduce 
symptoms and prevent exacerbations. Most prescribed pharmacological treatment are 
bronchodilators and inhaled corticosteroids. However, pharmacological treatment has no 
effect on mortality.[3] Moreover, non-pharmacological interventions are recommended to 
improve COPD status. These interventions include the reduction of exposure to risk factors 
and smoking cessation, education and self-management, adequate sleep, a healthy diet, 
exercise training and sufficient physical activity. Despite the existing treatment options, 
COPD is still in the top five leading causes of disability-adjusted life-years.[12] Therefore, 
more research is needed in factors that are related with poor outcomes in COPD to encour-
age the development of novel treatment options. In this thesis the focus is on morning 
symptoms and physical activity. 
MORNING SYMPTOMS IN COPD
Occurrence
In COPD, symptoms vary over the day.[13] However, for decades, morning symptoms 
were considered a feature of asthma.[14] In 2009, the first study with focus on morning 
symptoms in COPD was published.[15] This study showed that the majority of patients 
with COPD experience morning symptoms. Following this study, more research has been 
conducted in this field. Depending on the used questionnaire and the study population, 
39.8 to 94.4% of all COPD patients experience symptoms in the morning.[15-22] Most 
frequently occurring morning symptoms are coughing, sputum production and shortness 
of breath. Morning symptoms are in general mild to moderate.[16, 19, 22] Patients men-
tioned morning symptoms as a cause of work absenteeism.[23] 
Assessment
Nine years after the first publication about morning symptoms in COPD, a morning 
symptoms questionnaire was validated.[24] Before that, researchers used non-validated 
morning symptom questionnaires.[18, 25-30] These different questionnaires contained 
one to nineteen questions about morning symptoms and most of them evaluated the 
type of symptoms, severity of symptoms and the impact of the symptoms on daily life. 
Furthermore, some studies used non-COPD specific questionnaires that included one or 




It has been shown that morning symptoms are associated with night time symptoms, [19, 
21, 22] poorer health status,[19, 21, 22, 33, 34] current smoking, exacerbations,[19, 21, 
22] more depression,[19] more anxiety,[19] more use of oxygen in the previous week,[22] 
more use of rescue medication and more primary care visits. It is unknown whether morn-
ing symptoms could be a target for therapy to improve these outcomes since the causality 
between morning symptoms and other factors is still unknown. 
PHYSICAL ACTIVITY IN GENERAL
Definition and recommendations
Physical activity is defined as “any bodily movement produced by skeletal muscles that 
results in energy expenditure.”[35] As this definition already suggests, movements vary in 
intensity. The intensity of physical activity can be expressed in metabolic equivalents (METs). 
One MET is nearly equivalent to the energy expenditure of sitting quietly.[36] Activities that 
cost <3.0 MET are categorised as light intense activities, for example hair styling. Activi-
ties that cost 3.0 to 6.0 MET are categorised as moderate intense activities, for example 
walking the dog. Activities that cost >6.0 MET are categorised as (very) vigorous intense 
activities, for example jogging.[36] According to the physical activity recommendations of 
American College of Sports and Medicine, adults should be physically active for at least 
30 minutes a day in moderate intense physical activity in bouts of at least 10 minutes, for 
at least five days a week.[37] Another option to reach the activity recommendations is to 
be physically active 20 minutes a day in vigorous intense physical activity in bouts of at 
least 10 minutes, for at least three days a week. When physical activity recommendations 
are not reached, a person is physically inactive. Older adults are less likely to reach the 
activity recommendations than younger adults.[38] The physical activity domains in which 
people spent their time have changed during the past decades; less time is spent in work 
and transport-related physical activity due to the development of new technologies and 
urbanisation; and more time could be spent in leisure time physical activity. Changing 
physical activity is challenging, because physical inactivity is associated with several factors 
including low interest in physical activity, low education level, health related factors and a 
high body mass index.[39, 40]
Measurements
There are various methods to assess physical activity. One method to assess physical activity 
is the use of activity questionnaires. Activity questionnaires are easy to use in practice and 
they are cheap.[41] Disadvantages are recall bias and (gross) overestimation of physical 
activity.[41] Objective assessments of physical activity can be performed with devices. 
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Pedometers are most accurate in step counting.[42] However, pedometers do not contain 
information about movement intensity. (Triaxial) accelerometers are devices that assess 
acceleration in multiple directions and thereby reflect bodily movement. Several accelerom-
eters have been developed, with different features, designs and measured output.[43, 44] 
Disadvantages of accelerometry are lack of adherence and the need for technical expertise.
[41] In COPD, accelerometers are validated tools to evaluate physical activity.[44] 
Chronic diseases
Physical inactivity results in a higher risk of cardiovascular disease, various types of cancer, 
diabetes, obesity and mortality. [45-48] Physical inactivity is common in chronic diseases 
such as COPD, cardiovascular diseases, kidney disease and diabetes.[49] In a group of 
adults without a chronic disease about 50% is physically active, whereas only 30% of 
patients with a history of COPD reach the recommended physical activity levels.[49] 
PHYSICAL ACTIVITY IN COPD
Known activity characteristics
Physical activity is substantially lower in patients with COPD than their healthy peers.[50, 
51] Physical inactivity is not specific to severe COPD only; the decline is already present 
in mild and moderate COPD[52] and pulmonary function is only weakly associated with 
physical activity.[53] There is an annual decrease in physical activity.[54] Low physical activ-
ity in COPD is related to high mortality rates,[55] lower quality of life, more dyspnoea and 
more previous exacerbations.[56] Thus, physical inactivity seems to be a matter of concern 
in COPD that needs to be addressed. It is unknown whether COPD causes inactivity due to 
symptoms, or that it is actually the other way around: that physical activity is a risk factor 
for the development of COPD symptoms. Previous research has shown that patients with 
COPD have different activity characteristics when compared to their healthy peers: patients 
with COPD perform activities slower,[15] at a lower walking speed,[46] and there is an 
increased duration between steps.[57] Furthermore, they take more breaks[15] and they 
perform activities in fewer and shorter bouts.[53] 
Decrease in physical activity
Patients with COPD experience barriers to be physically active, such as a lack of infrastruc-
ture, lack of willpower, other psychological problems, lack of time, invalidating symptoms 
like dyspnoea and fatigue.[58, 59] Moderate and severe acute exacerbations of COPD 
drastically decrease physical activity.[60] Frequently, these exacerbations lead to hospital-
izations. Following hospitalization, it is difficult for patients to perform physical activities. 
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It generally takes more than one month to become as active as they were before the 
exacerbation, if they even return to their pre-exacerbation level.[61] 
Physical activity stimulation
Regular physical activity is recommended for all COPD patients.[3] Some level of physical 
activity results in less decline in pulmonary function when compared to patients who live 
a sedentary lifestyle.[54] Therefore, (easy) interventions to improve physical activity should 
be developed. Several interventions are proven to be effective: counselling, direct physical 
activity feedback and pulmonary medication. Physical activity counseling and real-time 
feedback were more successful in studies that included stable patients with COPD[62, 
63] than studies that included unstable patients. Placebo-controlled medication trials have 
shown positive effects of long-acting beta2 agonists (LABA)[64, 65] and a long-acting 
muscarinic antagonist (LAMA)/LABA combination on physical activity parameters.[66] 
Pulmonary rehabilitation is a multidisciplinary intervention with focus on exercise training, 
education and behaviour change to improve physical and psychological conditions.[67] 
The effects of pulmonary rehabilitation are inconsistent; some studies have shown no sig-
nificant effects on physical activity[68, 69], while others shown significant improvements.
[70, 71] Maintenance of the positive effects of pulmonary rehabilitation on the longer term 
is challenging.[72]
OUTLINE OF THE THESIS
There are no curative options for COPD yet. Nowadays, COPD is still in the top five of 
diseases that are responsible for disability-adjusted life-years worldwide.[12] Therefore, 
more research is needed to improve factors that are related with poor outcomes in COPD. 
The aim of this thesis was to gain more knowledge about morning symptoms and physical 
activity in COPD in search of novel treatment options. In the studies described in this thesis, 
morning symptoms were assessed with a questionnaire and physical activity was assessed 
with a physical activity questionnaire and/or accelerometry. 
Chapter 2 is a systematic review on the existing evidence about the association between 
morning symptoms and physical activity in COPD. Following this systematic review, the 
MOrning symptoms in-Depth observationAl Study (MODAS) was conducted to investigate 
the association between morning symptoms and objectively measured physical activity. The 
results of this study are described in chapter 3 and chapter 4. 
In the MODAS, the focus was on moderate to very severe COPD patients. However, physi-
cal inactivity is already present in mild and moderate COPD. Therefore, physical activity was 
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studied in non-severe COPD patients as well. We studied the associations between physical 
activity and other patient characteristics. The results are presented in chapter 5. 
This thesis continues with an evaluation of a novel systematic approach for asthma and 
COPD patients referred to secondary care pulmonology. The novel systematic approach 
consisted of a predefined diagnostic evaluation combined with an optional internet-based 
self-management support system. Outcomes of the systematic approach were compared 
with usual care. The results are shown in chapter 6. Finally, in chapter 7, a summary of 
the most important findings, a discussion and suggestions for further research and clinical 




CAT: COPD Assessment Test 
CCQ: Clinical COPD Questionnaire
COPD: chronic obstructive pulmonary disease
FEV1: forced expiratory volume in one second
FVC: forced vital capacity
GOLD: Global Initiative for Chronic Obstructive Lung Disease
LABA: Long-acting beta2 agonist
LABA: Long-acting muscarinic antagonist
LLN: lower limit of normal
METs: metabolic equivalents
mMRC: Medical Research Council
MODAS: MOrning symptoms in-Depth observationAl Study
WHO: World Health Organisation
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ABSTRACT
Morning symptoms are common in chronic obstructive pulmonary disease (COPD). Many 
COPD patients consider the morning as the most troublesome part of the day, in which 
they experience more symptoms and physical activity limitations.
To systematically report evidence of the association between morning symptoms and 
physical activity in COPD patients, a literature search was conducted using relevant MESH 
terms and text words in PubMed, Embase, Web of Science, COCHRANE, CINAHL and 
PsycINFO. Quality of the articles was assessed with validated checklists.
Eight studies were included. Morning symptoms were present in 39.8-94.4%. In 37.0-
90.6% of all COPD patients, there was an association between physical activity and 
morning symptoms. However, causality could not be proved. Morning symptoms were as-
sociated with a sedentary lifestyle (p<0.05). Treatment in line with the guidelines improved 
the degree of activity limitations due to morning symptoms (p<0.0001). 
Across all disease stages, COPD patients experience morning symptoms which are nega-
tively associated with physical activity. Physicians should consider morning symptoms as 
a treatment goal. Pharmacotherapy may improve the degree of activity limitations due to 
morning symptoms. More objective research should focus on symptoms, activity limitations 
and physical inactivity of COPD patients, especially in the morning.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) has a huge socio-economic impact. COPD is 
the fourth cause of years of life lost according to the latest findings of the Global Burden of 
Disease Study [1] whereas the World Health Organization stated COPD as the third leading 
cause of death in the period 2000-2012 [2]. COPD is not a curable disease; therefore, the 
main focus of pharmacotherapy is to limit or reduce symptoms as much as possible and to 
prevent acute exacerbations. In addition, reduction of mortality is an important treatment 
goal. However, so far, no pharmacological intervention has been able to reduce mortal-
ity in COPD patients [3]. The actual consensus report of the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) recommend non-pharmacological interventions such as 
smoking cessation, avoiding exposure to air pollution and increased physical activity as well 
as pharmacological treatment and adequate use of medication [4]. In current guidelines, 
severity of disease is categorised by lung function as well as symptoms and the occurrence 
of acute exacerbations. Symptoms have especially been found to have an important impact 
in overall health status [5] and are therefore of importance from the patient’s perspective. 
In addition, there is a strong association between increased shortness of breath and dif-
ficulty with physical activities [6;7]. Frequently, symptoms occur in the morning, resulting 
in limitations of morning activities and often in work absenteeism as well [8]. Despite the 
large impact of morning symptoms on activities and quality of life, morning symptoms are 
not a focus of current treatment guidelines and have not been mentioned in the official Eu-
ropean Respiratory Society statement on physical activity in COPD [3]. Still, there is growing 
awareness of the impact of COPD symptoms in the morning and an increasing number of 
tools to evaluate morning symptoms have been developed [8]. To further  investigate the 
impact of morning symptoms on patients with COPD and especially on physical activity, 
we performed a structural literature review of the current knowledge of the association 
between morning symptoms and physical activity in patients with COPD.
MATERIALS AND METHODS
Data sources and searches
An electronic search of the literature was performed on October 27, 2015, using relevant 
MESH terms and text words. The search was performed using PubMed, Embase, Web of 
Science, COCHRANE, CINAHL and PsycINFO. There was no limitation for date of publica-
tion. All types of studies were included, except meeting abstracts, reviews and articles from 
non-peer-reviewed journals. Original complete texts in all languages were used and  the 




Two authors (AvB and MK) screened the titles to include the relevant articles. Studies 
were included if the study population consisted of patients with the diagnosis COPD. 
Studies were excluded when the predefined outcomes did not comprise either morning 
symptoms or physical activity. After this first screening, two authors (AvB and MK) screened 
the abstracts to only include relevant articles (figure 1). Abstracts that did not include both 
morning symptoms and physical activity were excluded. If an abstract suggested that a 
substantial part of the article concerned morning symptoms and physical activity, it was 
included. A third author (NC) reviewed abstracts when there was a disagreement between 
AvB and MK. Of the remaining articles, AvB and MK read the full-texts. The same inclusion 
and exclusion criteria as for the abstracts were used for the full-texts. 
Synthesis and report strategy 
A Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow 
diagram [9] was used to give insight into the amount of excluded articles. To review the 
current knowledge of morning symptoms and physical activity in COPD patients, the occur-
rence of morning symptoms, the association of morning symptoms with physical activity 
limitations and the impact of medication on activity limitations associated with morning 
symptoms were evaluated. The occurrence of morning symptoms was studied in three 
ways. First, the incidence of morning symptoms in COPD was examined to determine the 
frequency of these symptoms. The occurrence of morning symptoms in all COPD patients 
and the type of morning symptoms was assessed in studies in which all COPD patients 
were included regardless whether they experienced symptoms or not. Second, in studies 
with patients with morning symptoms, the type of morning symptoms were examined to 
determine the most common. Third, in studies with patients with symptoms during any 
part of the day, the percentage of patients that reported morning as the worst time of 
the day was determined. Furthermore, the association between morning symptoms and 
physical activity was assessed. Thereafter, the impact of medication on physical activity 
limitations that were associated with morning symptoms was evaluated. No further statisti-
cal analysis or meta-analysis has been conducted, as all studies had different endpoints and 
the endpoints were measured with different tools. 
Quality assessment
The STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) check-
list [10] was used to assess the quality of observational, case control and cohort studies. 
The Consolidated Standards of Reporting Trials (CONSORT) checklist [11] was used for the 
quality assessment of randomized controlled trials. There is no consensus when an article 
may be indicated as high or low; however, previous research has shown that observational 
studies published in high-quality journals contain an average of 69% of the STROBE items 
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[12]. Consistent with this study and other studies who support this interpretation [13;14], 
a minimum of 15 (69%) reported items out of 22 indicated “high quality”, and lower than 
15 out of 22 indicated “moderate to low quality”. 
RESULTS
Search strategy
The search identified 390 articles. After removing duplicates, 195 individual articles 
remained. After screening titles, 117 articles were considered relevant. After reading 
abstracts, 32 articles remained. Full-texts of these articles have been read and 24 articles 
have been excluded. Eight remaining studies were included in this systematic review (figure 
1). Of the eight included studies, seven studies were observational studies and one was 
a randomised controlled trial. The quality of the studies was assessed using the STROBE 
checklist. The scores ranged from 14 to 18 out of 22 points. This means that six observa-
tional studies had high quality and one observational study had a moderate quality. One 
article was a randomised controlled trial and was assessed by the CONSORT checklist. This 
article scored 17 out of 25 points. This is a study that pooled analysis from two studies. 
The full methods of the two studies are not described in the present study. When using the 
methods of the original studies, the study would score a higher amount of points. None of 
the included articles had a low quality (see supplementary table S2).
Figure 1 Study flow diagram with the use of the official PRISMA (Preferred Reporting Items for System-
atic Reviews and Meta-Analyses) flow chart.
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General findings
The oldest study was published in 2009 and the most recent in 2015. The number of 
patients included in the studies ranged from 133 to 3394. Patients participating were at 
least 30 years old, 5.3-60.5% were female. In all studies, at least 24% of patients were 
current smokers. All stages of COPD were represented. The study population and the 
general conclusion of each study are reported in table 1. 
Morning symptoms
When analysing all patients with COPD, the most common morning symptoms were cough, 
sputum production and shortness of breath [15-17]. In this patient group the percentage 
of morning symptoms varied between 39.8 and 94.4% [15-20] (figure 2a). When only 
assessing the group of patients with morning symptoms, again cough, sputum produc-
tion and shortness of breath were frequently detected [19-21] (figure 2b). In symptomatic 
severe and very severe COPD patients, it was found that the morning was the worst time of 
the day for the symptom sputum production (in 70.9-87.2%), for cough (in 60.1-72.6%) 
and for shortness of breath (in 45.4-85.1%) [18;21;22] (Figure 2c). More than half of 
patients considered the severity of their symptoms to be mild to moderate [15;16;20]. The 
association between COPD severity and morning symptoms was analysed. Interestingly, 
morning symptoms could be detected across all stages of disease. One study that included 
COPD patients with all stages of the disease, concluded that morning symptoms were 
associated with the severity of COPD [16]. However, when only patients with severe and 
very severe COPD were included, no difference in pulmonary function between patients 
with or without morning symptoms could be detected [18]. Nevertheless, when patients 
over all disease stages were included, a significant decreased pulmonary function could 
be detected in patients with morning symptoms compared with those without morning 
symptoms [17]. Mostly, patients do not experience solely morning symptoms, but might 
experience daytime and night-time problems as well [16;17;20]. Most common night-time 
problems were night-time symptoms, sleep disturbances and early awaking [15-18;20;22]. 
The association between morning symptoms and physical activity  
All studies showed that COPD patients who experience morning symptoms also report a 
negative impact on physical activity. When analysing all patients with COPD, 37-90.6% 
of patients experienced physical activity limitations that were associated with morning 
symptoms [15;18;21] (table 2). When just patients with morning symptoms were assessed, 
34-79% of these patients reported limitations in morning activities due to these symptoms 
[19;20]. Most mentioned limited activities were getting up, taking a shower and dressing 
[18;19;22]. Reported routine activities took at least 10 min longer compared with the 
situation before morning symptoms had increased [19]. Half of patients reported to have 
2




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































made changes to their morning routines because of morning symptoms [19]. Patients’ 
core coping strategies were doing things slowly and taking more breaks [21]. Shortness of 
breath was the symptom most strongly correlated with the reduced ability to perform tasks 
[21]. One of the studies, which included only patients with severe to very severe COPD, 
reported that 9.4% was completely unable to exercise outside, 24.7% managing up to 30 
min·day−1, 32.9% between 30 and 60 min·day−1 and 30.9% reported walking outdoors 
longer than 1h·day−1 [22]. In another article, 30% of patients described themselves as 
sedentary, 38% as moderately active and 34% as active. There was a significant associa-
tion between morning symptoms and patients’ self-reported physical activity. Sedentary 
Figure 2 Occurrence of morning symptoms. a) In all studied chronic obstructive pulmonary disease 
(COPD) patients. b) Occurrence of different morning symptoms in COPD patients experiencing symp-
toms. c) Symptomatic COPD patients who report the morning as worst time of the day for that symptom 
(results for at waking and the rest of the morning are combined). #: Classification of airflow limitation 
according to Global initiative for Chronic Obstructive Lung Disease (GOLD). ¶: “Severe” was defined in 
this study as regular use of COPD medication plus a third level of breathlessness or above using Medical 
Research Council dyspnoea scale and one or more exacerbations in the preceding 12 months; +: in all 
included COPD patients.
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patients experience more morning symptoms and more symptoms the rest of the day 
when compared with moderately active or active patients (p<0.05) [16], although it was 
not reported whether inactivity was actually a result of morning symptoms. Besides morn-
ing activities, normal daily activities are also influenced by morning symptoms [17;19;22]. 
More detailed information about the sort of activities is given in supplementary table 3.
Treatment to improve activity limitations that are associated with morning 
symptoms
An internet survey stated that about 79% of COPD patients report that medication provides 
relief of symptoms in the morning [19]. A prospective non-interventional observational 
study in which patients were treated following present guidelines with pharmacological 
or non-pharmacological therapies, showed that the impairment of all activities that were 
associated with morning symptoms was significantly reduced [18] (table 3). Recently, data 
from two phase III, double-blind, randomised, parallel-group active- and placebo-controlled 
studies were pooled to compare the effect of a fixed dose combination of long acting 
 2-agonist (LABA) and long-acting muscarinic antagonist (LAMA) versus mono-therapy or 
placebo on morning symptoms and associated physical activity limitations [15]. In this 
analysis, there was a significant improvement of morning symptoms and the individual 
symptoms cough, wheezing, dyspnoea and sputum production in the morning after treat-
ment with the fixed  LABA/LAMA combination. In the same study, the fixed LABA/LAMA 
combination significantly improved severity scores for limitations of morning activities that 
are associated with morning symptoms when compared with LABA and LAMA alone (both 
p<0.05) (table 3). Furthermore, in an internet survey, it was found that improvement in 
the ability to perform morning activities is one of the patients’ expectations of treatment 
[19]. Nevertheless, patients reported that physicians were unlikely to ask about morning 
symptoms and the ability to perform morning activities [19;21]. Hence, physicians were 
unlikely to discuss how to cope with these symptoms and to describe what to expect from 
therapy for activity limitations.
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DISCUSSION
The aim of the present study was to systematically review the current evidence of the asso-
ciation between morning symptoms and physical activity in COPD patients. The most dated 
study included in this review was from 2009, suggesting that interest for the combination 
of these topics is relatively recent. None of the studies had a low quality when scored 











Effect medication on 
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medication on physical 









90.6% of all 
patients
FDC 400/12ug on severity 
scores: -0.23 units (-17.0%); 
aclidinium 400ug: -0.14 
units (-10.7%); formoterol 
12ug: -0.17 units (-13.6%) p 
<0.0001 vs. aclidinium and 
p <0.01 vs formoterol.#
Individual morning 
symptoms: p<0.05 vs. 
aclidinium for cough 
and difficulty bringing 
up phlegm, and vs. 
both monotherapies for 
wheezing and shortness of 
breath
Improvements in 
limitation of early 
morning activities: p 
<0.05 vs. aclidinium 
























(3.96 vs. 3.29, 
p<0.007)
79% of COPD patients who 
feel medications provides 
relief from symptoms in 
the morning enough
33% of patients 
considered 
”improvement of 
ability to carry out 
morning activities” a 
key treatment goal. 
21% of patients feel 
medication provides 
improvement in the 
ability to carry out 
morning activities




by the study 
protocol
57% of all 
patients
57% of all 
patients
LAMA and ICS plus LABA 
were used significantly less 
frequent in patients with 
morning symptoms. LAMA 
was a preventive factor for 
the presence of morning 
symptoms
Severity of all morning 
activities were 
significantly reduced 
after  two months 
follow-up. 
COPD: chronic obstructive pulmonary disease; FDC: fixed-dose combination; ICS: inhaled corticoste-
roids; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonists. #: Symptom severity 
measured on a score from 0 (no symptoms) to 4 (very severe symptoms).
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with the STROBE and the CONSORT tools. Therefore, all eligible articles were included in 
the present review. It was found that morning symptoms are common in patients with 
COPD across all stages. Importantly, these symptoms are associated with impaired physical 
activity. 
Morning symptoms in COPD were detected frequently in different studies. However, the 
percentage of patients with symptoms varied widely. One explanation might be that dif-
ferent definitions for morning were used. In the studies a lower percentage of morning 
symptoms could reflect just the symptoms immediately on awaking and a higher percent-
age of morning symptoms reflects the symptoms on awaking plus the symptoms that 
develop throughout the rest of the morning. There are some tools developed to evaluate 
morning symptoms [23-25], but none of them have been adequately validated. In the 
included articles, mostly self-developed questionnaires were used, and only one article 
used one of the previously mentioned tools. In some studies, only patients with severe and 
very severe COPD were included; while, in other studies, mild to moderate COPD patients 
were also included. It is of note that morning symptoms were apparent in all stages of 
COPD and that activity limitations associated with morning symptoms were detected in 
less severe COPD. This is in line with studies showing that physical activity of patients with 
COPD is already impaired in early disease stages [26]. Therefore, the difference in percent-
age of morning symptoms cannot be explained by the different study populations of the 
included studies. Currently, there is lack of evidence that morning symptoms increase as 
the degree of severity of COPD increases. In three included studies [19-21] lung function 
was unknown. In one study the authors made their own definition for “severe COPD” that 
was not linked to pulmonary function [21]. In other studies the authors did not analyse 
the patients by pulmonary function [15;19;22]. One further explanation for the diverse 
results might be that questionnaires are not always filled out by the patients. In some 
studies the physician scored the severity of symptoms, which could further explain the 
wide range of incidences of morning symptoms. Previous research has shown that there 
is a low level of concordance in assessing disease impact between COPD patients and 
physicians [27]. Furthermore, it can also be stipulated that differences in methods of data 
collection (electronically or by paper) could affect the results. However, we believe that the 
impact of different data collection methods is minimal, since data administered on paper 
are quantitatively comparable with measures administered on an electronic device [28;29]. 
There are some disorders and conditions that may affect symptoms in the morning as well. 
Mostly, patients do not experience only morning symptoms, but experience daytime and 
night-time symptoms as well. Symptoms during daytime or night-time negatively influ-
ence health status, anxiety and depression levels, sleep quality, physical activity levels and 
adherence to medication. Patients with morning symptoms were more likely to use oxygen 
in the previous week [20], to have poorer health status [16;17;20], to experience exacerba-
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tions [16;17;20], have a worse sleep quality [16] and have higher anxiety and depression 
levels [16]. It is not possible yet to distinguish whether morning symptoms are a particular 
phenotype in COPD or whether it is a feature of the disease.
A large group of COPD patients have physical activity limitations that are associated with 
morning symptoms. This raises the question whether people with morning symptoms are 
more inactive, or inactive patients have more morning symptoms. Until now, prospective 
comparative studies using objective measures of physical activity levels in relation to morn-
ing symptoms are lacking. Existing evidence about physical activity and morning symptoms 
mostly comes from observational studies. Thus, causality between morning symptoms and 
limitations of activities cannot be proven. It is has been shown that people with COPD 
are more physically inactive compared with their healthy peers [30;31]. However, it is not 
completely clear if the relationship between the level of inactivity is solely a result of COPD 
or if inactivity is a risk factor and contributes to the development of COPD itself. Indeed, 
patients report frequently that dyspnoea impairs everyday tasks [32]. Especially in the 
morning while performing tasks, patients’ main coping strategies are doing things slowly 
and taking frequent breaks [21]. This is in line with previous research demonstrating a low 
walking speed is typical for COPD patients compared with healthy controls [3]. Therefore, 
it has been suggested that patients with COPD may be in a downward spiral of symptom-
induced inactivity, as well as in the early stages of disease [30;31]. However, impaired 
physical inactivity is not an exclusive feature of patients with COPD but has been reported 
in many different chronic diseases such as stroke, kidney disease, diabetes, coronary heart 
disease, hypertension and obesity [33]. This suggests that also other factors such as be-
havioural, genetic, social, environmental, cultural and policy factors could contribute to 
impaired physical activity in chronic disease [3]. 
Previous research has shown that the impairment in activity is progressive as activity levels 
in COPD patients further decreases over time [26;34]. In only two of the studies included 
in this review, patients with COPD reported their activity levels [16;22]. Interestingly, their 
activity levels were higher compared with previous findings reported in literature [34]. A 
potential explanation may be that physical activity was self-reported in the studies included 
in our review, while the lower levels in the literature were objectively measured by a vali-
dated accelerometer. Of self-reported physical activity, it is known that it is often misjudged 
by participants; patients tend to underestimate standing time and overestimate walking 
time [35]. Therefore, the use of objective measures, such as accelerometers to adequately 
assess physical activity is recommended [36]. 
The present review showed that limitations in physical activity due to morning symptoms 
can be significantly reduced with medical treatment. This conclusion is based on two obser-
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vational studies and one study that pooled two large phase III, double-blind, randomised, 
parallel-group active- and placebo-controlled study. Despite two out of three studies being 
observational studies without a prespecified intervention and a change of recall bias, all 
conclusions pointed in the same direction: medical treatment results in a reduction of 
physical activity limitations and a reduction of morning symptoms. This is in line with 
other studies that found positive effects of pharmacotherapy on symptoms and morning 
routines [37-39]. These studies were not included in this review, since the authors did not 
examine the association between morning symptoms and physical activity. Therefore, it is 
unclear whether the improvements in physical activities were the result of improvements 
in symptoms or the other way around, or if these effects are independent from each other. 
One of the potential limitations of this review is that the search strategy could have missed 
some articles about morning symptoms if morning symptoms were not adequately high-
lighted in the abstract. However, this is unlikely because cross-references of the included 
articles were carefully checked as well. Another limitation of this review is the use of the 
STROBE and CONSORT checklists as a quality checklist for the included studies. These 
checklists were not developed to score the quality of reviews, but were developed as 
checklists to strongly report original studies. Therefore, there is no consensus when an 
article may be indicated has high or low and arbitrary rules are used to assess the qual-
ity. Another limitation of the included studies could be that some patients included in 
the studies had asthma. In most included articles, asthma was an exclusion criterion and 
only one study did not exclude patients with other lung diseases. In that study, 37% of 
the included patients had self-reported asthma as a co-diagnosis [19]. Also, it is possible 
that patients in the included studies have been misdiagnosed or wrongly coded as COPD 
patients. In one included study, 12.9% of patients had never smoked [20], which makes 
the diagnosis of COPD much more unlikely. It is presumable that the more asthma patients 
were wrongly included, the more morning symptoms occurred, since circadian variation 
of lung function and symptoms is well described in asthma [40]. Nevertheless, in COPD 
patients, symptoms vary as well, even with daily and weekly variation [21;40]. More than 
half of patients experience COPD symptoms throughout the whole 24-h day [16] and only 
a few patients experienced solely morning symptoms. The morning is the most trouble-
some part of the day with limitations in activities, probably due to circadian variation in 
lung function or because the morning is the most active period of the day. The night is the 
second most troublesome part of the day for patients with COPD [41;42]. Another limita-
tion is that most included articles were observational studies, with potential recall bias; 
patients might inadequately report some events or symptoms. Two of the observational 
studies were internet surveys [19;21]. Important limitations of internet surveys are that 
data is self-reported and there might be selection bias, since not all patients have access 
to internet, and internet access is influenced by age, social status and employment status. 
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This may result in a younger population and a higher socio-economic status. Two of the 
included studies [19;21] recruited patients from consumer panels. This might cause ”self-
selection bias” and the included patients are probably not representative for the whole 
COPD group. In one study [18], 94.7% of included patients were male and results of this 
study cannot be generalised to females. 
In conclusion, across all disease stages, COPD patients experience morning symptoms 
that are negatively associated with physical activity. However, it is not possible to prove 
causality yet, because of the observational designs of these studies. The important finding 
that morning symptoms are negatively associated with morning symptoms suggests that 
physicians should include the evaluation of morning symptoms in their clinical assessment 
and they should include the control of morning symptoms  as a goal of treatment, since 
there is evidence that treatment has positive impact on morning symptoms. There is also 
some evidence that pharmacotherapy improves morning symptoms and possibly reduces 
the degree of activity limitations by reducing morning symptoms. Up until now, studies 
using objective  evaluations of physical activity levels and the association with morning 
symptoms are lacking. Future studies, preferably prospective randomised trials, should 
focus on objectively measured physical activity in COPD patients especially in the morn-
ing. We also recommend validation of a tool to evaluate morning symptoms, because a 
validated tool is lacking. If more evidence supports the finding that morning symptoms and 
physical activity are related, these factors will be more emphasized and will find a place in 
guidelines and statements.
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LIST OF ABBREVIATIONS
CCQ: Clinical COPD Questionnaire
CONSORT: Consolidated Standards of Reporting Trials 
COPD: Chronic obstructive pulmonary disease
GOLD: Global Initiative for Chronic Obstructive Lung Disease
LABA: long acting beta-agonist 
LAMA: long-acting muscarinic antagonist
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
STROBE: STrengthening the Reporting of OBservational studies in Epidemiology
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SUPPLEMENTARY MATERIALS
Supplementary text 1. Full search
Our PubMed search on 27th October 2015 contains of this combination: 
((“Pulmonary Disease, Chronic Obstructive”[Mesh] OR “COPD”[tw] OR “Chronic Obstructive 
Pulmonary Disease”[tw] OR “Chronic Obstructive Pulmonary Diseases”[tw] OR “COAD”[tw] OR 
“Chronic Obstructive Airway Disease”[tw] OR “Chronic Obstructive Lung Disease”[tw] OR “Chron-
ic Obstructive Airway Diseases”[tw] OR “Chronic Obstructive Lung Diseases”[tw] OR “Chronic 
Airflow Obstructions”[tw] OR “Chronic Airflow Obstruction”[tw] OR “Chronic Bronchitis”[tw] 
OR “Pulmonary Emphysema”[tw]) AND (“Morning symptoms”[tw] OR ((morning*[tw] OR 
“time of day”[tw]) AND (symptom*[tw] OR routine*[tw] OR activit*[tw] OR limitation*[tw] 
OR complaint*[tw] OR “Signs and Symptoms, Respiratory”[Mesh] OR “Sputum”[mesh] OR 
“sputum”[tw] OR “cough”[tw] OR cough*[tw] OR breathless*[tw] OR “Shortness of Breath”[tw] 
OR “Breath Shortness”[tw] OR “short of breath”[tw] OR dyspnea*[tw] OR dyspnoe*[tw] 
OR “wheezing”[tw] OR “chest tightness”[tw]))) AND (“activity”[tw] OR “activities”[tw] OR 
“inactivity”[tw] OR “inactivities”[tw] OR “Motor Activity”[Mesh] OR “physical inactivity”[tw] 
OR “physical activity”[tw] OR “physical activities”[tw] OR “locomotor activity”[tw] OR “locomo-
tor activities”[tw] OR “motor activity”[tw] OR “motor activities”[tw] OR “Exercise”[tw] OR “Cir-
cuit-Based Exercise”[tw] OR “Cool-Down Exercise”[tw] OR “Muscle Stretching Exercises”[tw] 
OR “Physical Conditioning”[tw] OR “Plyometric Exercise”[tw] OR “Resistance Training”[tw] 
OR “Running”[tw] OR “Jogging”[tw] OR “Swimming”[tw] OR “Walking”[tw] OR “Warm-Up 
Exercise”[tw] OR “Cataleptic Freezing Reaction”[tw] OR “Tonic Immobility Response”[tw] OR 
“Pronation”[tw] OR “Supination”[tw] OR “Exercises”[tw] OR “Cool-Down Exercises”[tw] OR 
“Muscle Stretching Exercise”[tw] OR “Plyometric Exercises”[tw] OR “Warm-Up Exercises”[tw] 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary table 3. Detailed self-reported limitations due to morning symptoms
First author 
[ref.]
Limitations in morning activities Limitations in daily 
activitiesSelf-care Domestic activities Work
Bateman [15] NA NA NA NA
Stephenson 
[20]









Miravitlles [16] NA NA NA NA
O’Hagan [19] Getting up: 62%#;  
taking a shower: 43%#; 
grooming: 34%#; 
dressing: 43%#
Going up and 
down stairs: 79%#; 
making bed: 55%#; 
making breakfast: 
34%#; taking 
children to school: 




41% is not 
working# 
(unclear it 





Increased impact on 
normal daily activities 
(p=0.007)
Roche [17] For patients in paid 
employment, the 
disease’s impact on 
getting up and ready 
for the day was 
significantly higher in 
those with morning 
symptoms (2.99 vs. 2.4§, 
p<0.001)
NA 70.4% is 
not working 
(unclear it 









(2.86 vs. 2.51§, 
p=0.027)
Limits the amount of 
housework I can do: 
66%‡
Means that I am tired 
throughout the rest of 
the day: 64%‡
Means that I do not 
make commitments 
before a certain time: 
33%‡ 
Means that I cannot go 
grocery / supermarket 
shopping: 27%‡
Kim [18] Getting out of bed: 
82.9%#; washing 
yourself: 76.3%#;  
dressing yourself: 
70%#; using the 
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Supplementary table 3. Detailed self-reported limitations due to morning symptoms (continued)
First author 
[ref.]
Limitations in morning activities Limitations in daily 
activitiesSelf-care Domestic activities Work
Kessler [22] Washing 41.0%;  
dressing 40.7%;  drying 
36.2%; 
getting out of bed 
35.4% 
NA NA Going up and down 
stairs 82.5%; doing 
heavy household 
chores 56.9%; going 
shopping 43.1%
doing sport or hobbies 
35.9%
Partridge [21] Severity score¶ in 
severe/non severe+ 
COPD. 
Putting socks on 
6.7/4.4; showering 
6.1/3.8; drying 6.1/3.8; 
getting dressed 
6.0/3.8; getting out of 





cleaning your teeth 
3.5/2.4




stairs 8.6/6.2; making 
the bed 6.8/4.3; 
walking around the 
house in the morning 
5.4/3.5; washing 
dishes 5.0/3.3; 
going to the 
bathroom 4.2/2.6
NA NA
#: In patients with morning symptoms; ¶: Rated on a scale from 1 to 10, where 1= it is not affected at all 
and 10 = it is greatly affected; +“Severe” was defined in this study as: regular use of chronic obstructive 
pulmonary disease (COPD) medication plus a third level of breathlessness or above using Medical Re-
search Council dyspnoea scale and one or more exacerbations in the preceding 12 months; §: Measured 
on a 7-point Likert scale of 0=no impact to 7=constant impact; ‡: % of COPD patients whose rest of days 
are impacted by morning symptoms
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Purpose: The morning is the most bothersome period for COPD patients. Morning symptom 
severities in different Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages 
are not well studied. Furthermore, factors that are associated with morning symptoms, 
especially the associations with objectively measured physical activity are also not well 
described. 
Materials and methods: The aim of this cross-sectional observational study was to assess 
morning symptom severity in GOLD A, B, C and D patients, according to the definitions 
of the GOLD 2015 statement. Morning symptoms were assessed with the PRO-Morning 
COPD Symptoms Questionnaire. Differences in morning symptom severity between differ-
ent COPD stages were assessed with a one-way analysis of variance followed by post hoc 
analyses. The association between dyspnea severity (assessed with the modified Medical 
Research Council scale), health status, airflow limitation, lung hyperinflation, anxiety and 
depression, inflammatory parameters, exacerbations, objectively measured physical activity 
parameters retrieved from accelerometry and morning symptom severity was evaluated 
using linear regression analysis.
Results: Eighty patients were included (aged 65.6±8.7 years, forced expiratory volume in 
1 second [FEV1] %predicted 55.1±16.9). Mean (±SD) morning symptom score was 19.7 
(±11.7). Morning symptom severity was significantly different between COPD stages: 
mean (±SD) score in GOLD A was 9.7 (±7.2), in GOLD B 19.8(±10.7), in GOLD C 8.6(±9.3) 
and in GOLD D 23.8(±11.2) (p<0.001). Lower health status, more symptoms, increased 
anxiety and depression, less physical activity (all p<0.001) and lower FEV1 (p=0.03) were 
associated with an increased morning symptom severity.
Conclusion: Patients with overall more symptomatic COPD have significant higher morn-
ing symptom scores. Morning symptom severity was associated with important clinical 
outcomes: lower health status, more symptoms, increased anxiety and depression, fewer 
steps a day, less time in moderate and vigorous physical activity with bouts of at least 10 
minutes and lower FEV1. The data suggest that morning symptoms should be carefully 
assessed in addition to assessments by general COPD-specific questionnaires, especially in 
those with more symptomatic COPD. More research is needed on potential therapies to 
improve morning symptoms; this study shows potential targets for intervention.
Keywords: accelerometry, chronic obstructive pulmonary disease, physical activity, PRO-
Morning COPD Symptoms Questionnaire, morning symptoms
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INTRODUCTION
COPD is the fifth leading cause of disability-adjusted life-years worldwide.[1] COPD is 
characterized by airway obstruction, lung emphysema and chronic inflammation of the 
airways. Airway obstruction is usually progressive over time but variability over short time 
is low. Still, COPD symptoms vary throughout the day.[2] In recent years, it has become 
apparent that the morning is the most symptomatic part of the day for most COPD pa-
tients.[3] A recent review showed that the occurrence of morning symptoms in COPD 
varies widely from 38.9% up to 94.4% of patients and morning symptoms are present 
in all COPD severity classes.[4] However, the prevalence of morning symptoms seems to 
be heavily dependent on the used questionnaire.[5] In addition, few studies assessed the 
severity of morning symptoms in relation to COPD severity and identified factors that are 
associated with morning symptoms.[2, 6, 7]
One of the important factors in COPD patients is physical activity. People with COPD are 
more physically inactive compared to their healthy peers.[8, 9] This is also reflected in the 
observation that only 26% to 30% of patients with COPD fulfilled the WHO physical activ-
ity recommendations.[10, 11] The lack of sufficient physical activity is associated with more 
exacerbations, hospitalizations, all-cause mortality[12] and lower quality of life.[13] The 
aetiology of physical inactivity in COPD patients is not completely understood. The lack of 
activity could be due to the avoidance of pulmonary symptoms or it can be speculated that 
physical activity could be a risk factor to develop COPD. Self-reported low physical activity 
has been shown as a factor that is related with morning symptoms.[2] Half of the patients 
reported that they had made changes in morning routines, even in simple tasks, due to 
symptoms.[14] However, to our knowledge, no studies have been done that evaluate the 
relationship between objectively measured physical activity by triaxial accelerometry and 
morning symptoms.
The primary objective of the Morning symptoms in-Depth observAtional Study (MODAS) 
was to assess the severity of morning symptoms in different Global Initiative for Obstruc-
tive Lung Disease (GOLD) stages. The secondary objective was to evaluate the association 
between dyspnea severity, health status, airflow limitation, lung hyperinflation, anxiety 
and depression, inflammatory parameters, exacerbations, objectively measured physical 
activity parameters and morning symptom severity. We hypothesized that patients in more 
advanced GOLD stages have higher morning symptom scores. Furthermore, we expect that 




The MODAS was a single center, observational, cross-sectional study that was conducted 
from September 2015 until February 2017 in the Netherlands. The medical ethics com-
mittee from the Leiden University Medical Center (LUMC) approved the study (protocol 
number NL51951.058.15). 
Study subjects
Outpatients were recruited from a university medical center (the LUMC), a regional hospital 
(the Alrijne hospital) and were recruited by distributing flyers in local papers. Interested 
patients received the study information by letter. Upon agreeing to participate, a visit was 
scheduled. All patients gave written informed consent. 
Patients were eligible if they had a diagnosis of COPD by a physician, met the criteria for 
GOLD II-IV according to the definitions of the GOLD statement[15] and were aged 40 to 80 
years, a general symptomatic patient group. Furthermore, they had to be current smokers 
or ex-smokers with a lifetime tobacco exposure of ≥10 pack years. Patients were excluded 
if they had a diagnosis of asthma, history of sensitization to allergens or significant other 
lung disease. In addition, patients were excluded if they had comorbidities that significantly 
impaired exercise capacity in the opinion of the investigator (severe polyneuropathy, leg 
amputation). Other exclusion criteria were current malignant diseases or clinical signs of 
acute heart failure. Patients with mental impairment that could result in noncompliance 
with the study protocol were also excluded. Also, patients who were currently enrolled in 
a rehabilitation program or with an exacerbation in the previous 2 months were excluded. 
An exacerbation was defined as sustained worsening of respiratory symptoms during 48 
hours and requiring oral corticosteroid, antibiotic or a combination of this treatment that 
was initiated by a physician, a visit to the emergency department or hospitalization with or 
without intensive care visit. Respiratory symptoms included at least one of the Anthonisen 
criteria (increased dyspnea, sputum volume and sputum purulence).[16] 
Study procedures and outcomes
The study consisted of one visit to the study center. Patients were interviewed by a physi-
cian about their employment status, smoking status and COPD exacerbations in the previ-
ous year. Furthermore, morning symptoms, dyspnea severity, health status and pulmonary 
function were assessed and blood was drawn. All pulmonary function tests were performed 
between 8.30 and 11.00 AM. Immediately following this visit the patients wore a triaxial 
accelerometer for 7 consecutive days. To collect information regarding possible adverse 
events patients were contacted by telephone after these 7 days.  
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The occurrence and severity of morning symptoms were assessed with the PRO-Morning 
COPD Symptoms Questionnaire.[17] This questionnaire consists of six questions. Patients 
rated the severity of dyspnea, sputum production, chest tightness, wheezing and cough 
in the morning with a Likert scale ranging from 0 to 10 points for each question. 0 points 
represent no symptoms and 10 points represent symptoms as severe as they can imagine. 
Limitations in the morning due to COPD were scored with the same Likert scale. Total 
morning symptom scores ranged from 0 to 60. A total score of 0 indicated no symptoms 
at all in the morning. 
The American College of Sports Medicine (ACSM) and the American Heart Association 
stated that adults should perform moderate-intensity physical activity for a minimum of 30 
minutes (or bouts of at least 10 minutes) for 5 days each week or vigorous-intensity physi-
cal activity for a minimum of 20 minutes on 3 days each week.[18] To objectively measure 
physical activity, patients wore a validated triaxial accelerometer (Dynaport MoveMonitor, 
McRoberts BV, The Hague, the Netherlands)[19-21] 24 hours a day for 7 consecutive days 
after baseline visit. Due to non-water resistance, patients were not allowed to wear the 
accelerometer while taking a shower or a bath. Body posture and types of physical activity, 
as well the duration and intensity of the activity were measured. Steps, total duration of 
active and inactive periods, active time in light (1.5-3.0 metabolic equivalent task [MET]), 
moderate (3.0-6.0 MET) and vigorous-intensity (6.0-9.0 MET) activities, number of active 
and inactive periods and number of walking periods ≤10 seconds, 10 to 20 seconds and 
>20 seconds were taken as secondary outcomes derived from the accelerometer. Addition-
ally, to take the activity guidelines of the ACSM into account, active time in moderate 
physical activity (MPA), vigorous physical activity and moderate-to-vigorous physical activity 
(MVPA) in bouts of at least 10 minutes were measured. Activity was defined as standing, 
shuffling and walking combined; inactivity was defined as sitting and lying combined. 
Furthermore, the accelerometer measured the time that it was not worn. 
Symptom burden was assessed with the modified Medical Research Council (mMRC) scale 
with scores ranging from 0 to 5.[22] Health status was assessed using the COPD assess-
ment test (CAT).[23] Comorbidity was evaluated with the Charlson Comorbidity index 
(CCI).[24] High-sensitive C-reactive protein was measured in serum. Total leukocyte cells 
counts as well as absolute numbers of eosinophils were assessed. Lung function was as-
sessed post-bronchodilator via spirometry (CareFusion, Masterscreen PFT System) following 
European Respiratory Society (ERS)/American Thoracic Society (ATS) standards.[25] Forced 
vital capacity (FVC) and forced volume in one second (FEV1) were expressed in absolute 
and % predicted values, respectively (based on Global Lung Function Initiative 2012).[26] 
Total lung capacity and residual volume (RV) were measured by body box (Carefusion, 
Masterscreen Body)[27] and RV was expressed in % predicted values (based on European 
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Community for Coal and Steel). To assess hyperinflation, the ratio between RV and TLC 
was calculated. Severity of COPD was reported as GOLD A-D based on symptoms as-
sessed with the mMRC, airway obstruction and exacerbations in the previous year[15] 
(Supplementary materials). 
Statistical analysis
Descriptive data were reported as mean values ± standard deviations (SD) for continuous 
data with a normal distribution, median with interquartile ranges (IQR) for continuous 
data with a non-normal distribution or percentages for categorical data. To assess whether 
there was a normal distribution, histograms were made from each continuous individual 
variable and the shapes of the histograms were carefully assessed. Differences for age 
and gender between participants and nonparticipants were analyzed with an independent 
t-test and a chi-square test respectively. Differences in morning symptom severity between 
COPD stages A, B, C and D were assessed with a one-way analysis of variance followed by 
post hoc analyses. 
When the accelerometer was worn less than 22.5 hours a day (94%), the day was excluded 
from analysis. Mean values derived from the accelerometer were calculated as the mean 
per patient only from valid days. When there was an adverse event for which a health 
care provider visit was required during the study period, the patient was excluded from 
activity analysis since adverse events might have negative effects on physical activity. The 
association between physical activity, dyspnea severity, health status, anxiety and depres-
sion, airflow limitation, lung hyperinflation, laboratory results, the presence of at least 
one exacerbation in the previous year and morning symptom severity was analyzed with 
univariable linear regression analysis. We looked at the overall explained variance (R2) 
of morning symptoms. In addition, regression analyses were adjusted for gender, age, 
ethnicity, body mass index, current smoking, number of exacerbations in the previous 
year, long-acting muscarinic antagonist (LAMA) use since LAMAs probably protect against 
morning symptoms[17], employment status and comorbidity measured with the CCI. Miss-
ing data were not replaced. For all analyses, a p-value of <0.05 was considered statistically 
significant. We used SPSS version 23 for the statistical analysis. 
A sensitivity analysis was performed to examine the impact of the CAT instead of mMRC 
to calculate GOLD classes A-D since previous studies reported that the use of different 
questionnaires to categorize COPD patients can significantly alter the groups.[28, 29]
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RESULTS
Patients
Of the 168 eligible patients who received the patient information letter, 80 patients agreed 
to participate. No significant differences between participants and nonparticipants were 
observed for age (mean [±SD] 65.6[±8.7] and 66.3[±8.4] years respectively, p=0.79) and 
gender (54% and 44.3% males respectively, p=0.22). No patient dropped out of the study 
(Figure 1). Table 1 shows demographics and baseline characteristics of the participants. 
Patients had an airflow obstruction with an average FEV1 of 55.1% predicted and 26% of 
the patients were current smokers. 
Morning symptoms
Morning symptoms were present in 96% (77/80) of the patients. Mean (±SD) total severity 
score for morning symptoms was 17.9(±11.7) (Table 2). The most severe symptoms in the 
morning were dyspnea, cough and sputum production. Overall, 85.0% of all included patients 
reported physical activity limitations in the morning due to morning symptoms. Morning 
symptom scores were significantly different between patients with different COPD stages: 
mean (±SD) score in GOLD A was 9.7(±7.2), B 19.8(±10.7), C 8.6(±9.3) and D 23.8(±11.2) (F 
[df] = 10.3 [79], p<0.01) (Figure 2). Post hoc analyses showed differences between groups A 
and B (p <0.01), A and D (p<0.01), B and C (p=0.013) and C and D (p<0.01). 
Figure 1 Study flow diagram
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Table 1 Baseline characteristics
Characteristic COPD patients (N = 80)
General
Age in years, mean (SD) 65.6 (8.7)
Male, n (%) 43 (54%)
Caucasian ethnicity, n (%) 79 (99%)
Current smoking, n (%) 21 (26%)
Pack years, mean (SD) 42.2 (26.8)
Patients with exacerbation(s) in previous year, n (%) 42 (53%)
In current employment n, (%) 22 (28%)
BMI in kg/m2, mean (SD) 26.3 (5.1)
Lung function (post-bronchodilator)
FEV1 %predicted, mean (SD) 55.1 (16.9)
FVC in L, mean (SD) 3.5 (1.0)
RV %predicted, mean (SD)# 143 (42)
RV/TLC, mean (SD)# 117 (24)
GOLD stage
GOLD A n, (%) 20 (25%)
GOLD B n, (%) 21 (26%)
GOLD C n, (%) 7 (9%)
GOLD D n, (%) 32 (40%)
Laboratory
Leucocytes in x109/L, mean (SD) 8.3 (2.5)
Eosinophils in x109/L, median [IQR] 0.16 [0.11-0.22]
HsCRP in mg/L, median [IQR] 2.41 [0.26-5.42]
Medication
ICS, n (%) 6 (8%)
LABA, n (%) 19 (24%)
LAMA, n (%) 60 (75%)
ICS+LABA, n (%) 50 (63%)
LABA+LAMA, n (%) 7 (9%)
Oral corticosteroids, n (%) 3 (4%)
Questionnaires
CAT total score, mean (SD) 16.5 (7.3)
mMRC  total score,  mean (SD) 2.4 (1.3)
CCI (total score), median [IQR] 2.0 [1.0-3.0]
Myocardial infarction n, (%) 5 (6%)
Cerebrovascular disease n, (%) 10 (13%)
Uncomplicated diabetes mellitus n, (%) 9 (11%)
Moderate to severe chronic kidney disease n, (%) 6 (8%)
History of solid tumor without metastasis n, (%) 15 (19%)
HADS total score, mean (SD)# 9.2 (5.7)
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Physical activity
Eight patients reported an adverse event during the study period (Supplementary table 1) 
and one patient wore the accelerometer for an insufficient time each day of the study (7.2 
to 13.7 hours a day). Ninety-four percent of the measured days from the remaining 71 
patients were included in the analysis. The median number of days analyzed per patient 
was seven. Table 3 shows outcomes derived from accelerometry. Patients walked an aver-
age of 5.754 steps a day and they spent 11.4 minutes a day in MVPA with bouts of at least 
10 minutes.
Relationship between morning symptoms and other parameters
Table 4 shows the association between baseline patient characteristics and morning symp-
tom severity. When adjusted for confounders, lower health status (estimated regression 
coefficient =1.194, 95% CI 0.923 to 1.465), higher symptomatic burden (estimated re-
Table 1 Baseline characteristics (continued)
Characteristic COPD patients (N = 80)
Depression 4.7 (3.8)
Anxiety # 4.5 (3.2)
BMI: body mass index; CAT: COPD assessment test; CCI: Charlson co-morbidity index; COPD: chronic 
obstructive pulmonary disease: FEV1, Forced expiratory volume in 1 second: FVC, forced vital capacity; 
GOLD: global initiative for obstructive lung disease; HADS: hospital anxiety and depression scale; hsCRP: 
high sensitive C-reactive protein; ICS: inhaled corticosteroids; IQR: interquartile range; LABA: long acting 
beta2 agonist; LAMA: long acting muscarinic antagonist; mMRC: modified medical research council; 
RV: residual volume; SD: standard deviation; TLC: total lung capacity. #: For some variables data were 
missing: HADS (two patients did not fill out all questions about anxiety); body plethysmography (three 
patients were not able to produce reproducibly curves and 1 patient had claustrophobia).
Table 2 Occurrence and severity of morning symptoms 
Morning symptoms  N = 80
Total score (range 0-60)#, mean (SD) 17.9 (11.7)




Chest tightness 0.0 [0.0-2.8]
Wheezing 1.0 [0.0-3.0]
Cough 3.0 [1.0-4.8]
Limitations in the morning due to COPD 4.5 [2.0-7.0]
Data are median [IQR], unless otherwise indicated. COPD: chronic obstructive pulmonary disease; IQR: 
interquartile range; SD: standard deviation. #: Morning symptom score was assessed with the PRO-
morning COPD questionnaire, ¶:Score 0 (“no symptoms”) to 10 (“most worst symptoms”).
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Figure 2 Morning symptom scores in COPD GOLD A, B, C and D groups. COPD GOLD A (N=20), B 
(N=21), C (N=7), and D (N=32). COPD: chronic obstructive pulmonary disease. GOLD: global initiative 
for chronic obstructive lung disease. a: p<0.01, b: p<0.05.
Table 3 Daily physical activity parameters derived from accelerometry
Activity parameters 467 valid days# 
from 71 patients
Inactive parameters¶
Total duration in inactive time in minutes, mean (SD) 1161 (100)
Number of periods in inactive time, mean (SD) 128 (42)
Active parameters+
Steps, mean (SD) 5754 (3553)
Total duration in active time in minutes, mean (SD) 268 (98)
Total duration in light activities in minutes, mean (SD)§ 80 (33)
Total duration in moderate activities in minutes, mean (SD)§ 88 (39)
Total duration of vigorous activities in minutes, mean (SD)§ 0.9 [0.3;6.2]
Mean active time in MVPA with bouts of at least 10 minutes, in minutes, median 
[IQR)]§
11.4 [4.4;23.1]
Mean active time in moderate activity with bouts of at least 10 minutes, in 
minutes, median [IQR]§
11.5 [4.3;22.1]
Mean active time in vigorous activity with bouts of at least 10 minutes in minutes, 
median [IQR]§
0.0 [0.0;0.0]
Number of periods in active time, mean (SD) 1858 (810)
Number of periods walking ≤10 seconds, mean (SD) 317 (139)
Number of periods walking 10-20 seconds, mean (SD) 70 (37)
Number of periods walking >20 seconds, median [IQR] 24 [15;31]
IQR: interquartile ranges; MET: metabolic equivalent task; MVPA: moderate to vigorous physical activity; 
SD: standard deviation. #: valid days were defined as accelerometry for at least 22.5 hours (94%) a day. ¶: 
Inactive: sitting and lying combined. +: Active: standing, shuffling and walking combined. §Light: 1.5-3.0 
MET, moderate: 3.0-6.0 MET, vigorous: 6.0-9.0 MET.
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gression coefficient =4.193, 95% CI 2.384 to 6.002), increased anxiety and depression and 
lower FEV1 were associated with morning symptom severity. Furthermore, physical activity 
that was objectively measured by accelerometry was associated with morning symptom 
severity: fewer steps a day (estimated regression coefficient =-0.001, 95% CI -0.002 to 
-0.000), less time in MVPA with bouts of at least 10 minutes (estimated regression coef-
ficient =-0.135, 95% CI -0.233 to -0.037) and less time in MPA with bouts of at least 10 
minutes (estimated regression coefficient =-0.192, 95% CI -0.321 to -0.064) (Table 5). 
The explained variance of all studied patient characteristics was highest for the CAT (62%)
Sensitivity analysis
When the CAT was used instead of the mMRC scale to classify COPD severity, differences 
in the morning symptom severity were still present between the different GOLD stages. 
In addition, there was also a significant difference in morning symptom severity between 
patients with COPD GOLD B and D (Supplementary figure 1). 
Table 4 Associations between  health status, dyspnea severity, anxiety and depression, airflow 
limitation, lung hyperinflation, inflammatory parameters, exacerbations and morning symp-
tom severity




95% CI p R2 Regression 
coefficient
95% CI p
CAT 0.62 1.268 1.042;1.494 <0.001 0.67 1.194 0.923;1.465 <0.001
mMRC 0.30 4.991 3.270;6.712 <0.001 0.47 4.193 2.384;6.002 <0.001
HADS¶ 0.33 1.152 0.776;1.528 <0.001 0.51 1.098 0.706;1.490 <0.001
FEV1 (% predicted)§ 0.06 -0.173 -0.325;-
0.021
0.026 0.35 -0.170 -0.324;-0.017 0.030
RV/TLC ¶,§ 0.04 0.094 -0.019;0.207 0.10 0.34 0.063 -0.050;0.176 0.27
HsCRP 0.03 0.456 -0.128;1.039 0.12 0.31 0.242 -0.319;0.804 0.39
Leucocytes 0.02 0.656 -0.383;1.695 0.21 0.31 0.217 -0.801;1.236 0.67
Eosinophils 0.06 -14.68 -28.14;-
1.231
0.033 0.32 -7.772 -20.575;5.032 0.23
At least one 
exacerbation in 
the previous 12 
months
0.07 6.302 1.239;11.37 0.015 0.30 01.112 -8.539;6.314 0.77
CI: confidence interval; CAT: COPD assessment test; FEV1: Forced expiratory volume in 1 second; HADS: 
hospital anxiety and depression scale; hsCRP: high sensitive c-reactive protein; LAMA: long-acting 
muscarinic antagonist; mMRC: modified medical research council; R2: explained variance; RV: residual 
volume; TLC: total lung capacity. #: Morning symptoms were assessed with the PRO-morning COPD 
questionnaire, ¶: For some variables data were missing: HADS (two patients did not fill out all questions 
about anxiety); body plethysmography (three patients were not able to produce reproducibly curves and 
1 patient had claustrophobia). +: Adjusted for gender, age, ethnicity, body mass index, smoking, number 
of exacerbations, LAMA use, employment and comorbidity. §: Post bronchodilator.
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DISCUSSION
In the present study morning symptom severity was assessed in COPD GOLD A, B, C and 
D patients. Furthermore, the association between patient characteristics with special focus 
on physical activity and morning symptom severity was studied. As far as we know, this is 
the first time the relationship between morning symptom severity and objective measures 
of the physical activity by triaxial accelerometry has been studied. In the present study, 
patients with overall more symptomatic COPD had significant higher morning symptom 
scores. Lower health status, higher symptomatic burden, increased anxiety and depression, 
Table 5 Associations between minutes in active and inactive time, periods in activity and inac-
tivity and morning symptom severity 




95% CI p R2 Regression 
coefficient
95% CI p
Steps 0.09 -0.001 -0.002;0.000 0.013 0.30 -0.001 -0.002;0.000 0.043
Total active time§ 0.03 -0.019 -0.047;0.009 0.18 0.25 -0.010 -0.039;0.020 0.52
Total inactive time* 0.04 0.022 -0.005;0.049 0.11 0.26 0.012 -0.018;0.041 0.43
Light activities‡ 0.001 0.011 -0.073;0.095 0.79 0.26 0.035 -0.050;0.119 0.42
Moderate activities‡ 0.08 -0.082 -0.150;-0.014 0.019 0.27 -0.052 -0.150;0.019 0.15
Vigorous activities‡ 0.03 -0.130 -0.327;0.067 0.19 0.26 -0.097 -0.306;0.112 0.36
Time in MVPA with 
bouts‡
0.13 -0.151 -0.244;-0.058 <0.001 0.33 -0.135 -0.233;-0.037 <0.001
Time in moderate 
activity with bouts‡
0.15 -0.218 -0.344;-0.092 <0.001 0.35 -0.192 -0.321;-0.064 <0.001
Time in vigorous 
activity with bouts‡
0.03 -0.170 -0.387;0.047 0.12 0.26 -0.127 -0.357;0.103 0.27
Number of periods in 
inactive time*
0.01 -0.030 -0.096;0.036 0.37 0.25 0.003 -0.069;0.076 0.92
Number of periods in 
active time§
0.04 -0.003 -0.006;0.001 0.10 0.25 -0.001 -0.004;0.003 0.71
Periods in walking 
time ≤10 seconds
0.06 -0.021 -0.040;-0.002 0.034 0.26 -0.011 -0.032;0.009 0.28
Periods in walking 
time 10-20 seconds
0.04 -0.061 -0.134;0.012 0.099 0.26 -0.028 -0.105;0.050 0.48
Periods in walking 
time >20 seconds
0.07 -0.133 -0.249;-0.017 0.026 0.29 -0.111 -0.232;0.010 0.07
CI: confidence interval; MET: metabolic equivalent task; MVPA: moderate-to-vigorous physical activity; 
R2: explained variance.#: Morning symptoms were assessed with the PRO-morning COPD questionnaire, 
¶: Data from patients with an adverse event (N=8) or patients with no valid data from accelerometry 
(N=1) were excluded. Analyses were performed on data from 71 patient. +: Adjusted for gender, age, 
ethnicity, body mass index, smoking, number of exacerbations, LAMA use, employment and comorbid-
ity §: Active: standing, shuffling and walking combined. *: Inactive: sitting and lying combined. ‡: Light: 
1.5-3.0 MET, moderate: 3.0-6.0 MET, vigorous: 6.0-9.0 MET.
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lower FEV1 and fewer steps a day and less time in moderate and vigorous physical activity 
with bouts of at least 10 minutes that was objectively measured by accelerometry were 
associated with morning symptom severity.
Morning symptom scores were higher in patients with GOLD B and D compared with 
GOLD A and C stages. However, morning symptoms were not limited to more advanced 
COPD stages and were also present in patients of group A. These results are in line with the 
first and so far only study that described the relation between the occurrence of morning 
symptoms and severity of COPD with GOLD A-D classification.[7] In that study, patterns 
of morning symptom occurrence was more associated with the GOLD A-D categorization 
compared to GOLD 1-4 classification. GOLD 1-4 classification is based only on airflow 
limitation, whereas in GOLD A-D a combination of airflow limitation, general symptoms 
and exacerbations are used to classify the patients. Previous studies have shown associa-
tions between morning symptoms and airflow limitation,[2, 30] general symptoms [2, 3] 
and COPD exacerbations in the previous 12 months.[30-32] In the current study FEV1 and 
symptoms measured with the mMRC were significantly associated with the severity of 
morning symptoms. Furthermore, unadjusted analyses showed an association between 
exacerbations in the previous 12 months and morning symptom severity. Since overall 
symptoms and exacerbations, which are included in the GOLD A-D scheme, are associ-
ated with morning symptoms, we believe that GOLD A-D relates more closer to morning 
symptoms than GOLD 1-4. The sensitivity analyses showed that the differences in morning 
symptom severity between GOLD A, B, C and D groups were independent of the symptoms 
scale that was used and no difference between mMRC and CAT was found. Overall, our 
results are supported by the finding that the occurrence of nighttime symptoms was more 
closely related to the GOLD A-D classification than the GOLD 1-4 classification.[33] 
In the present study, the occurrence of morning symptoms was higher than that reported in 
other studies. The use of a different morning symptoms questionnaire could be responsible 
for the higher occurrence in the current study.[5] The prevalence of morning symptoms 
in the present study is in line with a previous trial that studied morning symptoms in 
more than 3,000 COPD patients.[34] In that study, 94.4% of patients with moderate to 
severe COPD suffered from morning symptoms, measured with Early-Morning Symptoms 
of COPD Instrument. In the current study, the PRO-morning symptoms questionnaire was 
used. One previous randomized trial used this questionnaire and found a mean morning 
symptom severity score of 16.7.[17] The MODAS showed a slightly higher mean morning 
symptom score. This could be due to a slightly different COPD population (lower FEV1, 
fewer males, less current smokers) or the unknown variance of the morning symptom 
score. Overall, morning symptoms score are relatively low. For example, analyses on 
3,394 COPD GOLD II and III patients have shown a mean morning symptom score of 1.3 
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(minimum 0; maximum 4).[34] Furthermore, we know from previous research that patients 
underestimated their symptoms and one third of patients who describe their symptoms 
as being mild to moderate are not able to leave the house due to breathlessness.[35] We 
think that the PRO-Morning COPD Symptoms Questionnaire can be a suitable tool to 
assess morning symptoms. Nevertheless, this questionnaire needs to be validated in further 
studies. Using a validated questionnaire with cutoff scores might help to indicate whether 
a score of 17.9 could be seen as high or as low impact. 
Previous studies that reported the association between morning symptoms and physical 
activity used self-reported physical activity questionnaires to evaluate physical activity.[2, 3, 
6, 14, 30, 34, 36, 37] However, it is known that self-reported outcomes show discrepancies 
to objective measured outcomes[38] and therefore we assessed physical activity using an 
established activity monitor.[19, 39] Indeed, when analyzing the data retrieved from these 
monitors we found a relationship between objectively measured physical activity and an 
increase in morning symptom severity. More specifically, an association between fewer 
steps a day, less time in MVPA with bouts of at least 10 minutes and less time in MPA 
with bouts of at least 10 minutes and increase in morning symptom severity was found. 
Interestingly, when we do not take these bouts into account, time in MPA and MVPA was 
not associated with morning symptom severity. This means that COPD patients with higher 
morning symptom scores are able to perform physical activity of moderate and vigorous 
intensity similar to those with less severe morning symptoms, but they rarely perform this 
activity longer than 10 minutes at a time. We suggest that these patients do not perform 
activities for increased amounts of time as an adaptation to, for example, avoid symptoms 
and they are therefore not used to being active for more than 10 minutes in moderate or 
vigorous activity. For light-intensity physical activity, no association with morning symptom 
severity was found. Sufficient physical activity is important for COPD patients because the 
lack of it is associated with more exacerbations, hospitalizations, all-cause mortality[12] 
and lower quality of life.[13] These results together underline the importance of morning 
symptoms and physical activity. Together, they seem to be a new important target for 
therapy.
The association between lower health status,[2, 7, 30, 37, 40] more dyspnea,[2, 3] increased 
anxiety and depression,[2, 30, 37, 40] lower FEV1[2, 30] and morning symptoms have been 
described earlier. The association between morning symptoms and overall symptoms might 
appear to be trivial, however, previous studies have shown that symptoms can vary over 
the day and therefore more precise assessment of symptoms seems necessary. The present 
study confirms this; the CAT does not fully cover morning symptoms with an explained 
variance of 62%. Based on this, we recommend assessing morning symptoms separately 
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from general symptoms in COPD patients, especially in those with more symptomatic 
COPD.
A strength of this study is the adjustment for multiple confounders in the regression 
analysis, which was omitted in previous studies.[2, 37] Furthermore, we believe that this 
study population is representative of the COPD population since patients were recruited 
from a  variety of sources, namely a university medical center, a regional hospital and 
recruitment via flyers. This resulted in a heterogeneous COPD patient group. However, the 
exclusion of COPD GOLD I patients can be seen as a limitation. We expect that including 
COPD GOLD I patients would result in a slightly lower mean morning symptom score since 
morning symptoms are also present in mild COPD.[2] However, in this study we decided 
to focus on more symptomatic patients since it was a cross-sectional study that explored 
factors that were associated with morning symptoms. One other limitation of this study 
is that there might be selection bias, since nonparticipants were most likely patients who 
were not able to come to the study center in the morning. This might have resulted in 
an underestimation of morning symptoms in the overall COPD population. A limitation 
for the use of a MoveMonitor was the non-water resistance. For some patients, taking a 
shower is the most intensive physical activity of the day, and this has not been measured. 
This resulted in an underestimation of active time. Furthermore, patients were not blinded 
for the accelerometer. This could have resulted in increased activity since patients felt they 
were being watched and would not be categorized as “inactive.” However, patients took 
a comparable amount or fewer steps than reported in previous studies[41, 42] suggesting 
that patients in the MODAS did not adapt their lifestyle to the study. Furthermore, with 
this observational study design it is not possible to prove causality. Therefore, we are not 
able to state whether physical activity limitations is a result of morning symptoms, or if it 
is the other way around: that physical inactivity causes deconditioning which results in an 
increase of morning symptoms. 
CONCLUSION
Patients with overall more symptomatic COPD have significant higher morning symptom 
scores. Furthermore, morning symptoms were associated with important clinical outcomes: 
lower health status, more symptoms, increased anxiety and depression, fewer steps a day, 
less time in moderate and vigorous physical activity with bouts of at least 10 minutes and 
lower FEV1. This was the first study that evaluated the relation between morning symptom 
severity and objective measures of physical activity by triaxial accelerometry. Morning 
symptoms should be assessed more precisely in addition to assessment by general COPD-
specific questionnaires, especially in those with more symptomatic COPD. Therefore, there 
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is need for the validation of a morning symptom questionnaire. In addition, more research 
is needed on potential therapies to improve morning symptoms, for example with the 
improvement of (a combination of) health status, symptoms, anxiety and depression, steps 
a day, time in moderate and vigorous physical activity with bouts of at least 10 minutes 
and FEV1.
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LIST OF ABBREVIATONS
ACSM: American College of Sports Medicine 
BMI: body mass index
CAT: COPD assessment test
CCI: Charlson Co-morbidity index
COPD: Chronic obstructive pulmonary disease
ECCS: European Community for Coal and Steel
FEV1: Forced expiratory volume in 1 second
FVC: Forced vital capacity
GLI: Global Lung Function Initiative
GOLD: Global Initiative for Chronic Obstructive Lung Disease
hsCRP: high sensitive C-reactive protein
ICS: inhaled corticosteroids
IQR: interquartile ranges
LABA: long acting beta2 agonist
LAMA: long acting muscarinic antagonist
MET: metabolic equivalent task
mMRC: modified Medical Research Council
MODAS: Morning symptoms in-Depth observAtional Study
MPA: moderate physical activity




TLC: total lung capacity 
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SUPPLEMENTARY MATERIALS
Supplementary text 1
To categorise the patients, the first step was to assess the symptom burden with the 
mMRC. A low symptom burden was defined as mMRC 0 to 1; a high symptom burden as 
2 or higher. Moreover, the exacerbation risk was evaluated by airflow obstruction, number 
of exacerbations in the previous year and number of exacerbations leading to hospital 
admission in the previous year. A low risk was defined as a FEV1 ≥50% and <2 exacerba-
tions a year and no hospital admission due to exacerbation COPD; a high risk was defined 
as a FEV1 <50% or ≥2 exacerbations in the previous year or ≥1 hospital admission due to 
exacerbation COPD. Group A was defined as a low symptom burden with low risk; group 
B as high symptom burden with low risk; group C as low symptom burden with high risk 
and group D as high symptom burden with high risk. 
Supplementary table 1. Adverse events during study period
Adverse event Number of 
patients
Pain in the hand 2
Migraine plus haematuria 1
Flu 1
Pneumonia 1
Exacerbation COPD that was treated by the GP 1
Rhino-sinusitis 1
Exhausted and dyspnoeic for multiple days due to the study visit 1
Total 8
COPD: chronic obstructive pulmonary disease; GP: general practitioner. 
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Supplementary figure 1. Morning symptom scores in COPD GOLD A, B, C and D patients, categoriza-
tion with CAT. Morning symptoms scores were significant different between patients with COPD GOLD 
A 6.3 (±4.4), B 18.4 (±10.1), C 4.0 (±4.7) and D 23.6 (±11.0) (F (df) = 13.0 (79), p<0.01). COPD GOLD 
A (N=12), B (N=29), C (N=5), and D (N=34). CAT: COPD Assessment Test, COPD: chronic obstructive 
pulmonary disease, GOLD: global initiative for chronic obstructive lung disease. a: p<0.01. b:  p<0.05.
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ABSTRACT
Background: Patients with chronic obstructive pulmonary disease (COPD) experience symp-
toms that vary over the day. Symptoms at the start of the day might influence physical 
activity during the rest of the day. Therefore, physical activity during the course of the day 
was studied in patients with low and high morning symptom scores.
Methods: This cross-sectional observational study included patients with moderate to very 
severe COPD. Morning symptoms were evaluated with the PRO-morning COPD Symptoms 
Questionnaire (range 0–60); the median score was used to create two groups (low and 
high morning symptom scores). Physical activity was examined with an accelerometer. 
Activity parameters during the night, morning, afternoon and evening were compared 
between patients with low and high morning symptom scores using independent t-tests 
or Mann-Whitney U tests.
Results: Seventy nine patients were included. Patients were aged (mean ± SD) 65.6 ± 8.8 
years with a mean forced expiratory volume in 1 s of 55 ± 17%predicted. Patients with low 
morning symptom scores (score < 17.0) took more steps in the afternoon (p = 0.015) and 
morning (p = 0.030). There were no significant differences during the evening and night.
Conclusion: Patients with high morning symptom scores took significantly fewer steps in 
the morning and afternoon than those with low morning symptom scores. Prospective 
studies are needed to prove causality between morning symptoms and physical activity 
during different parts of the day.
Keywords: Afternoon, Chronic obstructive pulmonary disease, Evening, Physical activity, 
Morning, Morning symptoms
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BACKGROUND
Chronic obstructive pulmonary disease (COPD) is a worldwide problem with a high 
prevalence of years lived with disability [1]. COPD is associated with dyspnoea, fatigue 
and decreased physical activity. Regular physical activity in patients with COPD is associ-
ated with a lower risk of admissions and mortality [2]. Most previous studies reported on 
physical activity during day time solely [3–6]. When physical activity was measured over the 
course of the day, nuanced reporting on physical activity during different parts of the day 
was generally lacking [7–10]. Therefore, only little is known about physical activity in COPD 
patients during the night and early morning. Studying physical activity during the course 
of the day is important, because a symptomatic start to the day might influence physical 
activity during the rest of the day. 
Patients with COPD experience the morning as most symptomatic part of the day [11, 12] 
and the night as second most symptomatic part of the day [12]. Studies have shown that 
morning symptoms are negatively associated with self-reported physical activity [13]. A 
negative association between morning symptoms and overall physical activity has been 
reported [14]. However, the relation between morning symptoms and objectively mea-
sured physical activity during different parts of the day has not been studied yet. From 
previous research it is known that morning symptoms influence self-care, housework and 
work activities [15]. We hypothesized that patients with high morning symptom scores are 
less active in the morning and during the rest of the day compared to patients with low 
morning symptom scores. Furthermore, detailed assessments of physical activity over the 
day could give insight which part might be most suitable for physical activity interventions. 
Therefore, the primary aim of this study was to examine physical activity during the course 
of the day depending on morning symptoms. In addition, self-reported physical activity 
was assessed to better understand which types of activities were generally undertaken.
METHODS
Research design
The Morning symptoms in-Depth observAtional Study (MODAS) was a single centre, obser-
vational, cross-sectional study (study NL51951.058.15; www.toetsingonline.nl). The study 
was conducted from September 2015 to February 2017. The medical ethics committee 
from the Leiden University Medical Center (LUMC) approved the study protocol.
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Participants
Detailed inclusion/exclusion criteria have been reported previously [14]. In summary, 
included in the study were patients aged 40 to 80 years. A physician had diagnosed 
them with COPD. They had moderate to very severe airflow limitation according to the 
Global initiative for Obstructive Lung Disease (GOLD) definitions [16]. Patients were 
exacerbation-free for at least 2 months. They were current or active smokers with at least 
10 pack-years. Main exclusion criteria were the diagnosis of asthma; significant other lung 
disease, comorbidities and severe pain syndromes that impair exercise capacity. Patients 
were recruited from the LUMC and Alrijne hospital in Leiden (The Netherlands). Patients 
who were considered to be eligible were notified about the study by telephone or during 
an outpatient visit. Furthermore, patients were recruited by flyers in local papers. Eligible 
interested patients received an information letter. If the patient agreed to participate in the 
study, a study visit was scheduled. During the visit, written informed consent was obtained.
Assessments
During the baseline visit, demographic data and comorbidities were obtained by a physician. 
Patients were asked about their medication use and this was verified with a medication 
overview of the pharmacy. COPD specific health-related quality-of-life, morning symptoms 
severity, self-reported physical activity and pre- and post-bronchodilator pulmonary func-
tion were assessed at the study center. After this visit, patients wore a triaxial accelerometer 
for seven consecutive days to objectively assess physical activity. When the physical activity 
measurements were finished, there was a follow-up telephone interview to report possible 
adverse events. 
Morning symptom severity was evaluated with the PRO-Morning COPD Symptoms Ques-
tionnaire (pre-morning doses assessment) [17]. This questionnaire consists of six questions 
about dyspnoea, cough, sputum production, wheezing, chest tightness and limitations in 
the morning. Patients rated the severity of these symptoms with a Likert scale from 0 to 10 
points. 0 for no symptoms; 10 points for symptoms as bad as they can imagine. The total 
score ranged from 0 to 60. 
Physical activity was objectively measured with an accelerometer (Dynaport MoveMonitor, 
McRoberts BV, The Hague, the Netherlands) [18, 19]. This accelerometer was worn on the 
waist during the entire day for seven consecutive days resulting in real-life activity record-
ing. To give insight into physical activity over the course of the day, days were divided in 
four parts of the day of each 6 hours: night (00.00 to 06.00), morning (06.00 to 12.00), 
afternoon (12.00 to 18.00) and evening (18.00 to 00.00). Duration of activity (stand-
ing, shuffling and walking) and inactivity (sitting and lying) in minutes was registered. 
The number of steps was recorded per part of the day and per hour. Patients were not 
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allowed to wear the accelerometer during bathing or showering. The duration that the 
accelerometer was not worn was automatically registered. A measurement was considered 
valid when patients wore the accelerometer at least 90% per part of the day. Averages of 
the outcomes of valid parts of the day were calculated for each patient. Patients with only 
invalid parts of the day were excluded from analysis.
Patients filled out the Dutch version of the international physically activity questionnaire 
(IPAQ) [20]. In this questionnaire patients reported the number of minutes per day and days 
per week they were physical active in a 7-day period. Physical activity was categorized in 
four domains: work, transport, housework or leisure time related. Patients who reported 
more than 960 min a day each day of the week were excluded from this analysis in line 
with the activity calculation instructions of the IPAQ. 
The Charlson Co-morbidity index was used to evaluate comorbidities (CCI) [21] and the 
three most common comorbidities were reported as percentage. COPD-specific health-
related quality-of-life was assessed with the St George’s Respiratory Questionnaire (SGRQ), 
[22] health status with the Clinical COPD Questionnaire (CCQ) [23] and dyspnoea in daily 
living with the medical modified research council (mMRC) [24]. All patients performed 
pre and post-bronchodilator spirometry following ERS/ATS (European Respiratory Society/
American Thoracic Society) standards in the morning between 08.30 and 11.00 (Care 
Fusion, Masterscreen PFT). [25–27] In this study, reported spirometry outcomes were post-
bronchodilator values. Forced volume in 1 second (FEV1) was expressed in % predicted 
values (based on the Global Lung Function Initiative 2012) [26].
Statistical analysis
Descriptive data were reported as percentages, mean values ± standard deviations (SD) 
for normal distributed continuous variables and median with interquartile ranges (IQR) for 
non-normal distributed continuous variables. The study cohort was divided in two equal 
groups using the median score on the PRO-morning COPD Symptoms Questionnaire as 
cut-off. Differences in baseline characteristics between the two groups were compared 
with an independent t-test for continuous normal distributed variables; a Mann-Whitney 
U test for continuous non-normal distributed variables and chi-square test for categorical 
variables. 
Differences in steps during the total day were compared between patients with low and 
high morning symptom scores using an independent t-test. Difference in steps and dura-
tion of (in)activity during different parts of the day were compared using an independent 
t-test or Mann-Whitney U test. To give an overview of the number of steps over the course 
of the day, steps per hour were plotted against hour of the day. Self-reported physical 
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activity was compared using a Mann-Whitney U test. An explorative subgroup analysis 
was performed to examine longacting pulmonary medication use. Long-acting pulmonary 
medication use was categorized in three groups: double bronchodilation (combination of a 
long-acting beta2 agonist (LABA) and long-acting muscarinic antagonist (LAMA)), a single 
bronchodilator (LABA or LAMA use) or no use of long-acting pulmonary medication. The 
difference in mean number of steps in the morning was evaluated with a one way ANOVA. 
Steps per hour were plotted against hour of the day for patients with low and high dyspnoea 
scores in daily living [16] to evaluate the impact of using a general symptom questionnaire 
instead of a specific morning symptom questionnaire to divide the study group. 
A sensitivity analysis was performed to evaluate the impact of adverse events during the 
study period; all patients who reported an adverse events, defined as self-reported illness 
or any somatic symptom for which the patient had to visit a health care provider, were 
excluded from the analyses. 
For all analyses, a p-value of < 0.05 was considered statistically significant. Missing data 
was not replaced. We used SPSS version 23 to perform the analyses. 
RESULTS
Patients
From 168 eligible patients who received the patient information form, 80 patients were 
included in the study and 79 patients had sufficient outcomes from accelerometry for 
analyses (Figure 1). Table 1 shows demographics and baseline characteristics. Patients were 
(mean ± SD) 65.6 ± 8.8 years old and 53% were male. They had a mean FEV1 of 55 ± 17% 
predicted. Most patients were classified as COPD GOLD D (40.5%) and B (27.8%). Mean 
morning symptom score was 17.9 ± 11.8 with a range between 0 and 47. The median 
morning symptom score was 17.0 and was used as cut-off to separate the study cohort in 
two equal groups (Table 1).
Physical activity
Seventy nine patients wore the accelerometer 7 consecutive days. Thus, data from 553 
days were collected from these 79 patients. 95.8% of the night, 91.0% of the morn-
ing, 96.7% of the afternoon and 93.9% the evening measurements fulfilled the quality 
standards and were included in the analysis. In each part of the day, most of the time was 
spent in inactivity (Table 2). 
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Mean number of steps per day was (mean ± SD) 5686 ± 3514. Patients with low morning 
symptom scores took 6598 ± 4243 steps a day; those with high morning symptom scores 
4727 ± 2209 steps a day (mean difference 1871, p = 0.017). Patients with high morning 
symptom scores took significantly fewer steps during the morning (mean difference 669, 
p = 0.030) and during the afternoon (mean difference 1013, p = 0.015) than patients 
with low morning symptom scores (Table 3). Patients with low morning symptom scores 
were active for longer during the afternoon (mean difference 19, p = 0.040) and spent 
more minutes walking during the morning (mean difference 8, p = 0.020) and afternoon 
(mean difference 11, p = 0.010). There were peaks in mean number of steps at 15:00 
(550 steps per hour) and at 12:00 (535 steps per hour) (Figure 2). When patients with 
low and high morning symptom scores were categorized on medication use, there was no 
significant difference in mean number of steps in the morning between the groups (p = 
0.057) (Supplementary materials: Figure S1). When patients were categorized on high and 
low mMRC score, there was a significant difference in number of steps in the morning, 
afternoon and evening (Supplementary materials : Figure S2).
Figure 1 Study flow diagram
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Self-reported daily activities
Patients’ median [IQR] self-reported physical activity was 715 [319;1448] minutes a week. 
Patients spent most of their self-reported physical activity during leisure time (Table 4). 
Patients with low morning symptom scores spent significantly more time in transport and 
Table 1 Baseline characteristics









Age in years, mean (SD) 65.6 (8.8) 66.4 (8.2) 64.7 (9.4) 0.38
Male, n (%) 42 (53) 25 (61) 17 (45) 0.15
Ethnicity Caucasian, n (%) 78 (99) 40 (98) 38 (100) 0.33
Current smoking, n (%) 21 (27) 8 (20) 13 (34) 0.14
Pack years, median [IQR] 37 [25-51] 34 [25-42] 41 [26-71] 0.06
In current employment, n (%) 21 (27) 12 (29) 9 (24) 0.58
BMI in kg/m2, mean (SD) 26.4 (5.1) 25.5 (4.8) 27.3 (5.3) 0.13
FEV1/FVC ratio, mean (SD) 45.5 (12.2) 45.6 (13.6) 45.5 (10.6) 0.99
FEV1 % predicted, mean (SD) 55.2 (16.9) 57.2 (19.3) 53.0 (14.0) 0.28
Exacerbation in the previous 
year, n (%)
41 (52) 16 (39) 25 (66) 0.017
GOLD stage
A, n (%) 19 (24.1) 17 (41.5) 2 (5.3) <0.001
B, n (%) 22 (27.8) 9 (22.0) 13 (34.2) 0.23
C, n (%) 6 (7.6) 6 (14.6) 0 (0.0) 0.014
D, n (%) 32 (40.5) 9 (22.0) 23 (60.5) <0.001
CCQ total score, mean (SD) 2.1 (1.1) 1.4 (0.86) 2.8 (0.9) <0.001
SGRQ total score, mean (SD) 43.0 (18.6) 32.1 (16.6) 54.8 (12.4) <0.001
Long-acting bronchodilation
Use of one long-acting 
bronchodilator, n (%)
17 (21.5) 10 (24.4) 7 (18.4) 0.52
Use of two long-acting 
bronchodilators, n (%))
58 (74.7) 28 (68.3) 31 (81.6) 0.18
No long-acting 
bronchodilator, n (%)
3 (3.8) 3 (7.3) 0 (0.0) 0.09
CCI score, median [IQR] 2 [1-3] 2 [1-3] 2 [1-3] 0.98
History of solid tumor without 
metastasis, n (%)
15 (19.0) 9 (22.0) 6 (15.8) 0.49
Cerebrovascular disease, n (%) 10 (12.7) 6 (14.6) 4 (10.5) 0.58
Uncomplicated diabetes 
mellitus, n (%)
9 (11.4) 3 (7.3) 6 (15.8) 0.24
BMI: body mass index; CCI: Charlson comorbidity index; CCQ: clinical COPD questionnaire; FEV1: Forced 
expiratory volume in 1 second; FVC: forced vital capacity; GOLD: global initiative for chronic obstructive 
lung disease; IQR: interquartile range; SD: standard deviation; SGRQ: St George Respiratory Question-
naire
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Table 2 Duration of different types of activity during the morning, afternoon, evening and 
night (N=79)
Activity Total duration in mean min (SD)
Morning Afternoon Evening Night
Active time# 85.5 (39.7) 112.4 (42.3) 57.2 (34.1) 8.8 (10.1)
Standing 54.9 (25.4) 67.8 (25.5) 38.7 (25.9) 6.1 (7.4)
Shuffling 8.7 (5.4) 11.6 (6.7) 5.2 (4.1) 0.8 (1.0)
Walking 22.0 (15.1) 33.0 (20.0) 13.2 (9.8) 1.9 (2.4)
Inactive time¶ 271.6 (39.7) 246.7 (42.0) 302.0 (34.1) 351.1 (10.1)
Lying 150.6 (63.9) 42.9 (45.8) 105.7 (78.5) 327.3 (51.2)
Sitting 120.9 (44.7) 203.8 (45.6) 196.3 (72.4) 23.8 (43.3)
Not worn 2.9 (4.7) 1.0 (1.8) 0.9 (2.2) 0.2 (0.7)
SD: standard deviation. #: Active: standing, shuffling and walking combined; ¶: inactive: lying and sitting 
combined. 
leisure time activities than those with high morning symptom scores. No significant differ-
ences were found for work, housework activities and total activity.
Figure 2 Steps during each hour of the day. Low morning symptom score: score <17.0; high morning 
symptom score: score ≥17.0.
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Sensitivity analysis
Seven patients reported an adverse event. One patient was exhausted due to the study 
visit, two patients reported pain in their hands, one had pneumonia, one had flu, one had 
Table 3 Differences in duration of activity during the night, morning, afternoon and evening 
between COPD patients with low and high morning symptom scores





Steps Night 97 [50-173] 92 [50-138] 0.60
Morning 2117 (1552) 1448 (1069) 0.030
Afternoon 3196 (2352) 2183 (1025) 0.015
Evening 1145 (858) 943 (861) 0.30
Active time (in minutes, mean 
(SD) or median [IQR])
Night 6 [2-11] 6 [3-10] 0.76
Morning 91 (39) 79 (40) 0.18
Afternoon 122 (45) 102 (38) 0.040
Evening 52 [37-79] 42 [33-77] 0.19
Standing (in minutes, mean 
(SD) or median [IQR])
Night 3 [1;7] 4 [2;8] 0.62
Morning 56 (24) 53 (28) 0.61
Afternoon 71 (25) 64 (26) 0.23
Evening 40 (24) 37 (28) 0.59
Shuffling (in minutes, mean 
(SD) or median [IQR])
Night 0 [0;1] 1 [0;1] 0.77
Morning 9 (6) 8 (5) 0.33
Afternoon 12 (7) 11 (6) 0.44
Evening 5 [2;8] 4 [2;6] 0.32
Walking (in minutes, mean (SD) 
or median [IQR])
Night 13 [7-19] 9 [6-15] 0.11
Morning 26 (17) 18 (12) 0.020
Afternoon 38 (24) 27 (12) 0.010
Evening 15 (10) 12 (10) 0.23
Inactive time (in minutes, mean 
(SD) or median [IQR])
Night 354 [349-358] 354 [350-357] 0.88
Morning 265 (40) 278 (39) 0.14
Afternoon 238 (44) 257 (37) 0.043
Evening 299 (33) 305 (36) 0.41
Lying (in minutes, mean (SD) or 
median [IQR])
Night 343 [322-353] 343 [330-355] 0.89
Morning 140 (52) 161 (74) 0.15
Afternoon 27 [5-50] 34 [12-68] 0.14
Evening 90 [44-138] 83 [53-151] 0.71
Sitting (in minutes, mean (SD) 
or median [IQR])
Night 9 [3-22] 10 [2-22] 0.74
Morning 125 (38) 117 (51) 0.45
Afternoon 203 (41) 205 (51) 0.85
Evening 198 (68) 195 (78) 0.86
COPD: chronic obstructive pulmonary disease; IQR: interquartile range; SD: standard deviation.
Night N=78, morning N=78, afternoon N=79, evening N=78. 
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sinusitis and one patient reported a visit to her general practitioner who prescribed a course 
of antibiotics and prednisone for pulmonary complaints. There were no serious adverse 
events. Patients with adverse events have a significant lower quality of life and reported 
higher morning symptom scores (Supplementary materials: Table S1). When excluding 
the patients with an adverse event from analyses, the cut-off on the PRO-morning COPD 
Symptoms Questionnaire to divide the cohort in two equal groups decreased to 15.0, since 
all patients with an adverse event were categorized in the high morning symptom score 
group. Results were nearly similar (Supplementary materials: Table S2 and S3 and Figure 
S3) apart from that there was no difference anymore in number of steps in the morning 
between patients with low and high morning symptom scores.
DISCUSSION
This study was designed to evaluate physical activity during the course of the day in patients 
with moderate to severe COPD with low and high morning symptom scores. This is one of 
the first studies that explored physical activity in more detail during the course of the day 
using objective methodology. We showed that patients with high morning symptom scores 
took significantly fewer steps in the morning and afternoon than those with low morning 
symptom scores. There were no differences in physical activity in the evening and night 
between these two groups. Patients with high morning symptom scores spent less time in 
transport and leisure time than patients with low morning symptom scores. 









Work, in minutes/week, median 
[IQR]
0 [0;0] 0 [0;30] 0 [0;0] 0.13




195 [53-514] 68 [0-270] 0.047
Housework, house maintenance and 




105 [0-495] 150 [0-698] 0.89




293 [15-604] 60 [0-263] 0.017




935 [533-1808] 665 [131-1298] 0.13
IPAQ: international physical activity questionnaire; IQR: interquartile range. #: 9 out of 79 patients were 
excluded: 6 patients did not fully complete the IPAQ; 3 patients filled out unreasonably high time in 
physical activity (more than 960 minutes a day each day of the week). 
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The present study showed that patients with high morning symptom scores took fewer 
steps during the total day. This is in line with previous studies that have shown that daily 
symptoms were associated with lower physical activity levels [10]. One study in a primary 
care setting in men who are aged between 71 and 92 years, of whom 50% had chronic 
conditions, [28] reported that men were most active in the morning, followed by a sub-
stantial decline in steps per hour, with peaks at times 10:00, 14:00 and 22:00. Our study 
showed that the afternoon is the most active part of the day for patients with COPD with 
peaks in steps per hour at times 12:00 and 15:00. Thus, patients with COPD have different 
activity patterns during the course of the day. These findings are in line with another 
study of activity in COPD patients; this study showed the highest activity levels during the 
late morning and early afternoon, followed by a decline in activity [5]. The difference in 
activity patterns between older men and COPD patients could possibly be explained by 
known activity characteristics that are typical for COPD patients: lower walking speed, [29] 
walking with increased duration in time between steps, [30] doing activities slower, [12] 
taking more breaks, [12] performing daily activities in fewer bouts [4] and shorter bouts [4]. 
When analysing the activity patterns in a more detailed way, the present study showed 
that patients with high morning symptom scores were less active during the morning 
and afternoon than patients with low morning symptom scores. Systematic reviews have 
shown that multiple determinants have impact on physical activity [31] and that morning 
symptoms are associated with physical activity [13]. The etiology of morning symptoms is 
unknown. It can be speculated that inactivity in the afternoon in patients with high morn-
ing symptom scores could be due to the long-lasting effects of morning symptoms. It could 
also be true that patients with morning symptoms have more symptoms during the rest of 
the day [32]. Interestingly, we found no difference in active time during the evening and 
night between patients with low and high morning symptom scores. We did not expect 
this, because we expected that morning symptoms would be associated with less physical 
activity during each part of the day as patients reported in previous studies in which physi-
cal activity was not objectively measured [15, 33]. Exploring the assumption that morning 
symptoms influence physical activity in the morning, but not in the evening, the evening 
might be a suitable part of the day in which physical activity could be enhanced, especially 
in those with high morning symptom scores. 
In line with previous research, the present study showed that patients spent most of their 
self-reported physical activity in leisure time [4]. Patients with high morning symptom scores 
spent less time in transport and leisure time activities than patients with low morning 
symptom scores. Encouraging physical activity in leisure time might result in more physical 
activity and can also increase quality of life [34]. A few previous studies have shown that 
inhaled medication decreased physical activity limitations due to morning symptoms [15, 
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35, 36]. An explorative analysis in the present study showed no differences in physical 
activity between no, single or double long-acting bronchodilator use. However, this study 
was not powered to show differences in medication use and future research regarding this 
topic is warranted. 
A strength of the current study was 24-h a day accelerometry. This resulted in real-life 
activity recording without missing physical activity during the evening and the night. How-
ever, we did not have information regarding the time patients go to bed and woke up. 
Consequently, patients who got out of bed early in the morning (and were already awake 
for a couple of hours), were compared with patients who had only just awoken. Previous 
studies that assessed the association between morning symptoms and physical activity 
used self-reported questionnaires, while accelerometers are superior in physical activity 
assessment than questionnaires [13, 37]. Another strength was the inclusion of patients 
from an academic medical center, a local hospital and patients recruited by flyers in local 
papers. This resulted in a heterogeneous population that is generalizable to all patients 
with moderate to very severe COPD. A limitation of the study was that the accelerometer 
was not waterproof and patients were not allowed to wear it while taking a shower. For 
some patients, taking a shower is one of the main physical activities during a day, and 
this activity was not measured. This means, active time was underestimated. A second 
limitation is that morning symptoms were evaluated with a non-validated questionnaire. 
However, there is no validated morning symptom questionnaire available yet. Patients filled 
in the questionnaire at the study center and not at home at the time they woke up. This 
might have result in recall bias that might cause higher (or lower) total morning symptom 
scores. The mean morning symptom score was slightly higher than in a previous study that 
used the PRO-Morning COPD Symptoms Questionnaire too [17]. Therefore, it could be 
possible that the cut-off point to separate high from low morning symptom scores was too 
high. However, when patients with an AE were removed and the cut-off point dropped to 
15.0, the outcomes were nearly the same. Another limitation is the observational design 
of the study. Therefore, it is not possible to prove whether morning symptoms are fully 
responsible for the differences in physical activity or that physical inactivity itself resulted in 
more symptoms due to muscle depletion and loss of physical condition. 
The ERS reported in the physical activity statement in COPD that there are only a few 
randomised controlled trials that studied effects of treatment on physical activity and 
that there is a need for additional well-designed trials [29]. Taking the outcomes of this 
study into account, we suggest for future research to focus on two targets to improve 
physical activity: first, study the etiology of morning symptoms. It would be valuable to 
measure night time symptoms, the effect of flow-limitation during the night (and the early 
morning) and the effects of spreading physical activity in relation to morning symptoms. 
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Improvement in morning symptoms consequently might increase the number of steps in 
the morning and afternoon. Second, develop activity programs that encourage physical 
activity in the evening in addition to daily physical activities. Physical activity programs can 
be supported by telecoaching and step counters that provide direct feedback [3].
CONCLUSION
This study showed that patients with moderate to very severe COPD were most active in 
the afternoon. Patients with high morning symptom scores took significantly fewer steps 
in the morning and afternoon than those with low morning symptom scores. Prospective 
studies are needed to prove causality between morning symptoms and physical activity 
during different parts of the day.
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LIST OF ABBREVIATIONS
ATS: American Thoracic Society
BMI: body mass index
CCI: Charlson Co-morbidity index
CCQ: clinical COPD questionnaire
COPD: Chronic obstructive pulmonary disease
ERS: European Respiratory Society
FEV1: Forced expiratory volume in 1 second
FVC: forced vital capacity
GOLD: Global Initiative for Chronic Obstructive Lung Disease
IPAQ: international physical activity questionnaire
IQR: interquartile ranges
LABA: long-acting beta2 agonist
LAMA: long-acting muscarinic antagonist
LUMC: Leiden University Medical Center
mMRC: modified medical research council
MODAS: Morning symptoms in-Depth observAtional Study
SD: standard deviation
SGRQ: St George’s Respiratory Questionnaire
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SUPPLEMENTARY MATERIALS
Supplementary figure 1. Number of steps in the morning. Error bare present 95% confidence inter-
vals. Low morning symptom score: score <17.0; high morning symptom score: score ≥17.0.
Supplementary figure 2. Steps during each hour of the day. Low mMRC <2 (N=27); high mMRC ≥2 
(N=52).
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Supplementary figure 3. Steps during the course of the day. Low morning symptom score <15.0; high 
morning symptom score ≥15.0
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Supplementary table 1 Baseline characteristics for patients with and without an adverse event
Characteristic All included 







Age in years, mean (SD) 65.6 (8.8) 69.4 (7.2) 65.2 (8.9) 0.23
Male, n (%) 42 (53) 4 (57) 38 (53) 0.83
Ethnicity Caucasian, n (%) 78 (99) 7 (100) 71 (99) 0.75
Current smoking, n (%) 21 (27) 1 (14) 20 (28) 0.44
Pack years, mean (SD) 37 [25-51] 51 [30-
110]
35 [25-50] 0.10
In current employment, n (%) 21 (27) 0 (0) 21 (29) 0.10
BMI in kg/m2, mean (SD) 26.4 (5.1) 30.5 (8.6) 26.0 (4.5) 0.22
FEV1/FVC ratio, mean (SD) 45.5 (12.2) 47.9 (6.6) 45.3 (12.6) 0.60
FEV1 % predicted, mean (SD) 55.2 (16.9) 60.6 (9.5) 54.6 (17.5) 0.38
Exacerbation in the previous year, 
n (%)
41 (52) 6 (85.7) 35 (48.6) 0.06
GOLD stage
A, n (%) 19 (24.1) 0 (0.0) 19 (26.4) 0.12
B, n (%) 22 (27.8) 2 (28.6) 20 (27.8) 0.96
C, n (%) 6 (7.6) 0 (0.0) 6 (8.3) 0.43
D, n (%) 32 (40.5) 5 (71.4) 27 (37.5) 0.08
CCQ total score, mean (SD) 2.1 (1.1) 3.0 (0.7) 2.0 (1.1) 0.029
SGRQ total score, mean (SD) 43.0 (18.6) 59.1 (11.5) 41.4 (18.4) 0.015
Long-acting bronchodilation
Use of one long-acting 
bronchodilator, n (%)
17 (21.5) 1 (14.3) 16 (22.2) 0.63
Use of two long-acting 
bronchodilators, n (%))
59 (74.7) 6 (85.7) 53 (73.6) 0.48
No long-acting bronchodilator, 
n (%)
3 (3.9) 0 (0.0) 3 (4.2) 0.58
CCI score, median [IQR] 2 [1;3] 2 [1;2] 2 [1;3] 0.91
History of solid tumor without 
metastasis, n (%)
15 (19.0) 0 (0.0) 15 (20.8) 0.18
Cerebrovascular disease, n (%) 10 (12.7) 0 (0.0) 10 (13.9) 0.29
Uncomplicated diabetes mellitus, 
n (%)
9 (11.4) 3 (42.9) 6 (8.3) 0.006
Morning symptom score, mean (SD) 17.9 (11.8) 29.3 (5.7) 16.8 (11.7) <0.001
AE: adverse event; BMI: body mass index; CCQ: clinical COPD questionnaire; CCI: Charlson co-morbidity 
index; FEV1: Forced expiratory volume in 1 second; FVC: forced vital capacity; IQR: interquartile range; 
SD: standard deviation, SGRQ: St George Respiratory Questionnaire
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Supplementary table 2 Differences in activity during the night, morning, afternoon and eve-
ning between patient with low and high morning symptom scores, N=72






Steps Night 89 [50;181] 91 [41;143] 0.47
Morning 2122 (1624) 1609 (1071) 0.12
Afternoon 3309 (2449) 2186 (990) 0.013
Evening 1182 (893) 883 (652) 0.11
Active time (in minutes, 
mean (SD) or median [IQR])
Night 6 [2;11] 5 [3;11] 0.85
Morning 92 (39) 85 (39) 0.44
Afternoon 125 (45) 103 (37) 0.023
Evening 55 [34;80] 46 [33;76] 0.21
Standing (in minutes, mean 
(SD) or median [IQR])
Night 3 [1;8] 3 [2;7] 0.66
Morning 57 (23) 57 (28) 0.97
Afternoon 72 (24) 65 (26) 0.21
Evening 42 (25) 39 (29) 0.63
Shuffling (in minutes, mean 
(SD) or median [IQR])
Night 0 [0;1] 0 [0;1] 0.80
Morning 9 (6) 8 (5) 0.37
Afternoon 13 (7) 10 (5) 0.11
Evening 5 [2;8] 4 [2;6] 0.31
Walking (in minutes, mean 
(SD) or median [IQR])
Night 13 [7;20] 10 [6;15] 0.15
Morning 26 (17) 20 (12) 0.11
Afternoon 40 (25) 27 (11) 0.008
Evening 15 (10) 11 (8) 0.11
Inactive time (in minutes, 
mean (SD) or median [IQR])
Night 354 [349;358] 354 [349;357] 0.88
Morning 264 (40) 273 (38) 0.36
Afternoon 234 (45) 256 (37) 0.023
Evening 297 (34) 304 (36) 0.40
Lying (in minutes, mean (SD) 
or median [IQR])
Night 343 [317;353] 342 [331;355] 0.75
Morning 140 (53) 154 (68) 0.31
Afternoon 27 [7;48] 44 [12;84] 0.08
Evening 79 [43;134] 100 [51;196] 0.35
Sitting (in minutes, mean 
(SD) or median [IQR])
Night 9 [3;31] 10 [2;16] 0.54
Morning 125 (40) 119 (46) 0.56
Afternoon 200 (40) 200 (49) 0.95
Evening 200 (66) 187 (81) 0.45
Night N=71, morning N=71, afternoon N=72, evening N=71. IQR: interquartile range; SD: standard 
deviation.
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Supplementary table 3 Daily physical activity
IPAQ Total 
(N=64)*






Work, in minutes/week, median 
[IQR]
0 [0;0] 0 [0;30] 0 [0;0] 0.31
Transport, in minutes/week, median 
[IQR]
155 [5;326] 210 [30;525] 60 [0;240] 0.015
Housework, house maintenance and 
caring for family, in minutes/week, 
median [IQR]
120 [0;653] 180 [0;540] 120 [0;780] 0.67
Recreation, sport and leisure time in 
minutes/week, median [IQR]
180 [0;465] 345 [20;615] 60 [0;285] 0.035




990 [600;1920] 540 [90;1285] 0.047
IPAQ: international physical activity questionnaire; IQR: interquartile range. *5 patients did not fully com-
plete the IPAQ; 3 patients filled out unreasonably high time in physical activity (more than 960 minutes 
a day each day of the week).
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ABSTRACT
Background: Physical inactivity is a characteristic of chronic obstructive pulmonary disease 
(COPD) and has so far especially been studied in more advanced COPD. Yet, inconsistent 
findings were reported about determinants of physical activity including COPD treatment. 
Further understanding of physical activity in non-severe COPD could lead to interventions 
that increase physical activity. Therefore, the aim of this study was to explore patient 
characteristics that are related with physical activity in COPD Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) stage 0-2. 
Methods: The study presents a cross-sectional analysis of baseline data of patients with 
physician diagnosed (N=77) and newly diagnosed (N=246) COPD GOLD 0-2 that were 
selected from the population-based Netherlands Epidemiology of Obesity study. Physical 
activity was reported using the Short Questionnaire to Assess Health-Enhancing Physical 
Activity (SQUASH) questionnaire and reported in hours per week of metabolic equivalents 
(MET-h/week). Associations between characteristics and physical activity were examined 
using regression analysis, adjusted for age and gender and weighted for body mass index. 
Results: Weighted median [IQR] reported physical activity was 31 [15-46] MET-h/week. In 
newly diagnosed patients, forced expiratory volume in one second (FEV1) (0.4 MET-h/week 
per percent FEV1, 95%CI 0.1,0.8) and forced vital capacity (FVC) (0.4 MET-h/week per 
percent FVC, 95%CI 0.1,0.7) were positively associated with physical activity. The presence 
of long-acting muscarinic antagonists (LAMA) and a combination of inhaled corticosteroids 
(ICS)/long-acting beta2 agonists(LABA)/LAMA were associated with less physical activity in 
newly diagnosed COPD. 
Conclusions: Intervention studies are needed to determine whether early pharmacological 
interventions and/or physical activity slow down COPD progression in non-severe COPD.
Keywords: General population, physical activity, chronic obstructive pulmonary disease, 
pulmonary function
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BACKGROUND
Physical inactivity is a common worldwide problem and is especially observed in patients 
with chronic diseases such as chronic obstructive pulmonary disease (COPD).[1] Only 26% 
to 30% of patients with COPD were reported to fulfil the World Health Organisation 
physical activity recommendations compared to 54% among apparently healthy adults.[1] 
Inactivity in COPD is associated with more hospitalizations and mortality.[2] The European 
Respiratory Society statement of physical activity in COPD recommends sufficient physical 
activity in COPD.[3] However, it is incompletely understood why patients with COPD are 
inactive. One possibility is that patients are inactive because they try to avoid worsening 
of COPD symptoms. Increased symptoms and dynamic hyperinflation during exercise can 
be observed in patients with mild COPD.[4] The decline in physical activity already starts in 
mild disease stages, even before the physician diagnosis of COPD is made.[5-8]
Defining patient characteristics that are associated with physical inactivity is important for 
the development of targeted interventions. Multiple characteristics have been reported to 
be related to physical activity in COPD[3], but the role of most characteristics is unclear 
and inconsistent findings have been reported.[9] Dyspnoea, quality of life and previous 
exacerbations are consistently associated with physical inactivity in COPD.[9] However, 
these characteristics together do not fully explain the lack of physical activity in COPD. 
In addition, in most previous studies regarding physical activity, only half of patients were 
non-severe COPD patients,[6, 8, 10-13] or the mean forced expiratory volume in one sec-
ond (FEV1) was lower than 50%.[14-20] Studies that included only non-severe COPD are 
sparse.[5, 7] However, especially in this patient population there appears to be most room 
for improvement. Therefore, better knowledge of the characteristics that are related with 
physical activity in COPD Global Initiative for Chronic Obstructive Lung Diseases (GOLD) 
0, 1 and 2 patients is needed. The aim of the present study was to explore physical activ-
ity and patient characteristics that were associated with physical activity in patients with 
COPD GOLD 0, 1 and 2. The focus was on patient characteristics of which inconsistent 
effects were described in previous studies.
METHODS
Study design
Cross-sectional analyses of baseline data from the Netherlands Epidemiology of Obesity 
(NEO) study are presented. The NEO study is a population-based prospective cohort study, 
with an oversampling of individuals with a body mass index (BMI) of 27kg/m2. From 2008 
to 2012 6,671 participants were included in the NEO study. The study design and popula-
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tion are described in detail elsewhere.[21] Briefly, men and women, aged between 45 and 
65 years with a self-reported BMI of 27kg/m2 or higher, living in the greater area of Leiden, 
the Netherlands, were invited to participate. In addition, all inhabitants aged between 45 
and 65 years in one municipality (Leiderdorp, the Netherlands) were invited irrespective of 
their BMI, allowing for a reference distribution of BMI. The Medical Ethical Committee of 
the Leiden University Medical Center approved the study design. All participants gave their 
written informed consent. 
Participants were invited to a baseline visit at the NEO study center of the Leiden University 
Medical Center. Prior to this study visit, participants completed questionnaires at home, 
including a physical activity questionnaire. During the study visit a physical examination 
was performed, height and weight were measured and BMI was calculated. During this 
visit pulmonary function tests were performed at the Department of Pulmonology at the 
Leiden University Medical Center. Fractional nitric oxide (FeNO) was measured with a Niox 
Mino (Aerocrine AB, Solna, Sweden). In 2013, medical history, International Classifica-
tion of Primary Care (ICPC) codes and medication prescription were obtained through the 
electronic medical record registry of the general practitioners.
Study population
For the present study, participants were included if they had physician diagnosed COPD 
with an ICPC code for COPD (R95). Since COPD is often underdiagnosed,[22] we also 
included patients who did not have physician diagnosed COPD, but met our definition 
of newly diagnosed COPD. Newly diagnosed COPD was defined as an obstructive lung 
function with a FEV1/forced vital capacity (FVC) <0.7 and not having a combination of 
a smoking history less than 20 pack-years and no pulmonary symptoms.[23] Pulmonary 
symptoms included dyspnoea, wheezing, cough, sputum production or other pulmonary 
symptoms that could be reported on the questionnaire. Participants were excluded if the 
FEV1 was lower than 50%, since the focus of this study was on non-severe COPD. Further-
more, participants were excluded if they had a diagnosis of asthma (defined as ICPC code 
R96) and/or were never smokers and/or had a FeNO concentration in exhaled breath of ≥25 
parts per billion, since these outcomes are more suggestive for asthma than for COPD. 
Participants with missing data on the key variables were excluded.
Data collection
Participants in the NEO study reported their usual weekly physical activity during the 
preceding four weeks with the validated Short Questionnaire to Assess Health-enhancing 
physical activity (SQUASH).[24] Participants reported the frequency and duration of their 
physical activity in leisure time which was expressed in hours per week of metabolic equiva-
lents (MET-h/week).
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A large number of characteristics might be associated with physical activity.[9] We exam-
ined three clusters of characteristics that were previously used in a systematic review.[9] 
These clusters were: sociodemographic and lifestyle characteristics; clinical and functional 
characteristics and pharmacological characteristics. The characteristics of which inconsis-
tent findings were reported in previous studies, were collected. For sociodemographic and 
lifestyle characteristics participants reported age, sex, pack-years, alcohol consumption, 
ethnicity education level, working status and smoking status. Ethnicity was grouped 
into white (reference) and other; education level into high and low (reference); working 
status into working and not working (reference), smoking status into current and former 
(reference). For clinical and functional characteristics information was collected regard-
ing pulmonary symptoms, presence of a physician diagnosed COPD, anxiety, depression, 
BMI, FEV1 and FVC. Pulmonary symptoms included dyspnoea, wheezing, cough, sputum 
production or other pulmonary symptoms that could be reported on the questionnaire. 
Participants reported symptoms or no symptoms (reference). They reported on the ques-
tionnaire whether they experienced an increase in symptoms in the morning or no increase 
(reference). Anxiety and depression were examined with the Beck Anxiety Inventory (BAI)
[25] and the Inventory of Depressive Symptomatology (IDS) questionnaire[26] respectively. 
Lung function was assessed by spirometry (Jaeger Masterscreen PFT; Viasys Healthcare, 
Hoechberg, Germany), that was performed according to the standards of the European 
Respiratory Society.[27] FEV1 and FVC were reported as percentage predicted normal based 
on sex, age and height. For pharmacological characteristics information was collected 
regarding pulmonary medication use. The following medications could be recorded: all 
short-acting medication, all long-acting medication, short-acting beta2 agonists (SABA), 
short-acting muscarinic antagonists (SAMA), inhaled corticosteroids (ICS), long-acting 
beta2 agonists (LABA), long-acting muscarinic antagonists (LAMA) or a combination of 
long-acting pulmonary medication: ICS/LABA or ICS/LABA/LAMA. No use of pulmonary 
medication was used as reference. 
Statistical analysis
Descriptive data of baseline characteristics were reported as percentages, mean and stan-
dard deviation (SD) when normally distributed, or as median and interquartile range (IQR) 
when not normally distributed. 
Patients were classified according to the GOLD 2011 statement: those with a FEV1/FVC 
≥0.7 were classified as COPD GOLD 0, those with a FEV1/FVC <0.7 and a FEV1 ≥80% 
predicted as GOLD 1, and those with a FEV1/FVC <0.7 and a FEV1 50-80% predicted as 
GOLD 2. Additionally, the patient group was divided in physician diagnosed (ICPC code 
R95 present) and newly diagnosed COPD (no ICPC code R95, but met the afore mentioned 
criteria for newly diagnosed COPD). For each GOLD stage, the median MET-h/week and the 
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presence of pulmonary symptoms were calculated. Differences in MET-h/week between 
the grades were examined by regression analysis.
Univariate regression analysis was used to evaluate the association between characteristics 
and physical activity for physician diagnosed COPD and newly diagnosed COPD separately. 
To investigate whether the association between determinants and physical activity was 
similar across the physician diagnosed group and the newly diagnosed group, the inter-
actions between each determinant and the group indicator (ICPC R95 present or not) 
were tested by fitting multiple linear regression models on both groups together. These 
models included the determinant and the group indicator, and the interaction between the 
determinant and group indicator. Also the covariates age and sex were included. When 
the interaction was not statistically significant (p value for heterogeneity >0.10), an overall 
estimated of the association between the determinant and physical activity was obtained. 
In the cluster sociodemographic and lifestyle characteristics the association of physical 
activity with education level, working, smoking and alcohol intake was examined; in the 
cluster clinical and functional characteristics the association between pulmonary symp-
toms, increase of symptoms in the morning, BMI, anxiety/depression, FEV1, FVC, a physi-
cian diagnosed COPD and physical activity was examined; in the cluster pharmacological 
characteristics the association between the use of pulmonary medication, short-acting 
pulmonary medication, long-acting pulmonary medication, ICS, LABA, LAMA or use of 
a combination and physical activity was examined. Since age and sex are associated with 
physical activity in healthy older people, as well as in COPD patients,[9, 28] analyses were 
adjusted for age and sex. We did not adjust for other characteristics, since age and sex 
were the only characteristics of which consistent results were found in previous studies.
[9] In view of the non-normal distribution of physical activity, regression coefficients and 
robust standard errors were used to calculate 95% confidence intervals.
All results were weighted to represent a general population with a normal BMI distribu-
tion.[29] This was done by weighting the participants towards the BMI distribution of 
participants from the Leiderdorp municipality, whose BMI distribution was similar to the 
BMI distribution of the general Dutch population. Consequently, the results apply to a 
population-based study without oversampling of participants with a BMI ≥27 kg/m2. 
Statistical analysis was performed using Stata Statistical Software version 14.1. (StataCorp, 
College Station, TX, USA). 
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RESULTS
From the 6,671 participants in the NEO database, 323 participants (4.8% of the total 
cohort) fulfilled the study criteria (Figure 1). Table 1 shows the baseline characteristics. 77 
patients had physician diagnosed COPD and 246 patients had newly diagnosed COPD. 
Those with physician diagnosed COPD were more frequently women, had a lower FEV1, 
were less physically active, and used more frequently pulmonary medication than those 
with newly diagnosed COPD. The majority (55.4%) of participants met the criteria for 
newly diagnosed COPD GOLD 1.
Figure 1 Flow chart of study design
COPD: chronic obstructive pulmonary disease; FeNO: fractional exhaled nitric oxide; FEV1: Forced expira-
tory volume in one second; FVC: forced vital capacity; NEO: Netherlands Epidemiology of Obesity
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Patients without a physician diagnosed COPD and a FEV1/FVC ≥0.7 were excluded; there-
fore, no patients were classified as newly diagnosed COPD GOLD 0. Participants reported 
a median [IQR] of 31 [15-46] MET-h/week in physical activity. Patients with physician diag-
nosed GOLD 0, 1 and 2 reported a median [IQR] of 26 [23;32], 14 [11;32] and 12 [6;32] 
MET-h/week in physical activity, respectively. Newly diagnosed GOLD 1 and 2 35 [22;59] 
and 29 [16;36] MET-h/week (Figure 2). Supplementary table 1 shows that in each group 
approximately half of the patients reported lung symptoms. 
Table 1. Characteristics of patients with physician diagnosed COPD (GOLD 0-2) and newly 







Sociodemographic and lifestyle characteristics
Age (years), median [IQR] 59 [54-64] 60 [54-63]
Sex (% female) 64 40
Education level (% high) 23 36
Working status (% working) 51 54
Smoking status (% current) 47 51
Alcohol intake (g/d), median [IQR] 15 [0-28] 21 [7-35]
Clinical and functional characteristics
BMI (kg/m2), mean (SD) 28 (5) 27 (4)
Anxiety (score), median [IQR] 4 [1-8] 3 [1-6]
Depression (score), median [IQR] 7 [6-17] 8 [5-13]
FEV1 (% predicted), mean (SD) 82 (16) 90 (15)
FVC (% predicted), mean (SD) 108 (17) 112 (16)
Pulmonary symptoms (% yes) 64.8 56.8
Morning symptoms (% yes) 7 18
Physical activity in leisure time (MET hours per week), median [IQR] 20 [11-32] 33 [20-55]
Pharmacological characteristics
Any pulmonary medication (% yes) 63.6 9.2
Short acting (% yes) 19.1 1.9
Long acting (% yes) 60.2 4.9
ICS (% yes) 46.3 4.8
LABA (% yes) 37.5 3.3
LAMA (% yes) 30.8 0.5
ICS/LABA (% yes) 14.5 3.0
ICS/LABA/LAMA (% yes) 19.1 0.3
BMI: body mass index; CI: confidence interval; COPD: Chronic obstructive pulmonary disease; FEV1: 
forced expiratory volume in 1 second; FVC: forced vital capacity; GOLD: global initiative for chronic ob-
structive lung disease; ICS: inhaled corticosteroids; LABA: long-acting beta-agonist; LAMA: long-acting 
muscarinic antagonist
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Table 2 shows associated characteristics of physical activity. The characteristics education, 
BMI, anxiety, depression, FEV1, FVC, LAMA and ICS/LABA/LAMA showed a statistically sig-
nificant heterogeneity (p<0.1) across physician diagnosed and newly diagnosed patients. 
In both groups, education, BMI and depression were not associated with physical activity. 
Anxiety was positively associated with physical activity in physician diagnosed patients. The 
regression coefficient was 0.9 (95% CI 0.3,1.6) MET-h/week, representing an increase in 
physical activity of 0.9 MET-h/week per point increase on the BAI. This association was not 
statistically significant in newly diagnosed patients. Statically significant positive associa-
tions between both FEV1 and FVC and physical activity were found in newly diagnosed 
patients, but not in physician diagnosed patients. The regression coefficients were 0.4 
(95% CI 0.1,0.7) and 0.34 (95% CI 0.1,0.6). This indicates an increase of 0.4 MET-h/
week per percent FEV1 and an increase of 0.3 MET-h/week per percent FVC. In the newly 
diagnosed COPD group, but not in physician diagnosed patients, there was negative as-
sociation between LAMA and ICS/LABA/LAMA use and physical activity (Table 2). 
For the determinants that showed no significant heterogeneity, we found a negative as-
sociation between working status and physical activity in the physician diagnosed group 
and a negative association between long acting therapy and physical activity in the total 
group (Table 2). 
Figure 2 Physical activity in physician diagnosed and newly diagnosed COPD GOLD 0, 1 and 2 
COPD: Chronic obstructive pulmonary disease; GOLD: global initiative for chronic obstructive lung dis-
ease; MET: metabolic equivalent task; NEO: Netherlands Epidemiology of Obesity
Bar plots represent the medians and error bars the interquartile range.
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95% CI Regression 
coefficient
95% CI
Sociodemographic and lifestyle characteristics
Education level (ref low) 6.7 -4.3;17.6 4.5 -6.4;15.4 -9.9 -20.8;0.9 -10.7 -21.6;0.24 0.088 - - - -
Working status (ref not 
working)
-11.1 -18.9;-3.3 -10.1 -18.6;-1.5 -9.0 -21.4;3.4 -5.7 -23.5;12.2 0.735 -9.4 -19.4-0.7 -6.7 -20.5;7.0
Smoking status (ref 
former)
-3.1 -12.2;6.0 -0.1 -9.7;9.5 -3.2 -15.7;9.2 -3.6 -15.5;8.3 0.462 -3.2 -13.4;6.9 -2.6 -12.8;7.7
Alcohol intake (g/d) 0.1 -0.1;0.3 0.0 -0.2;0.2 0.2 -0.3;0.7 0.2 -0.3;0.6 0.467 0.2 -0.2;0.6 0.1 -0.2;0.5
Clinical and functional characteristics
BMI (kg/m2) 0.4 -0.3;1.0 0.4 -0.3;1.1 -1.2 -2.9;0.4 -1.1 -2.6;0.5 0.098 - - - -
Anxiety (score) 0.7 -0.1;1.5 0.9 0.3;1.6 -0.4 -1.2;0.4 -0.3 -1.1;0.6 0.016 - - - -
Depression (score) 0.3 -0.3;0.8 0.4 -0.0;0.9 -0.3 -1.0;0.4 -0.3 -0.9;0.4 0.097 - - - -
Worsening of symptoms 
in the morning (ref no 
worsening)
-8.8 -20.0;2.4 -6.5 -18.9;5.9 10.9 -16.9;38.6 10.4 -15.0;35.9 0.263 8.8 -16.2;33.8 8.9 -14.5;32.3
FEV1 (% predicted) 0.0 -0.3;0.3 -0.0 -0.3;0.3 0.5 0.1;0.8 0.4 0.1;0.8 0.056 - - - -
FVC (% predicted) -0.2 -0.4;0.1 -0.2 -0.5;0.1 0.4 0.1;0.7 0.4 0.1;0.7 0.002 - - - -
Pulmonary symptoms 
(ref no)




-6.0 -13.9;2.0 -6.0 -13.5;1.5 -4.0 -17.1;9.1 -4.1 -17.4;9.2 0.798 -4.8 -13.3;3.7 -4.9 -13.4;3.7
Short acting therapy 
(ref no)
-1.3 -12.2;9.6 -1.2 -12.8;10.5 18.5 -20.4;57.4 21.0 -17.9;60.0 0.295 5.2 -11.9;22.2 6.1 -11.9;24.2
Long acting therapy 
(ref no)
-6.8 -14.6;1.1 -6.8 -14.2;0.6 -4.6 -15.0;5.9 -6.0 -16.2;4.3 0.872 -5.8 -12.3;0.7 -6.4 -12.5;-0.2
ICS (ref no) -2.1 -11.4;7.2 -4.0 -12.4;4.5 -4.2 -14.7;6.3 -5.4 -15.5;4.7 0.930 -3.0 -9.8;3.8 -5.0 -11.9;2.0
LABA (ref no) 2.0 -8.2;12.1 1.0 -8.7;10.7 -2.3 -14.1;9.5 -5.6 -18.3;7.2 0.463 0.4 -7.0;7.9 -1.7 -9.4;6.0
LAMA (ref no) -8.0 -16.0;0.1 -7.2 -15.6;1.1 -21.7 -30.8;-12.5 -27.9 -40.5;-15.3 0.009 - - - -
ICS/LABA (ref no) 8.9 -8.0;25.8 8.6 -6.2;23.4 0.0 -11.2;11.2 -2.9 -14.8;9.1 0.293 4.5 -5.5;14.5 2.1 -7.8;12.1
ICS/LABA/LAMA (ref no) -3.7 -13.8;6.3 -4.8 -15.9;6.2 -24.7 -33.8;-15.6 -31.0 -42.7;-19.2 0.001 - - - -
Results were based on analyses weighted towards the BMI distribution of the general population
BMI: body mass index; CI: confidence interval; COPD: Chronic obstructive pulmonary disease; FEV1: 
forced expiratory volume in 1 second; FVC: forced vital capacity; GOLD: global initiative for chronic ob-
structive lung disease;  ICS: inhaled corticosteroids; LABA: long-acting beta-agonist; LAMA: long-acting 
muscarinic antagonist; MET: Metabolic Equivalent Task. *Adjusted for age and sex. $Models include 
determinant and group. #Models include determinant, group, age, sex. 
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-1.3 -12.2;9.6 -1.2 -12.8;10.5 18.5 -20.4;57.4 21.0 -17.9;60.0 0.295 5.2 -11.9;22.2 6.1 -11.9;24.2
Long acting therapy 
(ref no)
-6.8 -14.6;1.1 -6.8 -14.2;0.6 -4.6 -15.0;5.9 -6.0 -16.2;4.3 0.872 -5.8 -12.3;0.7 -6.4 -12.5;-0.2
ICS (ref no) -2.1 -11.4;7.2 -4.0 -12.4;4.5 -4.2 -14.7;6.3 -5.4 -15.5;4.7 0.930 -3.0 -9.8;3.8 -5.0 -11.9;2.0
LABA (ref no) 2.0 -8.2;12.1 1.0 -8.7;10.7 -2.3 -14.1;9.5 -5.6 -18.3;7.2 0.463 0.4 -7.0;7.9 -1.7 -9.4;6.0
LAMA (ref no) -8.0 -16.0;0.1 -7.2 -15.6;1.1 -21.7 -30.8;-12.5 -27.9 -40.5;-15.3 0.009 - - - -
ICS/LABA (ref no) 8.9 -8.0;25.8 8.6 -6.2;23.4 0.0 -11.2;11.2 -2.9 -14.8;9.1 0.293 4.5 -5.5;14.5 2.1 -7.8;12.1
ICS/LABA/LAMA (ref no) -3.7 -13.8;6.3 -4.8 -15.9;6.2 -24.7 -33.8;-15.6 -31.0 -42.7;-19.2 0.001 - - - -
Results were based on analyses weighted towards the BMI distribution of the general population
BMI: body mass index; CI: confidence interval; COPD: Chronic obstructive pulmonary disease; FEV1: 
forced expiratory volume in 1 second; FVC: forced vital capacity; GOLD: global initiative for chronic ob-
structive lung disease;  ICS: inhaled corticosteroids; LABA: long-acting beta-agonist; LAMA: long-acting 
muscarinic antagonist; MET: Metabolic Equivalent Task. *Adjusted for age and sex. $Models include 
determinant and group. #Models include determinant, group, age, sex. 
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DISCUSSION
The aim of the present study was to explore physical activity and associated characteristics 
of physical activity in patients with very mild to moderate COPD (GOLD 0, 1 and 2). The fo-
cus was on patient characteristics of which inconsistent effects were described in previous 
studies. The main conclusion is that several characteristics were associated with physical 
activity. In the total group, long acting therapy was negatively associated with physical 
activity. Whereas pulmonary function and anxiety were positively associated with physical 
activity in newly diagnosed and physician diagnosed respectively, the use of LAMA and 
ICS/LABA/LAMA combination therapy were negatively associated with physical activity in 
physician diagnosed COPD. Working status was negatively associated with physical activity 
in physician diagnosed COPD. We found no association of physical activity with education 
level, smoking status, alcohol intake, BMI, depression, pulmonary symptoms or morning 
symptoms. 
In the present study, patients reported a median [IQR] of 31 [15-46] MET-h/week in physical 
activity. A study in patients with non-severe COPD that used accelerometry to evaluate 
physical activity, has previously reported lower physical activity.[7] Other studies that in-
cluded COPD patients with mild and moderate COPD, but also patients (very) severe COPD, 
reported physical activity of the total study group and did not make a distinction in physical 
activity between severe and non-severe COPD patients which makes it difficult to compare 
the results with those of the present study. 
In newly diagnosed patients FEV1 was associated with physical activity which is in line with 
some,[10, 15, 16, 30, 31] but not all[14, 17] previous studies in patients with COPD. Per 
decrease of percent FEV1, patients spent 0.4 MET-h/week less time in leisure time physical 
activity. This outcome is a likely relevant number of MET-h/week in COPD, since the effect 
of intensive exercise training in COPD is only five minutes more walking a day (which 
is equivalent to 1.75 MET-h/week).[32] The severity of the consequences of mild airflow 
limitation should not be underestimated. Patients with mild COPD have objectively mea-
sured greater ventilatory inefficiency than controls,[4, 33] which might explain the lower 
physical activity. This is supported by another study in newly diagnosed COPD patients, 
showing that a lower diffusion capacity was associated with lower physical activity.[7] 
Intervention studies are needed to determine whether early pharmacological interventions 
and/or physical activity slow down COPD progression in non-severe COPD.
LAMA and ICS/LABA/LAMA use were associated with less physical activity in this study 
in newly diagnosed patients, whereas ICS, LABA and ICS/LABA use were not associated 
with physical activity. Two cross-sectional studies have shown no differences in beta2-
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agonists, anticholinergics or ICS use in moderate to very severe COPD patients or patients 
post-exacerbation between those with low, moderate and high physical activity.[14, 15] 
However, in those studies nearly all patients were using medication which makes the prob-
ability of finding a difference low. It is not likely that the use of pulmonary medication 
contributed to lower physical activity since placebo-controlled trials have shown positive 
effects of a LABA[34, 35] or a LAMA/LABA combination on physical activity.[36]. The most 
likely explanation is that patients with pulmonary medication have more severe COPD or 
experience more severe symptoms that result in less physical activity. However, we cannot 
test this hypothesis because of the cross-sectional design of the study. Furthermore, there 
was no data available regarding physical activity status before medication use. 
The presence of an increase in symptoms in the morning was not associated with physical 
activity in this study. In patients with physician diagnosed COPD the regression coefficient 
was negative, indicating that patients with morning symptoms spent less MET-h/week in 
leisure time. This is in line with the notion that the morning is the most troublesome part 
of the day for COPD patients resulting in activity limitations.[37] In the total and newly di-
agnosed population, the regression coefficient was positive. We did not expect this result, 
since a systematic review has reported that morning symptoms were associated with less 
physical activity in COPD, also in non-severe COPD stages.[38] However, the difference in 
the direction of the regression coefficient can be due to the severity of airflow limitation 
or to symptom severity, since it was shown in previous studies that patients with more 
severe morning symptoms are those that also report in general more severe symptoms.[39] 
Furthermore, only 16% of patients reported an increase in symptoms in the morning in the 
present study. We speculate that the reporting of morning symptoms would be have been 
higher if there was an additional question in which patients had the possibility to score the 
severity of the symptoms, as in other studies.[40, 41] This would have likely resulted in a 
less positive (or a negative) regression coefficient in the total studied population.
Newly diagnosed patients reported a higher physical activity than those with physician 
diagnosed COPD, which could be explained by the presence of a higher degree of airflow 
limitation in patients with physician diagnosed COPD. It is known that physical activity is 
lower in more severe COPD stages.[6] Patients with physician diagnosed COPD were more 
likely to be treated with pulmonary medication. There was no difference in the presence 
of pulmonary symptoms between patients with physician diagnosed COPD and those with 
newly diagnosed COPD. This demonstrates that also those with previously undiagnosed 
COPD did experience symptoms, although their symptoms may have been less severe. Fur-
thermore, it can be speculated that inactivity or activity limitations, rather than symptoms, 
are reasons for patients to seek medical attention. This is in line with a previous study 
reporting that COPD patients experience the physical effects associated with the occur-
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rence of symptoms as a greater challenge than the symptoms themselves.[37] However, 
this suggestion was made based on reporting of morning symptoms and may not be fully 
applicable for symptoms in general.
Strengths and limitations
Since analyses were weighted for BMI, our cohort reflects a general COPD population in 
which the mean BMI is comparable to that in other COPD studies.[7, 15] A strength of 
this study was that patients with physician diagnosed and newly diagnosed COPD were 
included, while other studies only included patients with physician diagnosed COPD and 
thereby missed undiagnosed patients. The prevalence of COPD is underestimated[22] 
and half of the patients already have COPD GOLD 2 when the diagnosis is confirmed by 
spirometry.[42] 
A limitation of this study is that patients might have been included with an obstructive pul-
monary function but another diagnosis than COPD (for example asthma, acute and chronic 
bronchitis, bronchiectasis, cystic fibrosis, and bronchiolitis).[43] However, the incidences 
of these diagnoses are lower than for COPD, except for asthma. Patients with asthma or 
asthma-COPD overlap syndrome (ACOS) might have been included since data regarding 
reversibility in pulmonary function was not available. However, patients with a ICPC code 
R96, never smokers and those with a high FeNO (more likely to be asthma) were excluded 
to avoid misclassification. Including asthmatics might have resulted in an overestimation of 
physical activity since patients with asthma are as physically active as non-asthmatics.[44] 
Not having post-bronchodilator data can be seen as a weakness. However, this is inherent 
to population based studies and the results were also used in a previous report from our 
group.[45] For future studies in physical activity we suggest to include the non-smoking 
population as reference group. Another limitation of this study is the use of the SQUASH 
questionnaire to examine physical activity. However, this questionnaire has been used in a 
previous study that included COPD patients.[46] A disadvantage of the use of activity ques-
tionnaires is that many patients overestimate their physical activity.[47] However, when all 
patients overestimate their physical activity, associations with other patient characteristics 
will still be present. A third limitation is the limited sample size, which resulted in large 
confidence intervals for some characteristics. Although a larger sample size would have 
resulted in narrowing of confidence intervals and might have revealed more associations 
(for example a negative association between BMI and physical activity), the fact that we 
did detect the reported associations with a relative limited sample size also stresses their 
potential clinical relevance. 
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CONCLUSIONS
Patients with newly diagnosed COPD are more active than those with physician diagnosed 
COPD. The present study showed that in newly diagnosed patients pulmonary function 
was positively associated with physical activity. Furthermore, the use of LAMA and ICS/
LABA/LAMA was negatively associated with physical activity in newly diagnosed patients. 
The most likely explanation is that patients with pulmonary medication experience more 
severe symptoms that result in less physical activity. In physician diagnosed patients an 
association between anxiety and working status,  and physical activity was found. We 
found no association between education level, working status, smoking status, alcohol 
intake, BMI, depression, morning symptoms and physical activity. Intervention studies are 
needed to determine whether early pharmacological interventions and/or physical activity 
slow down COPD progression in non-severe COPD.
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LIST OF ABBREVIATIONS
BAI: Beck Anxiety Inventory
BMI: body mass index
CI: confidence interval
COPD: Chronic obstructive pulmonary disease
FeNO: fractional exhaled nitric oxide
FEV1: forced expiratory volume in 1 second
FVC: forced vital capacity
GOLD: global initiative for chronic obstructive lung disease
ICPC: International classification of primary care
ICS: inhaled corticosteroids
IDS: Inventory of Depressive Symptomatology
IQR: interquartile range
LABA: long-acting beta2 agonist
LAMA: long-acting muscarinic antagonist
MET-h/week: hours per week of metabolic equivalents
NEO: Netherlands Epidemiology of Obesity
SABA: short-acting beta2 agonist
SAMA: short-acting muscarinic antagonist
SD: standard deviation
SQUASH: Short Questionnaire to Assess Health-Enhancing Physical Activity
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SUPPLEMENTARY MATERIALS
Supplementary table 1. Distribution of symptomatic and non-symptomatic patients with phy-
sician diagnosed and newly diagnosed early stage COPD
COPD stage Percentage without 
pulmonary symptoms
Percentage with pulmonary symptoms
Physician diagnosed GOLD 0 41.9 58.1
Physician diagnosed GOLD 1 45.8 54.2
Newly diagnosed GOLD 1 49.5 50.5
Physician diagnosed GOLD 2 18.1 81.9
Newly diagnosed GOLD 2 29.1 70.9
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ABSTRACT
Introduction: An (inter)national systematic approach for patients with asthma COPD re-
ferred to secondary care is lacking. Therefore, a novel systematic approach was designed 
and tested in clinical practice.
Methods: This was a retrospective observational study of data from the electronic record 
system of the Leiden University Medical Center. Asthma and COPD patients were included 
if they were evaluated with a novel systematic approach or if they had a new record for 
asthma or COPD and received usual care. The novel systematic approach consisted of a pre-
defined diagnostic evaluation combined with an optional internet-based self-management 
support system. Diagnostic tests, final diagnosis, lifestyle advices, symptoms and individual 
care plans in the electronic records, number of patients referred back to primary care, and 
time to referral back to primary care were compared between the systematic approach and 
usual care groups using t-tests and chi-squared tests.
Results: A total of 125 patients were included, of which 22 (21.4%) were evaluated with 
the systematic approach. Mean (±SD) age was 48.8 (±18.4) years and 59.2% were women. 
Mean (±SD) number of diagnostic tests was higher in the systematic approach group com-
pared with the usual care group (7.6±1.0 vs 5.5±1.8, P<0.001). Similarly, in the systematic 
approach group, more lifestyle advices (81.8% vs 29.1%), symptom scores (95.5% vs 
21.4%), and indi vidual care plans (50.0% vs 7.8%) were electronically recorded (P<0.001), 
and more patients were referred back to primary care (81.8% vs 56.3%, P=0.03). There 
were no differences in the final diagnoses and time to referral back.
Conclusion: Our study suggested that not all tests that were included in the systematic 
approach are regularly needed in the diagnostic work-up. In addition, a designated system-
atic approach stimulates physicians to record lifestyle advices, symptoms, and individual 
care plans. Thus, this approach could increase the number of patients referred back to 
primary care.
Keywords: asthma, COPD, diagnostics, eHealth, outpatient clinic, systematic approach
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INTRODUCTION
Asthma and COPD are common obstructive lung diseases. It is important to differentiate 
between asthma, COPD, and other (lung) diseases to phenotype these diseases even if 
the asthma/COPD is not severe as well as to design individual care plans. International 
guidelines have suggested on the parameters that should be assessed to evaluate asthma 
and COPD.[1-3] However, the guidelines do not provide suggestions on the additional tests 
that should be necessarily added to decrease the likelihood of other diagnoses, nor on the 
tests that should preferably be performed to identify treatable traits. A review showed 
that the use of care pathways results in a reduction of costs, improved quality of life, 
reduced number of complications, increased patient satisfaction, improved communication 
between doctors and nurses, and reduced time that healthcare providers spent carrying 
out paperwork.[4] However, for unknown reasons, a uniform international systematic ap-
proach for assessment of asthma and COPD patients referred to secondary care is lack ing. 
Therefore, a diagnostic approach has been developed for asthma and COPD patients in the 
Netherlands. This diagnostic approach includes functional tests in addition to additional 
tests to acquire detailed insights into symptoms, functional limitation, and quality of life, 
ultimately to create a personal ized treatment plan.[5] Patients are involved in this treat-
ment plan in formulating their own treatment goals. However, it is thought that patient 
involvement could be increased by the use of eHealth. The previous diagnostic approach 
has been successfully implemented. However, the effects of the use of this diagnostic 
approach on the number of diagnostics, final diagnoses, referrals back to primary care, 
and long-term out comes have not been evaluated yet. In addition, eHealth could be used 
as a method to integrate the individual care plans.[6] Therefore, in the LUMC, a novel 
systematic approach was developed that consisted of a predefined diagnostic evaluation 
combined with an optional internet-based self-management support system. Since March 
2016, patients with (suspected) asthma or COPD who were referred by a GP to secondary 
pulmonary care were systematically evaluated with this sys tematic approach. The primary 
aim of this study was to deter mine whether there was a difference between the system-
atic approach and usual care in terms of type of diagnostic tests, number of diagnostic 
tests, final diagnosis, recorded lifestyle advices, symptoms and individual care plans in the 
electronic records, number of patients referred back to primary care, and time to referral 
back to primary care. The secondary aim of this study was to evaluate the number of 
patients who used the internet-based self-management support system. We hypothesize 
that a systematic approach could lead to a more specified diagnosis, more lifestyle advices, 
symptoms and individual care plans that are recorded in the electronic records, and more 




Since March 2016, a novel systematic approach to evaluate patients with (suspected) 
asthma or COPD was released at the outpatient clinic of the department of pulmonology 
at the LUMC. A pulmonologist who was not involved in the study assessed the urge of the 
GP referrals. Patients with urgent complaints were scheduled at the outpatient clinic for 
acute respiratory complaints. The other patients were scheduled either within the novel 
systematic approach or by usual outpatient clinic care, depending on the first pos sibility 
at the outpatient clinic. With usual care, physicians decided which diagnostic tests to 
be performed based on outcomes of the clinical history and personal preferences. The 
systematic approach consisted of a predefined systematic diagnostic evaluation combined 
with an optional internet-based self-management support system. There were two or three 
visits, or more if there was a medical reason for additional diagnostic tests (Figure 1). Dur-
ing the first visit, a nurse practitioner obtained general information, vital parameters, and 
evaluated inhaler technique. The same day, lung function tests (spirometry before and after 
broncho dilation and DLCO) were performed. FeNO was measured and a chest X-ray, ECG, 
and laboratory tests (including hemoglobin, erythrocyte sedimentation rate, white blood 
cell count with differential, sodium, potassium, creatinine, radioallergosorbent test, thyroid 
stimulating hormone, N-terminal pro B-type natriuretic peptide, total immuno globulin E, 
25-hydroxyvitamin D, and alpha 1-antitrypsin) were performed. The nurse informed the 
patients about the internet-based self-management support system in the form of “Pa-
tientCoach”. PatientCoach has been developed by the LUMC specifically for patients with 
chronic diseases and con tains information about asthma and COPD, self-monitoring, an in-
dividual care plan, and e-visits.[7] The GP can also access PatientCoach. If a patient agreed 
to use PatientCoach, he or she was asked to complete the Nijmegen Clinical Screening 
Instrument[8] and asthma control questionnaire[9] or the clinical COPD questionnaire[10] 
at home. In addition, patients formu lated their own personal treatment goals. During the 
second visit, the nurse practitioner discussed the outcomes of the questionnaires and the 
personal goals. The second visit was canceled if the patients refused to use PatientCoach.
During the last planned visit, a pulmonologist or a pul monology resident discussed the 
outcomes of the diagnostic tests with the patient and an individual care plan was created. 
If a patient used PatientCoach, the individual care plan was integrated in PatientCoach. If 
additional diagnostic tests, eg, chest CT scan or sputum cultures, were needed, patients 
were scheduled for a fourth or later follow-up visit. If no more visits in the hospital were 
necessary, patients were referred back to primary care. The GP and the patient still had 
access to PatientCoach, enabling the continuation of eHealth in further care.
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Study design
This was a retrospective observational study of real-life data that were retrieved from the 
electronic record system of the LUMC. Data were collected between November 2017 and 
January 2018 from patients who attended the outpatient clinic of the LUMC for the first 
time between March 2016 and July 2017. The medical ethical committee of the LUMC 
waived the need for ethical approval due to the retrospective nature of the study. Conse-
quently, the need for informed consent was not applicable.
Figure 1 Novel systematic approach for asthma and COPD at the LUMC. ECG: electrocardiography; 
FeNO: Fractional exhaled nitric oxide; LUMC: Leiden University Medical Center.
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Study population
Patients were included if they were evaluated with the systematic approach or if they had 
a new record for asthma or COPD and were evaluated by usual outpatient clinic care. 
Patients were included if they attended the outpatient clinic of the LUMC for the first time 
between March 2016 and July 2017. Patients were excluded if they attended the dyspnea 
clinic of the LUMC, if they had a previous record of asthma or COPD at the department of 
pulmonology at the LUMC, if they were solely admitted to the clinical ward; if they were 
not referred by a GP, if the first visit was at the emergency room or in the clinical ward, if 
the reason for referral was not asthma or COPD, or if the patient did not show up at the 
outpatient visits.
Data collection
Baseline characteristics were collected from the electronic records from the first visit at the 
department of pulmonology at the LUMC. Type of diagnostic tests, number of diagnos tic 
tests, final diagnosis, lifestyle advices, symptoms and individual care plans in the electronic 
records, number of patients referred back to primary care, and time to referral back to 
primary care were collected from the electronic records as primary outcomes. The second-
ary outcome was the number of patients who used PatientCoach.
Diagnostic tests, needed for the work-up to the final diagnosis, were evaluated. The type of 
diagnostic tests that were assessed included laboratory tests, lung-specific labo ratory tests 
(including arterial blood gas analysis, alpha-1 antitrypsin, and radioallergosorbent test), spi-
rometry, histamine provocation test, FeNO, DLCO, chest X-ray, CT (including pulmonary CT 
angiography), bronchoscopy, sputum cultures, six-minute walking test, and ECG. The final 
diagnosis that was registered in the electronic records was evaluated. Predefined diagnoses 
were asthma, COPD, a combination of asthma and COPD, another pulmonary disease, 
no pulmonary disease, obesity-related symptoms, or no diagnosis. If the final diagnosis 
was asthma and/or COPD, the phenotype was evaluated. Predefined phenotypes included 
allergic, nonallergic, late-onset asthma, asthma with fixed airflow limitation, and asthma 
with obesity.[1] Alpha-1 antitrypsin deficiency, emphysema/hyperinflation, and frequent 
exacerbators[11] (including the GOLD group B and D[2]) were predefined phenotypes in 
COPD. The number of reported symptom scores, lifestyle advices, and individual care plans 
were collected from the electronic records. The number of patients who were referred back 
to primary care was collected. The number of days between referral and first visit, between 
first visit and final diagnosis, between first visit and the latest diagnostic test, and between 
first visit and referral back to primary care were calculated.
The number of patients who logged in at least once in PatientCoach was collected from 
the electronic records.
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Statistical analysis
Patients with missing data on the key variables were excluded (N=2). Descriptive data were 
reported as percentages and mean values±SD for continuous variables. To compare means 
between the systematic approach and usual care groups for continuous baseline charac-
teristics as age and BMI, unpaired t-tests were used. To compare percentages between the 
systematic approach and usual care groups for categorical baseline characteristics as per-
centage women and smoking status, chi-squared tests were used. To compare percent ages 
of performed diagnostic tests between the systematic approach and usual care groups, 
chi-squared tests were used. To compare the mean time between referral and other time 
points and the mean number of performed diagnostic tests, between the systematic ap-
proach and usual care groups, unpaired t-tests were used. To compare percentages of 
final diagnosis as asthma and COPD, electronically recorded lifestyle advices, electronically 
recorded symptoms scores, electronically recorded individual care plans, and referrals back 
to primary care, between the systematic approach and usual care groups, chi-squared tests 
were used.
Since the use of PatientCoach was optional and a part of patients refused to use it, the 
number of patients who logged in at least once in PatientCoach was collected. The number 
of patients who logged in at least once in PatientCoach was expressed as percentage of 
the total number of patients who were included in the diagnostic approach. To compare 
means between patients in the systematic approach group who used PatientCoach and 
who did not for continuous baseline charac teristics, unpaired t-tests were used. To compare 
percentages between patients in the systematic approach group who used PatientCoach 
and who did not, for categorical baseline char acteristics, chi-squared tests were used. 
Furthermore, a sen sitivity analysis was performed to evaluate the differences in primary 
outcomes between the patients in the usual care and those in the diagnostic approach 
who used PatientCoach. All analysis were conducted using SPSS version 23.0.
ETHICS STATEMENT
The medical ethical committee of the LUMC waived the need for ethical approval due to 
the retrospective nature of the study. Consequently, the need for informed consent was 




In total, 125 out of 608 patients were included in the analysis (Figure 2), of which 22 
(21.4%) were evaluated with the systematic approach. Baseline characteristics of all 
included patients are presented in Table 1. In total, 67.2% of patients were referred for 
asthma. Mean (±SD) age was 48.8 (±18.4) years and 59.2% of patients were women. 
There were no significant differences in baseline characteristics between patients who 
were evaluated with the systematic approach compared with usual care.
Diagnostic tests
The most frequently performed diagnostic test was spirometry (97.6%) (Table 2). The mean 
(±SD) number of diagnostic tests was significantly higher in the systematic approach group 
compared with the usual care group (7.6±1.0 vs 5.5±1.8). Laboratory tests, lung-specific 
laboratory tests, FeNO, DLCO, chest X-rays, and ECG were more frequently performed in 
the systematic approach group than in the usual care group. 
Figure 2 Flow diagram. GP: general practitioner; LUMC: Leiden University Medical Center
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Table 1 Baseline characteristics
Characteristics Total group (N 
= 125)
Usual care 
(N = 103 )
Systematic 
approach
(N = 22 )
Difference
(P-value)
Age in years (mean, (SD)) 48.8 (18.4) 48.2 (18.2) 51.8 (19.5) 0.41
Sex, n (% women) 74 (59.2) 58 (56.3) 16 (72.7) 0.16
BMI in kg/m² (mean, (SD)) 27.0 (6.8) 26.7 (6.7) 28.2 (7.6) 0.37
Cardiovascular comorbidities, n (% yes) 28 (22.4) 23 (22.3) 5 (22.7) 0.97
Reason of referral, n (% asthma) 84 (67.2) 69 (67.0) 15 (68.2) 0.91
Smoker status 
Never smoker, n (% yes) 55 (44.0) 43 (41.7) 12 (54.5) 0.27
Former smoking, n (% yes) 44 (35.2) 39 (37.9) 5 (22.7) 0.18
Current smoker, n (% yes) 26 (20.8) 21 (20.4) 5 (22.7) 0.81
Medication use at baseline
SABA, n (% yes) 73 (58.4) 57 (55.3) 16 (72.7) 0.13
LABA, n (% yes) 79 (63.2) 63 (61.2) 16 (72.7) 0.31
SAMA, n (% yes) 16 (12.8) 14 (13.6) 2 (9.1) 0.57
LAMA, n (% yes) 29 (23.2) 23 (22.3) 6 (27.3) 0.62
ICS, n (% yes) 90 (72.0) 73 (70.9) 17 (77.3) 0.54
LTRA, n (% yes) 9 (7.2) 6 (5.8) 3 (13.6) 0.20
Antihistamines, n (% yes) 36 (28.8) 28 (27.2) 8 (36.4) 0.39
ICS: inhaled corticosteroids; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic-antag-
onist; LTRA: leukotriene receptor antagonist; SABA: short-acting beta2-agonist; SAMA: short-acting 
muscarinic-antagonist.
Table 2 Diagnostic tests at the outpatient clinic for the evaluation of asthma and COPD
Diagnostic tests Total group
(N = 125)







Laboratory tests, n (% yes) 108 (86.4) 86 (83.5) 22 (100.0) 0.040
Lung-specific laboratory tests, n (% yes) 100 (80.0) 79 (76.7) 21 (95.5) 0.046
Spirometry, n (% yes) 122 (97.6) 100 (97.1) 22 (100.0) 0.42
Histamine provocation test, n (% yes) 40 (32.0) 34 (33.0) 6 (27.3) 0.60
FeNO, n (% yes) 85 (68.0) 64 (62.1) 21 (95.5) 0.002
DLCO, n (% yes) 88 (70.4) 66 (64.1) 22 (100.0) 0.001
Chest X-ray, n (% yes) 97 (77.6) 76 (73.8) 21 (95.5) 0.027
Chest CT scan, n (% yes) 23 (18.4) 18 (17.5) 5 (22.7) 0.56
Bronchoscopy, n (% yes) 1 (0.8) 1 (1.0) 0 (0.0) 0.64
Sputum cultures, n (% yes) 46 (19.2) 18 (17.5) 6 (27.3) 0.29
Six-minute walking test, n (% yes) 1 (0.8) 1 (1.0) 0 (0.0) 0.64
ECG, n (% yes) 38 (30.4) 18 (17.5) 20 (90.9) <0.001
Number of diagnostic tests (mean (SD)) 5.8 (1.9) 5.5 (1.8) 7.6 (1.0) <0.001
CT: computed tomography; DLCO: diffusing capacity for carbon monoxide; ECG: electrocardiography; 
FeNO: fractional exhaled nitric oxide
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Final diagnosis and registered symptom scores, lifestyle advices, and individual 
care plans
Most patients were finally diagnosed with asthma (53.6%), COPD (25.6%), or no pulmo-
nary disease (9.8%). There were no differences in final diagnosis and phenotypes between 
the systematic approach and usual care groups (Table 3). In the systematic approach group, 
more lifestyle advices (81.8% vs 29.1%), symptom scores (95.5% vs 21.4%), and indi-
vidual care plans (50.0% vs 7.8%) were electronically registered compared with the usual 
care group (all P<0.001).
Time to final diagnosis and referral back to primary care
There were differences in the number of days between refer ral and first visit (difference 4.4 
days), between first visit and latest diagnostic test (difference 22.7 days), and between first 
Table 3 Final diagnosis, phenotypes, and treatment plans in the diagnostic pathway compared 
with usual care











Asthma, n (%) 67 (53.6) 56 (54.4) 11 (50.0) 0.71
Phenotyped, n (% yes) 57 (85.1) 46 (82.1) 11 (100.0) 0.13
Allergic asthma, # n (% yes) 44 (65.7) 35 (62.5) 9 (81.8) 0.22
Non-allergic asthma, # n (% yes) 11 (16.4) 9 (16.1) 2 (18.2) 0.86
Late-onset, # n (% yes) 7 (10.4) 6 (10.7) 1 (9.1) 0.87
With fixed airflow limitation, # n (% yes) 4 (6.0) 4 (7.1) 0 (0.0) 0.36
Asthma with obesity, # n (% yes) 0 (0.0) 0 (0.0) 0 (0.0) NA
COPD, n (%) 32 (25.6) 27 (26.2) 5 (22.7) 0.73
Phenotyped, n (% yes) 18 (56.3) 16 (59.3) 2 (40.0) 0.43
AAT deficiency, # n (% yes) 0 (0.0) 0 (0.0) 0 (0.0) NA
Emphysema/hyperinflation, # n (% yes) 6 (18.8) 6 (22.2) 0 (0.0) 0.24
Frequent exacerbations, # n (% yes) 12 (37.5) 10 (37.0) 2 (40.0) 0.90
Combination of asthma and COPD, n (%) 1 (0.8) 1 (1.0) 0 (0.0) 0.64
Phenotyped, n (% yes) 1 (100.0) 1 (100.0) 0 (0.0) NA
Other pulmonary disease, n (% yes) 6 (4.8) 4 (3.9) 2 (9.1) 0.30
No pulmonary disease, n (% yes) 12 (9.6) 10 (9.7) 2 (9.1) 0.93
Obesity related symptoms, n (% yes) 3 (2.4) 2 (1.9) 1 (4.5) 0.47
No diagnosis, n (% yes) 2 (1.6) 2 (1.9) 0 (0.0) 0.51
Lifestyle advices, n (% yes) 48 (38.4) 30 (29.1) 18 (81.8) <0.001
Symptom scores, n (% yes) 43 (34.4) 22 (21.4) 21 (95.5) <0.001
Individual care plans, n (% yes) 19 (15.2) 8 (7.8) 11 (50.0) <0.001
AAT: alpha 1 antitrypsin. #Patients could be categorised in more than one phenotype.
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visit and final diagnosis (difference 34.1 days) between the systematic approach and usual 
care groups. However, these differences did not reach significance (Table 4). More patients 
in the systematic approach group were referred back to primary care compared with the 
usual care group (81.8% vs 56.3%, P=0.03).
Use of PatientCoach
In the systematic approach group, 14 out of 22 patients (63.6%) logged in at least once 
on PatientCoach. Patients who used PatientCoach were significantly younger and had 
less cardiovascular comorbidities than those who did not use PatientCoach. Reasons to 
refuse the use of PatientCoach were not having a computer (N=2), lack of computer skills 
(N=4), definitely no desire to use PatientCoach without a further rea son (N=1), and for one 
patient the reason was not applicable.
Sensitivity analysis
After removing eight patients who attended the systematic approach, but refused the use 
of PatientCoach, the statistically significant differences between the systematic approach 
and usual care were still present (Supplementary tables S1 and S2).
DISCUSSION
This study was conducted to evaluate a systematic approach combined with an optional 
internet-based self-management support system for asthma and COPD patients referred 
to secondary care. In the systematic approach group compared with the usual care group, 
mean number of diagnostic tests was higher; more lifestyle advices, symptom scores, and 
individual care plans were electronically recorded; and more patients were referred back 
to primary care. There were no differences in final diagnosis and time to referral back. 










From referral to first visit in days (mean 
(SD))
37.7 (23.6) 38.4 (24.6) 34.0 (17.8) 0.43
From first visit to final diagnosis in days 
(mean (SD))
68.3 (88.0) 72.3 (91.7) 49.6 (66.9) 0.28
From first visit to latest diagnostic test in 
days (mean (SD))
116.7 (127.3) 122.7 (128.7) 88.6 (119.2) 0.26
Referred back to primary care, n (%) 76 (60.8) 58 (56.3) 18 (81.8) 0.03
Time from first visit and referral to 
primary care in days (mean (SD)) 
114.1 (97.7) 113.3 (96.0) 116.5 (105.8) 0.91
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More than half of patients were interested in an internet-based self-management support 
system when it was offered in addition to a systematic approach.
To our knowledge, this is the first study that evaluated a systematic approach in combina-
tion with an optional internet-based self-management support system as a method to 
evaluate diagnosis and symptoms and to integrate individual care plans in secondary care 
pulmonology. More diagnostic tests were performed in the systematic approach compared 
to usual care in the present study. This could be expected since the diagnostic approach 
consisted of more diagnostic tests than are stated in the guidelines. Since there were no 
differences in the final diagnoses made by pulmonologists and the process was not faster, 
this suggests that not all tests included in the systematic approach are regularly needed 
in the diagnostic work-up. In another systematic approach that has been developed for 
asthma and COPD patients in the Netherlands, other standard diagnostic tests were used: 
capillary blood gas analyses, metronome-paced hyperventila tion test, and physical activity 
assessment by accelerometry were performed in all patients; X-rays, FeNO, and allergic 
assessment were performed only in selected patients.[5] Taking the results of the present 
study and the previous Delphi study into account, it can be suggested that lung-specific 
laboratory tests, DLCO, X-rays, FeNO, and an ECG should preferably be performed on 
indication and should not be included in a systematic approach in nonselected patients, 
since these additional tests did not lead to other diagnoses. This decision will decrease the 
number of diagnostic tests and thereby costs. On the other hand, it is possible that the 
additional diagnostic tests contributed more certainty to a diagnoses of asthma or COPD, 
resulting in more referrals back to primary care, as observed in our study. This follows the 
Dutch guidelines to refer patients back to primary care when the diagnostic work-up is 
completed and patients are clinically stable.[12] Another explanation of more referrals 
back to primary care might be the higher number of written care plans, since pulmonolo-
gists might believe that the care plans will support the GP and patients in the continuation 
of care. The present study shows that if physicians are directed to register individual care 
plans, this was done more frequently than with usual care. This is in line with a systematic 
review that the use of clinical pathways result in improved documentation.[13] We think 
that more than 48.5% of patients in the usual care group did receive lifestyle advices 
and individual care plans, but these advises were given verbally and were not necessarily 
registered in the medical records. However, international guidelines recommend written 
care plans and not solely spoken arrangements.[1, 2] A designated pathway within an 
outpatient clinic could thus add to improve registration of individual care plans.
The internet-based self-management support system was accepted by 63.6% of patients, 
which is in line with a previ ous study that showed that 63% of patients would definitely or 
probably use an eHealth application if it was offered.[14] In the present study, reasons to 
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refuse eHealth were mostly computer (skill) related. A previous study showed that patients 
who do not use eHealth do not recognize the advantages of eHealth and should be con-
vinced first.[15] Patients who do have experience with the use of eHealth are positive.[15] 
The use of PatientCoach may be lower than 63.6%, because only the first login was evalu-
ated, and it is known from previous research that some patients stop using the application.
[16] Probably, more patients would use PatientCoach when previously determined barriers 
such as sufficient functionalities to tailor PatientCoach and personal guidance are further 
optimized.[17] An advantage of the use of eHealth is that patients considered eHealth as 
a possibility to take more responsibility in their own care.[15]
A strength of the present study was that the outcomes seem to be generalizable to all 
asthma and COPD patients referred to secondary care since we included nonselected 
patients and not only severe asthma and COPD patients. For difficult to manage asthma, 
systematic approaches exist[18, 19] with positive effects on asthma control, quality of life, 
and exacerbation frequency.[19] However, the results are only applicable for <15% of all 
asthma patients.[20] Care pathways for in-hospital management of exacerbated COPD 
exist, with positive effects on 30-day readmission rate. The present study shows that a 
systematic approach seems to be beneficial for all patients with asthma as well as COPD 
referred to secondary care pulmonology. However, we based our conclusions on a limited 
number of patients who were evaluated with the systematic approach. However, there 
were no differences in baseline characteristics compared with the usual care group that 
consisted of 103 patients. A limitation of the present study is the possibility of bias during 
the selection process whether patients were evaluated with the systematic approach or 
with usual care. This could have led to patients with less severe disease in the systematic 
approach since patients with acute complaints were evalu ated at the outpatient clinic 
for acute respiratory complaints. However, there were no differences in the number of 
days between referral and first visit, suggesting that a limited number of patients within 
the usual care group were referred for acute respiratory complaints. Another limitation is 
that the data were retrieved from only one university hospital. This could have resulted 
in more complex disease combined with comorbidities. Consequently, the results could 
be less generalizable to local hospitals. However, in this study only patients who were 
referred by the GP were included and those who were referred for second or third opinion 
were excluded. A third limitation is that patients who were evaluated with the systematic 
approach were evaluated by a limited number of pulmonologists, whereas the patients 
who received usual care were seen by multiple pulmonolo gists of the department. We 
do not think this affected the results, since all patients in the systematic approach group 
were systematically evaluated and the pulmonologist could not influence the standard 
diagnostic tests, whereas in the usual care group, the diversity of physicians reduces the 
possibility of a physician-dependent preference for diag nostic work-up.
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Giving the results of the present study, we recommend the use of systematic approaches 
that direct physicians to register lifestyle advices, symptoms, and individual care plans in 
daily practice, with a limited number of standard diagnostic tests. We recommend prospec-
tive evaluation of the impact of this systematic approach on disease control, quality of life, 
lifestyle changes, and costs.
CONCLUSION
A predefined systematic approach in combination with an optional internet-based self-
management support system is useful in clinical practice. Since there were no differences 
in the final diagnoses, this suggests that not all tests that were included in the systematic 
approach are regularly needed in the diagnostic work-up. The outcomes suggest that a 
desig nated systematic approach stimulates physicians to record lifestyle advices, symp-
toms, and individual care plans. Subsequently, this approach could increase the number of 
patients referred back to primary care, according to national healthcare guidelines in the 
Netherlands.
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SUPPLEMENTARY MATERIALS
Supplementary table 1. Final diagnosis, phenotypes and treatment plans in the diagnostic pathway 
compared with usual care










Asthma, n (%) 65 (55.6) 56 (54.4) 9 (64.3) 0.48
Phenotyped, n (% yes) 55 (84.6) 46 (82.1) 9 (100) 0.17
Allergic asthma,# n (% yes) 43 (66.2) 35 (62.5) 8 (88.9) 0.12
Non-allergic asthma, # n (% yes) 10 (15.4) 9 (16.1) 1 (11.1) 0.70
Late-onset, # n (% yes) 6 (9.2) 6 (10.7) 0 (0.0) 0.30
With fixed airflow limitation, # n (% yes) 4 (6.2) 4 (7.1) 0 (0.0) 0.41
Asthma with obesity, # n (% yes) 0 (0.0) 0 (0.0) 0 (0.0) NA
COPD, n (%) 29 (24.8) 27 (26.2) 2 (14.3) 0.33
Phenotyped, n (% yes) 17 (58.6) 16 (59.3) 1 (50.0) 0.80
AAT deficiency, # n (% yes) 0 (0.0) 0 (0.0) 0 (0.0) NA
Emphysema/hyperinflation, # n (% yes) 6 (20.7) 6 (22.2) 0 (0.0) 0.45
Frequent exacerbations, # n (% yes) 11 (37.9) 10 (37.0) 1 (50.0) 0.72
Combination of asthma and COPD, n (%) 1 (0.9) 1 (1.0) 0 (0.0) 0.71
Phenotyped, n (% yes) 1 (100) 1 (100) 0 (0.0) NA
Other pulmonary disease, n (% yes) 5 (4.3) 4 (3.9) 1 (7.1) 0.57
No pulmonary disease, n (% yes) 11 (9.4) 10 (9.7) 1 (7.1) 0.76
Obesity related symptoms, n (% yes) 2 (1.7) 2 (1.9) 0 (0.0) 0.60
No diagnosis, n (% yes) 2 (1.7) 2 (1.9) 0 (0.0) 0.60
Lifestyle advices, n (% yes) 43 (36.8) 30 (29.1) 13 (92.9) <0.001
Symptom scores, n (% yes) 36 (30.8) 22 (21.4) 14 (100) <0.001
Individual care plans, n (% yes) 16 (13.7) 8 (7.8) 8 (57.1) <0.001
AAT: alpha 1 antitrypsin. #Patients could be categorised in more than one phenotype.
Supplementary table 2. Time between referral, first visit, final diagnosis, latest diagnostic test 










From referral to first visit in days (mean (SD)) 37.7 (23.7) 38.4 (24.6) 32.1 (14.1) 0.35
From first visit to final diagnosis in days (mean 
(SD))
69.6 (89.3) 72.3 (91.7) 49.7 (69.4) 0.38







Referred back to primary care, n (%) 70 (59.8) 58 (56.3) 12 (85.7) 0.04
Time from first visit and referral to primary 
care in days (mean (SD)) 










The aim of this thesis was to gain more knowledge about morning symptoms and physical 
activity in chronic obstructive pulmonary disease (COPD) in search of novel treatment op-
tions. According to the latest information of the World Health Organisation (WHO), COPD 
is the third leading cause of death worldwide.[1] There are no curative options for COPD 
yet. Major treatment goals in COPD are reduction of symptoms and prevention of acute 
exacerbations. However, COPD is still in the top five leading causes of disability-adjusted 
life-years.[2] Therefore, more research is needed into factors that are related with poor 
outcomes in COPD to encourage the development of novel treatment options. In this thesis 
there is a focus on morning symptoms and physical activity. 
COPD is responsible for pulmonary symptoms such as dyspnoea, chronic cough and spu-
tum production, which can occur during any part of the day. Patients reported the morning 
as most problematic part of the day.[3] After having been overlooked for several years, the 
first study of morning symptoms in COPD was published in 2009. Nowadays, it is known 
that the majority of COPD patients suffers from symptoms in the morning.[3-10] However, 
the relation between morning symptoms and other patient characteristics is not extensively 
studied hitherto. 
Patients with COPD are less physically active when compared to their healthy peers.[11, 12] 
Low self-reported activity levels are associated with poor outcomes, such as higher mortal-
ity rates and hospitalizations.[13] It is difficult to increase physical activity, because regular 
physical activity is a lifestyle choice. In COPD, health related factors play an important role 
as well; pulmonary symptoms and fatigue are frequently mentioned as barriers to perform 
activities. There is a negative association between morning symptoms and physical activity. 
However, in earlier studies physical activity was self-reported, and the relation between 
objectively measured physical activity and morning symptoms has not been studied yet. 
The studies described in this thesis target morning symptoms and physical activity. Fur-
thermore, the association between objectively measured physical activity and morning 
symptoms is studied. The studies described in this thesis include a systematic review, results 
of a cross-sectional observational study, cross-sectional analyses of a previous cohort study 
and a real life study. In the current chapter, general conclusions from those studies are 
presented. Then, the discussion continues with methodological considerations. Thereafter, 
we discuss the questions whether morning symptoms cause physical inactivity and whether 
morning symptoms are a distinct phenotype in COPD. Then, we give our perspectives on 
the use of systematic approaches in secondary care pulmonology. Finally, we provide direc-
tions for future research and clinical practice.
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GENERAL CONCLUSIONS
In the studies in this thesis, we highlighted that morning symptoms and physical activity 
are important for COPD patients, especially for those with more symptomatic COPD. From 
existing evidence, we concluded that there was a negative association between morning 
symptoms and self-reported physical activity. We confirmed this association in the MOrn-
ing symptoms in-Depth observationAl Study (MODAS), whereby we objectively measured 
physical activity. Furthermore, we were the first group that looked at activity patterns 
during the course of the day while taking morning symptoms into account. We showed 
differences in the number of steps in the morning and afternoon between patients with 
high morning symptom scores when compared to patients with low morning symptom 
scores. Thus, morning symptoms and physical activity are associated and they are impor-
tant targets for therapy in moderate to very severe COPD. Also, we showed that there is an 
association between lower health status, increased anxiety and depression, lower physical 
activity, lower pulmonary function and morning symptoms. Furthermore, we observed in 
non-severe COPD that pulmonary function was associated with physical activity. Those 
findings make morning symptoms and physical activity even more interesting as a target 
for intervention. With our research, we gained new insights for future (interventional) 
studies in morning symptoms and physical activity in COPD. Furthermore, for clinical prac-
tice we encourage the use of a systematic approach for patients with (suspected) asthma 
and COPD referred to secondary care pulmonology, since we showed that a  systematic ap-
proach stimulates physicians to record lifestyle advice including physical activity, symptoms 
and individual care plans.
METHODOLOGICAL CONSIDERATIONS
In research it is important to design high quality studies and minimize the risk of bias.
[14] In studies that investigate symptoms or lifestyle as physical activity in general, we 
should be aware that the results of the studies may suffer from selection bias. The most 
symptomatic or disabled patients probably do not participate in such studies. Thus, the 
studies presented in this thesis may be less generalizable for the most symptomatic and 
disabled patient group. 
Study designs
The studies described in this thesis include a systematic review, results of a cross-sectional 
observational study, cross-sectional analyses of a previous cohort study and a real life study. 
All study designs have their advantages and disadvantages.[15] Systematic reviews and 
meta-analyses are at the top of the evidence based medicine hierarchy.[14] However, in the 
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systematic review included in this thesis, outcomes from previous studies were not always 
comparable, since different tools were used to assess morning symptoms and physical 
activity. Therefore, a pooled meta-analysis was not possible. Cross-sectional observational 
studies are designed to test a hypothesis in a prespecified patient population, under op-
timal circumstances and controlled for confounders. A main advantage of cross-sectional 
studies is that they can be used to identify new research fields. In the MODAS, this was 
the association between morning symptoms and objectively measured physical activity. In 
the Netherlands Epidemiology of Obesity (NEO) study, these were patient characteristics 
of non-severe COPD patients that were related with physical activity. On the other hand, 
disadvantages of cross-sectional studies are that outcomes are less generalizable to real 
life situation due to the optimally created circumstances and longitudinal outcomes are 
lacking. For example, in the NEO study the use of nearly all pulmonary medication was 
associated with less physical activity. However, we did not know the physical activity levels 
before the use of pulmonary medication, resulting in the situation that we were probably 
looking at already improved activity levels. Real life studies do not have this disadvantage, 
but they have low internal validity and registration can be suboptimal. In this thesis, differ-
ent study designs contributed to different outcomes. However, different study populations, 
different morning symptom questionnaires and different tools to assess physical activity 
also contributed to differences in results, and will be discussed in the next paragraphs. 
Study population
Morning symptoms and physical inactivity are already present in non-severe COPD stages. 
Therefore, it is important to study all disease stages. In the systematic review, the severity 
of COPD was not an in- or exclusion criterion. In the NEO study, patients were included in 
the analyses if they had physician diagnosed COPD with an International Classification of 
Primary Care (ICPC) code for COPD (R95) or if patients met our criteria for newly diagnosed 
COPD. Patients with a forced expiratory volume in 1 second (FEV1) <50% were excluded, 
since the focus of the study was on non-severe COPD. In this study, 76% of patients met 
the criteria for newly diagnosed COPD. This could have influenced the outcomes, since 
probably some of the patients do not suffer from COPD and suffer from another obstruc-
tive pulmonary disease such as asthma. Participants of the NEO study were recruited by 
general practitioners or through advertisements. In contrast, patients who participated in 
the MODAS, were those with moderate to very severe COPD and they were mainly recruited 
at the department of pulmonology in hospitals. COPD patients treated in secondary care 
pulmonology have in general more exacerbations, high symptom scores, coping problems, 
severe to very severe airway obstruction or hypoxia.[16] Patients who participated in the 
MODAS have a high burden of disease and were in advance more likely to have morning 
symptoms or activity limitations when compared to patients with a low burden of COPD 
who participated in the NEO study. 
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Morning symptom questionnaire
The use of different morning symptom questionnaires largely contributed to different 
occurrence rates of morning symptoms. For many years, researchers created their own 
morning symptom questionnaires that did not undergo a validation process.[6, 17-22] For 
explorative research in this field, we agree with the use of non-validated questionnaires. In 
the NEO study, that was a large population-based cohort study that was designed to help 
better understand development of diseases especially in obesity, participants filled in one 
non-COPD specific question about the increase of symptoms in the morning. Participants 
were not able to rank the severity of their morning symptoms. We think that the outcome 
of this question would have been different if there was an additional question about the 
severity of symptoms. It is reasonable to suppose that more patients would have filled in 
that they experience symptoms in the morning if this additional questionnaire was present, 
because it is known that patients with COPD tend to underestimate their symptoms if 
they are not severe enough, in their experience.[23] Furthermore, the time period of the 
morning was not clearly defined, whereby it could be unclear for participants whether 
they should rate their symptoms at the moment of awaking or during the entire morn-
ing. In the MODAS the primary outcome of the study was morning symptom severity. 
The PRO-morning COPD Symptom questionnaire was used to evaluate these symptoms. 
The PRO-morning COPD Symptom questionnaire is a six itemed questionnaire that was 
especially developed to evaluate morning symptoms in COPD. The pre-bronchodilator 
mean morning symptom score in the MODAS was only slightly higher than in a previous 
study that used this morning symptom questionnaire as well.[19] This questionnaire is not 
validated, but seems to be a reliable method to assess morning symptoms since the mean 
score in the MODAS was nearly comparable with mean morning symptom score in the 
above mentioned study. Furthermore, the six included questions in the questionnaire are 
in accordance with a recent validated morning symptom questionnaire.[24] This validated 
questionnaire consists of a 6-item symptom severity score, an overall symptom severity 
score, an activity limitation score, the use of rescue medication and includes a clear defini-
tion of the morning period. Thus, in the NEO study the occurrence of morning symptoms 
may be underestimated, while in the MODAS the occurrence of morning symptoms seems 
more reliable. For future research, we encourage the use of a validated morning symptom 
questionnaire. Using the same questionnaire results in more comparable outcomes and the 
minimal clinical important difference can be estimated. 
Physical activity assessment
Physical inactivity is common in COPD and associated with poor patient related outcomes.
[13] Therefore, it is important to search for factors that influence physical activity. In the 
NEO study, the short questionnaire to assess health-enhancing physical activity (SQUASH)
[25] was used. It should be noted that the SQUASH has not frequently been used in 
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COPD patients. A disadvantage of the use of activity questionnaires in general is that 
patients overestimate standing time and underestimate sitting time.[26] However, in a 
large population-based cohort study it used to be too expensive and too time consuming 
to use objective methods to assess physical activity. Though, nowadays, with new tech-
nologies as smartphones with integrated pedometers, it is possible to objectively measure 
physical activity in large groups of patients. However, the use of smartphones is relatively 
new in this field and needs to be validated in COPD patients.[27, 28] In the MODAS, the 
international physical activity questionnaire (IPAQ) was used to evaluate which activities 
were performed. Furthermore, the MoveMonitor, a validated accelerometer,[29, 30] was 
used to assess physical activity. Patients were instructed to wear the accelerometer day 
and night for seven consecutive days. This resulted in 24-hour real life physical activity 
recording. Results of objectively measured physical activity as shown in chapter 3 were 
not in accordance with the results of the IPAQ in chapter 4. This confirms that patients 
overestimate self-reported physical activity levels. Thus, we should carefully interpret 
physical activity that was evaluated with questionnaires. However, accelerometers have 
disadvantages as well. In the MODAS the major disadvantages of the used accelerometer 
were the lack of adherence to the wearing instructions, absence of difficulty scores and 
the non-water resistance of the accelerometer. In the MODAS 6% of the measured days 
were not included in the analyses due to non-adherence to wearing instructions vs. 1% of 
patients in the NEO study that did not complete the activity questionnaire. Furthermore, 
accelerometers do not capture the experience and difficulty of physical activity. Experience 
and difficulty are important for patients. It was reported that patients consider the physical 
effects associated with the occurrence of symptoms in the morning as a greater challenge 
than the symptoms themselves.[9] Therefore, in 2015 a PROactive tool was developed that 
combined variables retrieved from accelerometry with difficulty scores retrieved from a 
questionnaire.[31] Also, the accelerometer is not water resistant. In the context of physical 
inactivity due to morning symptoms, this is an important limitation, since most self-care 
routines such as taking a shower or bathing are undertaken in the morning. This could 
have resulted in an underestimation of physical activity in the morning. Since we used 
an accelerometer, we could compare the number of steps taken during different parts of 
the day between patients with high and low morning symptom scores (chapter 4). This 
study was the first study that described activity patterns during the course of the day while 
taking morning symptoms into account. 
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MORNING SYMPTOMS CAUSE PHYSICAL INACTIVITY, OR IS 
IT THE OTHER WAY AROUND?
The morning is the most symptomatic part of the day for patients with COPD.[3] One of 
the factors that is negatively associated with morning symptoms is physical activity (chap-
ter 2), which we confirmed in the MODAS, using an accelerometer to objectively measure 
physical activity (chapter 3). Chapter 4 showed that patients with low morning symptom 
scores took more steps in the morning and in the afternoon than patients with high morn-
ing symptoms scores. Given the results of previous studies and the MODAS, the following 
question arises: are morning symptoms the reason why patients are inactive? Or is it the 
other way around, and is physical inactivity the reason why patients have symptoms in the 
morning? We will discuss the hypotheses “morning symptoms cause physical inactivity” 
and “physical inactivity causes morning symptoms” based on existing evidence. 
Morning symptoms cause physical inactivity
If morning symptoms cause physical inactivity, morning symptoms will be an important 
target for intervention. Patients experience symptoms as an important barrier to being 
physically active.[32, 33] Dyspnoea has been shown to be the most important factor to 
explain physical inactivity.[34] Dyspnoea is one of the most common (chapter 2) and most 
severe (chapter 3) symptoms in the morning. The morning is the most active period of the 
day in which many self-care activities are undertaken that can cause or worsen symptoms.
[22] Physical inactivity could be a coping mechanism to avoid or reduce symptoms. Many 
patients with COPD reported that they reduce physical activities and changed their morn-
ing routines due to symptoms.[8] Physical inactivity resulting in less symptoms, could be 
the explanation why we found no association between morning symptoms and physical 
activity in the NEO study (chapter 5). In the MODAS, patients with high morning symptom 
scores spend a comparable number of minutes on moderate to vigorous intensity physical 
activity when compared to patients with low morning symptoms scores. However, when 
looking at bouts of at least ten minutes, these patients spend significantly less minutes 
doing moderate to vigorous intensity physical activity. This suggests that patients are able 
to be physically active, but their stamina is decreased. Thus, morning symptoms can cause 
serious physical activity limitations that need to be recognised.
Previous studies have shown positive effects of inhaled medication on morning symptoms 
and physical activity. [4, 6, 8, 22, 35-37] This indicates that there could be causality be-
tween morning symptoms and physical activity: when morning symptoms were improved, 
physical activity was improved as well. It should be noted that the effect of an once-daily 
formula in the evening on morning symptoms has not been studied yet. Since pulmonary 
symptoms vary over the day,[5] studying the effects of taking medication during differ-
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ent parts of the day is necessary. Another promising method to decrease symptoms and 
increase physical activity is the combination of interventions, such as the combination of a 
self-management program with bronchodilators.[38]
Physical inactivity causes morning symptoms
It could also be true that physical inactivity is the cause of morning symptoms. Physical 
inactivity results in a downward spiral of muscular disuse, muscular dysfunction,[39] mus-
cular depletion and deconditioning.[40] The lower limbs are affected, as well the diaphrag-
matic muscles. One third of patients with COPD have muscular dysfunction, including in 
the early stages of the disease. Deconditioning and muscle weakness cause progressive 
shortness of breath during exercise. Thus, the consequences of physical inactivity con-
tribute to symptoms. We think that symptoms in general can be extrapolated to morning 
symptoms, because in this context, the underlying origin is the same. Whereas exercise 
causes a temporary increase in symptoms, prolonged periodic exercise finally results in 
more fatigue-resistant muscles.[41] The American College of Sports and Medicine recom-
mends to perform 8 to 10 muscle strength exercises on two or more non-consecutive days 
each week[42]. COPD patients are encouraged to follow this recommendation, to become 
less symptomatic.
In conclusion, yet, both hypotheses could be true since prospective studies in this field 
are lacking and the existing evidence mostly stems from observational studies. Previous 
qualitative studies clearly showed that patients experience struggles in the morning due to 
morning symptoms. Therefore, we conclude that morning symptoms cause activity limita-
tions. On the other hand, other previous studies showed muscle dysfunction in COPD on 
molecular base. Therefore, we have to search for (a combination of) interventions that 
target morning symptoms as well physical activity.
ARE MORNING SYMPTOMS TO A DISTINCT PHENOTYPE IN 
COPD?
In obstructive lung diseases, phenotyping has become more an important topic. In the last 
years, it has become apparent that different phenotypes in COPD patients need different 
therapeutic approaches. Patients with higher blood eosinophil counts seem to benefit from 
inhaled corticosteroids,[43] while the use of bronchodilators results in improvement of 
exercise performance in patients with dynamic hyperinflation.[44] Phenotyping can result 
in more tailored treatment on an individual patient level. It would be of interest if patients 
with high morning symptoms comprise a distinct phenotype and become a new treatable 
phenotype in COPD. 
146 Chapter 7
Definition of a phenotype
One previous study that investigated the hypothesis that morning symptoms are a distinct 
phenotype of highly symptomatic patients not captured by Clinical COPD Questionnaire, 
concluded that morning symptoms belong not a distinct phenotype in COPD.[45] This was 
based on the fact that only a small proportion of patients with low or slightly lower COPD 
health status, had high morning symptoms scores.[45] However, before we can speak 
about a phenotype, we should have a broader look at the definition of a phenotype. A 
phenotype in COPD has been defined as “a single or combination of disease attributes that 
describe differences between individuals with COPD as they relate to clinically meaningful 
outcomes.”[46] Hitherto, the predictive value of morning symptoms for meaningful out-
comes as symptoms, exacerbations, disease progression and mortality are not well known. 
The MODAS was a cross-sectional study, so did also not contribute to the predictive value 
of morning symptoms. Increasing the knowledge of the aetiology of morning symptoms 
can be helpful to inform the discussion on phenotyping better. 
Possible aetiology of morning symptoms
Yet, the aetiology of morning symptoms is not known. Morning symptoms are not an 
independent factor in COPD, but are dependent on multiple other factors that can be 
influenced. Here we discuss associated characteristics that are described in chapter 3 as 
possible underlying mechanisms of morning symptoms. First, pulmonary function was 
associated with morning symptoms. Possibly, morning symptoms reflect the circadian 
variation of pulmonary function, since the worst pulmonary function is between 3 and 
6a.m.[47] However, not all patients experience morning symptoms on each day and pul-
monary function is only poorly correlated with symptoms in general.[48] Therefore, the 
severity of airflow limitation does contribute to symptoms in the morning, but it is not the 
only factor. Another characteristic that was associated with morning symptoms is lower 
health status. Health status reached the highest explained variance for morning symptoms 
in the MODAS. The association has been described frequently in previous studies.[9, 10, 
45, 49, 50] In the MODAS, morning symptoms were associated with increased anxiety 
and depression and this association was also found in previous studies, although causality 
is not known.[7, 9, 10, 49] A previous study showed that dyspnoea is the symptom that 
concerns patients the most.[51] Anxiety for dyspnoea can lead to a down-ward spiral of 
anxiety-induced dyspnoea and further increased anxiety.[52] These factors together can 
contribute to symptoms in the morning. Another characteristic that was associated with 
morning symptoms in the MODAS was higher burden of symptoms. Maybe, the persistent 
high symptom scores are due to different types of dyspnoea with different underlying 
mechanisms. Whereas air hunger is caused by chemoreflex activity which is inhibited 
by pulmonary (hyper)inflation; the feeling of increased work of breathing is caused by 
muscle weakness; chest tightness is caused by bronchospasm; and tachypnoea is caused 
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by stimulation of pulmonary C fibres.[53] It is known from previous research that morning 
symptoms are associated with symptoms in other parts of the day, such as the evening 
and night.[7, 10, 45] This suggests that there is a factor in these patients that persists 
over the day that causes symptoms during several parts of the day. This might be due 
to local inflammation that causes mucus hypersecretion[54] and increased systematic 
inflammation that contributes to more exacerbations.[55] In chapter 4, patients with high 
morning symptoms scores were more likely to have had an exacerbation in the previous 
year when compared to patients with low morning symptom scores. In chapter 3, in the 
unadjusted regression analysis, there was also an association between morning symptoms 
and exacerbations. The association between morning symptoms and exacerbations has 
been described frequently. [7, 9, 45] It was suggested in a previous study that there might 
be an overlap between the chronic bronchitis phenotype and the patient group with morn-
ing symptoms.[9] 
Other underlying mechanisms that may cause morning symptoms, but have to our knowl-
edge not been studied, include sputum retention during the night, immune mediated causes 
and circadian variation in cortisol levels. When asleep, cough reflex sensitivity is diminished 
when compared to a waking state and there are less external stimuli that induce cough.
[56] Impaired cough during the night can cause sputum retention during the night, which 
results in symptoms, such as cough and dyspnoea in the morning. We also hypothesize 
that the immune system influences symptoms in the morning. In asthma and allergy, which 
are T-helper 2 (Th2) diseases, patients experience an increase of symptoms in the morning.
[57] If patients with morning symptoms are those with more Th2 inflammation, this can be 
the cause of morning symptoms. Finally, pulmonary function is not the only system with a 
circadian variation. There is a possibility that circadian variation in cortisol levels may affect 
morning symptoms as well. The cortisol awakening response occurs 30 to 45 minutes after 
awakening and during sleep the level drops to the lowest point.[58, 59] Altered responses 
in cortisol have been shown to be associated with psychological disorders as fatigue and 
depression. Depression is associated with morning symptoms. Furthermore, a recent study 
among police officers showed that sufficient physical activity could be protective against 
diminished awaking cortisol levels that were associated with poor sleep quality.[60] 
We can conclude that morning symptoms are related to other factors that are associated 
with poor outcomes in COPD. However, it is not possible yet to state that morning symp-
toms are a distinct phenotype in COPD since we should first know the effects of morning 
symptoms on long term. In this chapter, we provided several relevant factors that can be 
studied to enlarge our knowledge about morning symptoms, which is needed to verify 
whether morning symptoms are a distinct phenotype in COPD. 
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SHOULD PULMONOLOGISTS EVALUATE ALL COPD PATIENTS 
WITH A SYSTEMATIC APPROACH?
An (inter)national systematic approach for COPD patients referred to secondary care does 
not exist. However, it be questioned whether pulmonologists need a systematic approach 
to diagnose obstructive lung diseases and improve treatment plans. Previous studies have 
shown that physicians do not always adhere to guidelines, because of low familiarity with 
the guidelines, low self-efficacy, and time constraints.[59] In chapter 6, we found that 
more lifestyle advice, more symptom scores and more individual care plans were recorded 
in the electronic records of patients who were evaluated with the systematic approach 
when compared to usual care. However, the systematic approach did not contribute to a 
more specific diagnosis. The outcomes of the study suggest that conditions and impact 
of COPD become more emphasized when a systematic approach is used when compared 
to usual care. This is in line with the fact that clinicians are most likely to discuss domains 
that are related to clinical features.[61] Therefore, we recommend the use of systematic 
approaches in clinical practice. We encourage to include morning symptoms and physical 
activity assessments in systematic approaches as well. Morning symptoms are common 
and important for COPD patients. However, these symptoms are not mentioned in inter-
national COPD guidelines and statements yet.[62] This might be due to that the aware-
ness for morning symptoms is relatively new in COPD after being overlooked for several 
years. When morning symptoms are integrated in upcoming guidelines and statements, 
we expect that physicians will often forget to ask about morning symptoms, because 
they are not used to doing it, even though. Patients have reported that they need to 
discuss morning symptoms.[8] When integrated in a systematic approach, this could help 
to facilitate the discussion and awareness. In the real life study (chapter 6), there was no 
physical activity assessment included in the systematic approach, although it was included 
in the outcome lifestyle advice. However, including objectively measuring physical activity, 
will help to get insight in actual physical activity levels, since it is difficult for patients to 
correctly estimate activity levels. Furthermore, it will lead to the recognition of physical 
inactivity and adverse effects of physical inactivity. We are aware that the implementation 
of objective physical activity assessments will result in large-scale use of accelerometers 
resulting in higher costs. Also, expertise in evaluating physical activity patterns is needed. 
However, an accurate measurement of physical activity gives opportunities regarding pa-
tient tailored activity recommendations. We think that new technologies as smartphones 
with integrated pedometers provide a relatively easy method to objectively measure 
physical activity. However, the use of such tools in clinical practice needs to be validated in 
future studies.[27, 28] 
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DIRECTIONS FOR FUTURE RESEARCH AND CLINICAL 
PRACTICE
As discussed above in the discussion section, more research is needed to further increase 
the knowledge about morning symptoms and the relation with physical activity. First, 
the aetiology of morning symptoms should become more clear. Various factors, such as 
health status, anxiety and depression, physical activity, pulmonary function, exacerbations, 
sputum retention during the night, immune mediated causes and circadian variation in 
cortisol levels can be studied in the light of morning symptoms. When designing prospec-
tive studies, meaningful outcomes such as symptoms, exacerbations, disease progression 
and mortality should be used. With the results of such studies, we can determine whether 
morning symptoms constitute a distinct phenotype in COPD. Hopefully, the outcomes 
will encourage the integration of morning symptoms in future guidelines, statements and 
systematic approaches. For future research in the morning symptoms field, we recom-
mend the use of a validated morning symptom questionnaire. Morning symptoms are not 
severe in all COPD patients. We think that patients who are referred to secondary care 
pulmonology are more prone to have more severe morning symptoms. Especially in this 
patient group, physicians should carefully assess morning symptoms in addition to general 
COPD-specific questionnaires. To implement this in usual care, we recommend the use 
of systematic approaches, since this improves the documentation of symptoms. Morning 
symptoms can be treated with medication. However, the effect of an once-daily formula in 
the evening on morning symptoms has not been studied yet. Since pulmonary symptoms 
vary over the day, the effects of taking medication on different parts of the day should be 
studied. As discussed above, the long-term effect of physical activity increase is expected to 
result in a decrease in morning symptoms. Physical activity should be assessed with objec-
tive methods in research, but also in clinical practice. A combination with a questionnaire 
that evaluates the difficulty to perform physical activity is warranted. With this approach, it 
becomes more clear whether patients are they limited by symptoms, by physical inactivity 
or both. A possibility to improve physical activity in patients with high morning symptom 
scores, is offering physical activity programs in the evening instead of morning/afternoon. 
If patients suffer from symptoms in the morning and have already made changes in morn-
ing routines due to symptoms, it might in our opinion not be effective to stimulate physical 
activity in the morning. Offering physical activity programs in the evening will potentially 
result in less interference with daily activities. This can result in more adherence to activity 
recommendations, also in the post-rehabilitation period. Since physical inactivity is already 
present in non-severe COPD stages, we recommend to include patients with non-severe 
COPD in studies as well. We think that physical activity interventions have the potential 
to slow down disease progression. It is promising to combine interventions to improve 
morning symptoms as well as physical activity. Examples of interventions are presented in 
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figure 1. Combining interventions can potentially result in synergistic positive effects, but 
this needs to be studied in future studies.  
Figure 1. Relation between morning symptoms and physical activity. A) Untreated situation: morning 
symptoms causes physical inactivity. B) Untreated situation: physical inactivity causes morning symptoms. 
C) Interventions to increase physical activity and morning symptoms. A combination of interventions 




COPD: chronic obstructive pulmonary disease
FEV1: forced expiratory volume in 1 second
IPAQ: international physical activity questionnaire
LUMC: Leiden University Medical Center
MODAS: MOrning symptoms in-Depth observationAl Study
NEO: Netherlands Epidemiology of Obesity
SQUASH: short questionnaire to assess health-enhancing physical activity
TH2: T-helper 2
WHO: World Health Organisation
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Chapter 1 provided an overview of chronic obstructive pulmonary disease (COPD) in gen-
eral, morning symptoms in patients with COPD, physical activity in general and physical 
activity in COPD. The World Health Organisation (WHO) showed in their most recent report 
on the top ten causes of death that COPD is the third leading cause of death worldwide. 
There are no curative options for COPD yet. However, COPD is a treatable disease, whereby 
reduction of symptoms and prevention of acute exacerbations are seen as most important 
treatment goals. Symptoms can occur during each part of the day, whereby the morning is 
the most symptomatic part of the day. Exacerbations are defined by the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) as a sudden worsening of respiratory symptoms 
that result in additional therapy. COPD can be treated with bronchodilators, inhaled corti-
costeroids and lifestyle advises such as smoking cessation, exercise training and sufficient 
physical activity. Physical activity is defined by the WHO as “any bodily movement produced 
by skeletal muscles that results in energy expenditure.” Unfortunately, physical inactivity 
is common in COPD. Physical inactivity in COPD is related to high mortality rates, lower 
quality of life, more dyspnoea and more previous exacerbations. Despite the mentioned 
treatment options, COPD frequently causes disability. More research is needed in factors 
that are related with poor outcomes in COPD, such as morning symptoms and physical 
inactivity. The aim of this thesis was to gain more knowledge about morning symptoms 
and physical activity in COPD in search of novel treatment options.
In chapter 2, the results of a systematic review on the current evidence of the association 
between morning symptoms and physical activity in patients with COPD were shown. Eight 
studies were included in this review. Across all COPD stages, 37.0 to 90.6% of patients 
reported a relation between more morning symptoms and lower self-reported physical 
activity. All included studies used questionnaires to assess physical activity. 
Following the results of the systematic review, we designed the MOrning symptoms in-Depth 
observationAl Study (MODAS) to evaluate the association between morning symptoms, 
other patient characteristics and objectively measured physical activity. The MODAS was 
a single center cross-sectional study that was conducted at the Leiden University Medical 
Center (LUMC). 80 patients with moderate to very severe COPD were included. Morning 
symptoms were assessed with the PRO-Morning COPD symptoms questionnaire. Patients 
ranked the severity of dyspnoea, sputum production, chest tightness, wheezing, cough in 
the morning and limitations due to symptoms in the morning. The total score of the PRO-
Morning COPD symptoms questionnaire ranged from 0 to 60. A low scores indicates less 
morning symptoms than a high score. Physical activity was objectively measured with an 
accelerometer that was worn on the lower back for seven consecutive days, 24-hour a day. 
An accelerometer is a device that measures acceleration in different axes. In chapter 3, 
we showed that patients had a mean morning symptom score of 19.7. We demonstrated 
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that patients with overall more symptomatic COPD have higher morning symptom scores. 
Therefore, we concluded that morning symptoms should be carefully assessed in addition to 
general COPD-specific questionnaires measuring symptoms, especially in those with more 
symptomatic COPD. Furthermore, lower health status, increased anxiety and depression, 
lower objectively measured physical activity and lower pulmonary function were associated 
with an increased morning symptom severity. These factors can be potential targets for 
intervention to improve morning symptoms. In chapter 4, we described physical activity 
patterns during the course of the day. Patients were divided into two groups of comparable 
size based on their morning symptom score: 41 patients had low a morning symptom 
score (total morning symptom score <17.0) and 39 patients had a high morning symptom 
score (total morning symptom score ≥17.0). We showed that patients with low morning 
symptom scores took more steps in the morning and afternoon than patients with high 
morning symptom scores. There was no significant difference in number of steps during 
the evening and night between patients with low and high morning symptoms scores. 
This was the first study that investigated activity patterns in patients with COPD during 
the course of the day, while taking morning symptoms into account. However, causality 
between morning symptoms and physical activity during different parts of the day could 
not be proven, due to the cross-sectional design of the study. We speculated that physical 
activity programs in the evening instead of the morning or afternoon might be helpful for 
COPD patients with morning symptoms, as the evening seems to be the most suitable part 
of the day for increasing physical activity. 
Since physical inactivity is already present in mild and moderate COPD, we focussed in 
chapter 5 on physical activity and associated characteristics in non-severe COPD patients. 
We used baseline data from the Netherlands Epidemiology of Obesity (NEO) study, a large 
population-based cohort study that was conducted from 2008 to 2012 in the greater area 
of Leiden, the Netherlands. Patients were included in the analyses if they had physician 
diagnosed COPD with an International Classification of Primary Care (ICPC) code for COPD 
(R95) or if patients met our criteria for newly diagnosed COPD. 323 patients were included, 
of which 77 met the criteria for physician diagnosed COPD and 246 met the criteria for 
newly diagnosed COPD. We showed that pulmonary function was positively associated 
with self-reported physical activity in patients with non-severe COPD. The presence of a 
physician diagnosed COPD and the use of nearly all pulmonary medication were associated 
with less self-reported physical activity. In this study, we found no association between 
increased symptoms in the morning and self-reported physical activity. We concluded that 
prospective intervention studies are needed to determine whether early pharmacological 
interventions and/or physical activity could slow down COPD progression in non-severe 
COPD. It is important to include patients with non-severe COPD in studies, because there 
is room for improvement in this specific patient group. 
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In chapter 6, we evaluated a novel systematic approach for patients with (suspected) 
asthma and COPD referred to secondary care pulmonology. Patients visited the outpatient 
clinic of the department of pulmonology at the LUMC. The systematic approach consisted 
of a predefined systematic diagnostic evaluation. An internet-based self-management 
support system was a non-obligatory part of the systematic approach. Outcomes were 
compared to usual care. 125 patients were included in the study, of which 22 (21.4%) were 
evaluated with the systematic approach. Patients who were evaluated with the systematic 
approach underwent more diagnostic tests when compared to usual care. There were no 
differences in the final diagnoses. This suggests that only a part of the diagnostic tests 
that were included in the systematic approach are regularly needed to make specific diag-
nosis. More lifestyle advice, symptom scores and individual care plans were electronically 
recorded. Furthermore, more patients were referred back to primary care when compared 
to usual care. We showed in our study that it is possible to use a systematic approach in 
secondary care pulmonology and that this stimulates physicians to record lifestyle advice, 
symptoms and individual care plans. Further research is needed to evaluate the impact of 
this systematic approach on disease control, quality of life, lifestyle changes and costs.
In chapter 7, we provided a general summary, we discussed hypotheses based on the 
studies in this thesis and gave directions for future research and clinical practice. We 
started the discussion with methodological considerations. We concluded that different 
study populations, morning symptom questionnaires, tools to assess physical activity and 
study designs contributed to differences in study outcomes. Thereafter, we discussed 
the question whether morning symptoms cause physical inactivity, or is it the other way 
around. There is a relation between morning symptoms and physical activity as shown in 
the MODAS and previous studies. We believe that it is twofold; morning symptoms can 
cause physical inactivity, but physical inactivity can cause morning symptoms as well. Yet, 
it is not possible to prove causality between morning symptoms and physical activity since 
prospective studies are lacking. Therefore, we have to search for (a combination of) inter-
ventions that target morning symptoms as well physical activity. Then, we discussed the 
question whether morning symptoms are a distinct phenotype in COPD. A phenotype in 
COPD has been defined as “a single or combination of disease attributes that describe dif-
ferences between individuals with COPD as they relate to clinically meaningful outcomes.” 
We concluded that morning symptoms are related to other factors that are associated with 
poor outcomes in COPD. However, it is not possible yet to state that morning symptoms 
are a distinct phenotype in COPD since we should first know the effects of morning symp-
toms on long term. Thereafter, we discussed the question whether pulmonologists need a 
systematic approach to diagnose obstructive lung diseases and improve treatment plans. 
We concluded that a systematic approach is not necessary to make specific diagnoses, but 
it can be used as a tool to pay attention for patient characteristics that can be overlooked 
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in clinical practice. In this thesis we argued for the implementation of the assessment of 
morning symptoms and objectively measured physical activity in systematic approaches. 
The studies in this thesis highlighted the importance of morning symptoms and physical 
inactivity in patients with COPD. With our research, we gained new insights in morning 
symptoms and physical activity in COPD. These factors can be used as targets for therapy 
in future interventional studies. Combining interventions can potentially result in even 
greater positive effects, but this needs also to be studied in future studies.   
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LIST OF ABBREVIATIONS AND EXPLANATIONS
Accelerometer: a device that measures acceleration in different axes 
COPD: chronic obstructive pulmonary disease
GOLD: Global Initiative for Chronic Obstructive Lung Disease
ICPC: International Classification of Primary Care
LUMC: Leiden University Medical Center
MODAS: MOrning symptoms in-Depth observationAl Study
NEO study: Netherlands Epidemiology of Obesity study
Phenotype: “a single or combination of disease attributes that describe differences be-
tween individuals with COPD as they relate to clinically meaningful outcomes”
Physical activity: “any bodily movement produced by skeletal muscles that results in energy 
expenditure”








Hoofdstuk 1 geeft een overzicht van chronische obstructieve longziekte (COPD) in het 
algemeen en longklachten in de ochtend bij mensen met COPD. Daarnaast geeft dit 
hoofdstuk een samenvatting over lichamelijke activiteit in het algemeen en lichamelijke ac-
tiviteit bij mensen met COPD. COPD is op dit moment wereldwijd doodsoorzaak nummer 
drie (Bron: Wereldgezondheidsorganisatie). Heden ontbreken er behandelingen die COPD 
genezen. De belangrijkste doelen bij de behandeling van COPD zijn het verminderen van 
longklachten en het voorkomen van longaanvallen. Longklachten kunnen op ieder moment 
van de dag voorkomen, maar de meeste mensen met COPD ervaren de ochtend als meest 
problematische periode van de dag. Een longaanval is een plotselinge verslechtering van 
longklachten waar aanvullende behandeling voor nodig is (Bron: richtlijn Global Initiative 
for Chronic Obstructive Lung Disease 2018). COPD kan behandeld worden met luchtwe-
gverwijders, ontstekingsremmers en lifestyleadviezen. Voorbeelden van lifestyleadviezen 
zijn stoppen met roken, spier- en botversterkende oefeningen en lichamelijke activiteit. 
Lichamelijke activiteit wordt gedefinieerd als “iedere beweging van het lichaam, opgewekt 
door skeletspieren, die energie verbruikt” (Bron: Wereldgezondheidsorganisatie). Helaas 
komt lichamelijke inactiviteit vaak voor bij mensen met COPD. Lichamelijke activiteit bij 
mensen met COPD heeft een relatie met hogere kans op sterfte, lagere kwaliteit van leven, 
meer benauwdheidsklachten en meer longaanvallen. Ondanks de hierboven genoemde 
behandelopties, is COPD verantwoordelijk voor beperkingen in het dagelijks leven. Om de 
ontwikkeling van nieuwe behandelopties aan te moedigen, is er meer onderzoek noodza-
kelijk naar negatieve factoren bij COPD, zoals longklachten in de ochtend en lichamelijke 
inactiviteit. Het doel van dit proefschrift was om meer inzicht te krijgen in longklachten in 
de ochtend en lichamelijke activiteit.
Hoofdstuk 2 richt zich op bestaande literatuur die de relatie tussen longklachten in de 
ochtend en lichamelijke activiteit bij mensen met COPD beschrijft. Acht gepubliceerde 
onderzoeken werden geïncludeerd. Alle ziektestadia waren vertegenwoordigd. Er werd 
geconcludeerd er bij 37.0 tot 90.6% van de mensen met COPD een relatie was tussen het 
hebben van meer longklachten in de ochtend en minder zelf-gerapporteerde lichamelijke 
activiteit. Als kanttekening werd geplaatst dat alle onderzoeken die gebruikt werden om 
tot deze conclusie te komen, gebruik maakten van vragenlijsten om lichamelijke activiteit 
te meten en er hadden geen objectieve metingen plaatsgevonden. 
In reactie hierop, werd een onderzoek opgezet met de naam “MOrning symptoms in-
Depth observationAl Study” (MODAS), om de relatie tussen longklachten in de ochtend, 
andere patiëntkenmerken en objectief gemeten lichamelijke activiteit bij mensen met COPD 
te bestuderen. De MODAS werd uitgevoerd in het Leids Universitair Medisch Centrum 
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(LUMC). 80 mensen met matig tot zeer ernstig COPD werden geïncludeerd. Longklachten 
in de ochtend werden gemeten met een vragenlijst, de PRO-Morning COPD symptoms 
questionnaire. Met deze vragenlijst konden patiënten de ernst van de benauwdheid, de 
slijmproductie, het strakke gevoel om de borst, de piepende ademhaling, het hoesten in 
de ochtend en de beperkingen door deze symptomen scoren. De totale score was tus-
sen 0 en 60. Hoe lager de score, des te minder klachten heeft de patiënt. Elke patiënt 
bezocht één dag het LUMC. Daarna werd er 24 uur per dag een accelerometer op de 
onderrug gedragen voor zeven aaneengesloten dagen. Accelerometers zijn apparaten met 
bewegingssensoren die bewegingen in meerdere richtingen registreren. In hoofdstuk 3 
worden de uitkomsten van dit onderzoek beschreven. Patiënten hadden een gemiddelde 
score van 19.7 op de PRO-Morning COPD symptoms questionnaire. Er werd vastgesteld 
dat patiënten met ernstiger COPD, ook ernstigere longklachten in de ochtend hebben. We 
konden concluderen dat het uitvragen van longklachten in de ochtend belangrijk is, in het 
bijzonder bij patiënten met ernstiger COPD. Daarnaast werd er een relatie gevonden tussen 
een lagere COPD-gerelateerde gezondheidsstatus, hogere algemene longklachtenscores, 
hogere angst- en depressiescores, minder lichamelijke activiteit die objectief gemeten is, 
slechtere longfunctie en ernstigere longklachten in de ochtend. Deze factoren zouden we 
als behandeldoelen kunnen zien om indirect longklachten in de ochtend te verbeteren. 
In hoofdstuk 4 worden activiteitenpatronen gedurende de dag van de patiënten die 
deelnamen aan de MODAS beschreven. De totale groep werd in twee groepen verdeeld 
van ongeveer gelijke grootte, op basis van de ernst van de longklachten in de ochtend. 
41 patiënten hadden weinig longklachten in de ochtend (totale score op de PRO-Morning 
COPD symptoms score <17.0) en 39 patiënten hadden veel longklachten in de ochtend 
(totale score op de PRO-Morning COPD symptoms score ≥17.0). Patiënten met veel 
longklachten in de ochtend, zetten minder stappen in de ochtend en in de middag dan 
patiënten met weinig longklachten in de ochtend. Er is geen relevant verschil waargenomen 
tussen de twee groepen in de hoeveelheid stappen die gezet werden in de avond en nacht. 
Dit was het eerste onderzoek dat gedaan is naar activiteitenpatronen gedurende de dag 
waarbij de ernst van de longklachten in de ochtend in acht werden genomen. Helaas 
kunnen we met dit onderzoek niet zeggen of de longklachten in de ochtend de oorzaak is 
van de verminderde lichamelijke activiteit in de ochtend en de middag of dat het juist het 
gevolg is; daar is vervolgonderzoek voor nodig. We opperden dat activiteitenprogramma’s 
wellicht beter in de avond plaats kunnen vinden dan in de ochtend of middag, omdat het 
lijkt dat er in de avond ruimte is voor toename van lichamelijke activiteit.  
Lichamelijke inactiviteit is geen kenmerk voor alleen ernstig COPD; ook bij patiënten met 
mild en matig COPD is er sprake van vermindering in lichamelijke activiteit. In hoofd-
stuk 5 wordt de relatie beschreven tussen patiëntkenmerken en lichamelijke activiteit bij 
patiënten met niet-ernstig COPD. Hiervoor is gebruikt gemaakt van de basisgegevens van 
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mensen die deelnamen aan het “Netherlands Epidemiology of Obesity” (NEO) onderzoek. 
Dit is een grootschalig onderzoek dat van 2008 tot 2012 is gedaan bij vrijwilligers uit 
de regio van Leiden. In de analyses werd er onderscheid gemaakt tussen mensen die de 
diagnose COPD door een arts hadden gekregen waarbij de code voor COPD (R95) ook 
geregistreerd stond in het elektronische dossier; en mensen die voldeden aan onze criteria 
voor nieuw gediagnosticeerd COPD. In totaal werden 323 patiënten geïncludeerd waarvan 
77 patiënten de diagnose COPD door een arts hadden gekregen en 246 patiënten vold-
eden aan de criteria voor nieuw gediagnosticeerd COPD. We vonden een relatie tussen 
het hebben van een betere longfunctie en meer lichamelijke activiteit. Daarnaast werd er 
een relatie gevonden tussen het hebben van COPD dat door een arts gediagnosticeerd 
was, het gebruik van bijna alle longmedicijnen en verminderde lichamelijke activiteit. Er 
was in deze groep geen relatie tussen lichamelijke activiteit en het hebben van toename 
van longklachten in de ochtend. We concludeerden dat vervolgonderzoeken noodzakelijk 
zijn om het effect van vroege behandelingen met medicatie en/of lichamelijke activiteit op 
achteruitgang van COPD in kaart te brengen. Het huidige onderzoek benadrukt dat het 
ook belangrijk is om onderzoek te doen bij mensen met niet-ernstig COPD. In deze groep 
is het COPD nog niet vergevorderd en is er ruimte voor verbetering. 
In hoofdstuk 6 wordt de evaluatie van een nieuw zorgpad beschreven, waarbij patiënten 
met (een verdenking op) astma en/of COPD op een systematische wijze werden gezien 
op de longpolikliniek van het LUMC. Een zorgpad is een complexe interventie op de 
gemeenschappelijke besluitvorming en organisatie van zorgprocessen te verwezenlijken 
voor een specifieke groep van patiënten gedurende een gedefinieerd tijdskader (Bron: 
European Pathway Association). Dit betekende voor de patiënten in het LUMC dat ze 
allemaal dezelfde vooraf bepaalde aanvullende onderzoeken ondergingen. Daarnaast 
kregen patiënten de mogelijkheid om via internet gebruik te maken van een elektronisch 
hulpprogramma om zelfredzaamheid in het kader van astma en COPD te vergroten. De 
uitkomsten werden vergeleken met “gewone” zorg. 125 patiënten werden geïncludeerd, 
waarvan 22 (21.4%) werden gezien volgens het nieuwe zorgpad. Patiënten die volgens 
het zorgpad gezien werden, ondergingen meer aanvullende onderzoeken in vergelijking 
met patiënten die niet volgens het zorgpad gezien werden en “gewone” zorg kregen. Er 
werden geen verschillen gevonden in de gestelde diagnoses. Dit suggereert dat niet alle 
testen die opgenomen zijn in het zorgpad, ook daadwerkelijk nodig zijn om een goede 
diagnose te stellen. Echter, werden er meer lifestyleadviezen, meer symptoomscores en 
meer individuele zorgplannen elektronisch gedocumenteerd bij patiënten die volgens het 
zorgpad gezien werden in vergelijking met “gewone” zorg. Uiteindelijk werden er meer 
patiënten terugverwezen naar de huisarts. Een zorgpad stimuleert longartsen om life-
styleadviezen, symptoomscores en individuele zorgplannen elektronisch te registreren. Het 
zorgpad kan er voor zorgen dat meer mensen worden terugverwezen naar de huisarts. We 
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hebben met dit onderzoek laten zien dat het mogelijk is om een zorgpad voor astma en 
COPD te gebruiken in de dagelijkse praktijk. Meer onderzoek is nodig om de effecten van 
het zorgpad op andere uitkomstparameters als kwaliteit van leven, lifestyleveranderingen 
en kosten te evalueren.
In hoofdstuk 7 worden een algemene samenvatting, hypotheses gebaseerd op de stud-
ies uit dit proefschrift en richtingen voor vervolgonderzoek en voor de klinische praktijk 
gegeven. De discussie startte met methodologische overwegingen. We concludeerden dat 
verschillende studiepopulaties, vragenlijsten om longklachten in de ochtend te evalueren, 
methoden om lichamelijke activiteit te meten en de opzet van de studie hebben bijge-
dragen aan verschillen in uitkomsten. Vervolgens bediscussieerden we de stelling dat 
longklachten in de ochtend lichamelijk inactiviteit veroorzaken, of dat het juist de andere 
kant op werkt: dat lichamelijke inactiviteit longklachten in de ochtend veroorzaakt. In de 
MODAS en in andere onderzoeken is aangetoond dat er een relatie is tussen symptomen 
in de ochtend en lichamelijke activiteit. Er valt echter met deze onderzoeken niet aan te 
tonen of longklachten in de ochtend lichamelijk inactiviteit veroorzaken, of dat het juist 
de andere kant op werkt. We denken het inderdaad beide kanten op werkt. Daarom 
moeten we gaan zoeken naar (een combinatie van) behandelingen die zowel longklachten 
in de ochtend, als lichamelijke activiteit verbetert. Daarna bediscussieerden we de stelling 
dat het hebben van longklachten in de ochtend een fenotype is in COPD. Een fenotype 
is een enkele of combinatie van ziekte eigenschappen die verschillen beschrijven tussen 
individuen met dezelfde ziekte, die een relatie hebben met klinisch relevante uitkomsten. 
We concluderen dat er een relatie is tussen het hebben van longklachten in de ochtend 
en andere factoren die negatieve invloed hebben op COPD. Echter, kunnen we nog niet 
concluderen dat het hebben van longklachten in de ochtend een fenotype is in COPD, 
omdat we het effect op de lange termijn niet weten. Vervolgens bediscussieerden we de 
stelling dat longartsen een systematische werkwijze nodig hebben om specifieke diag-
noses te stellen en betere behandelplannen te maken. We concludeerden dat longartsen 
geen systematische werkwijze nodig hadden om specifieke diagnoses te stellen. Wel kan 
er gebruik worden gemaakt van een systematische werkwijze om meer aandacht te heb-
ben voor specifieke patiëntkenmerken die anders in de dagelijkse praktijk over het hoofd 
gezien worden. In dit proefschrift pleiten we voor het invoegen van vragenlijsten die gaan 
over longklachten in de ochtend en het objectief meten van lichamelijke activiteit. De 
onderzoeken beschreven in dit proefschrift, hebben bijgedragen aan het onderstrepen 
van het belang van longklachten in de ochtend en lichamelijke inactiviteit bij mensen met 
COPD. Met ons onderzoek hebben we nieuwe inzichten gegeven in longklachten in de 
ochtend en lichamelijke inactiviteit. Deze factoren kunnen worden beschouwd als poten-
tiele behandelopties om negatieve factoren in COPD positief te beïnvloeden. Mogelijk kan 
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een combinatie van behandelingen resulteren in een elkaar versterkend effect. De effecten 
zullen moeten worden onderzocht in vervolgonderzoeken. 
AFKORTINGEN EN TOELICHTING TERMINOLOGIE
Accelerometer: Dit is een apparaat met bewegingssensoren die bewegingen in meerdere 
richtingen registreert
COPD: chronische obstructieve longziekte
Fenotype: een enkele of combinatie van ziekte eigenschappen die verschillen beschrijven 
tussen individuen met dezelfde ziekte, die een relatie hebben met klinisch relevante uit-
komsten
Lichamelijke activiteit: iedere beweging van het lichaam, opgewekt door skeletspieren, die 
energie verbruikt
LUMC: Leids Universitair Medisch Centrum
MODAS: MOrning symptoms in-Depth observationAl Study 
NEO onderzoek: Netherlands Epidemiology of Obesity onderzoek
Zorgpad: een complexe interventie op de gemeenschappelijke besluitvorming en or-
ganisatie van zorgprocessen te verwezenlijken voor een specifieke groep van patiënten 
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